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The Thesis embodies the work on the chemical investigation of two plants, 
Asparagus racemosus Willd (Asparagacae) and Withania somnifera Dunal 
(Solanecae). It includes a short review of literature on these plants. It also includes 
synthesis of class of bridgehead nitrogen heterocycles. Manuscript of the thesis 
comprises of four chapters. 
Chapter-1 
Review of literature 
This chapter has been devoted to the summary statement of a review on different 
types of compounds isolated from plants, Asparagus racemosus and Withania 
somnifera. These are presented in tabular form describing the new structures, plant 
source, reference to the isolation and structure elucidation. In addition, a short 
review of pharmacological properties of the constituents of Asparagus racemosus 
and Withania somnifera have also been included. References to the relevant 
literature have been incorporated at the end of this chapter. 
Chapter-2 
Chemical investigation of Asparagus racemosus Willd and Withania somnifera 
Dunal 
The second chapter of the thesis is divided into two parts. 2.2 deals with the 
chemical investigation of Asparagus racemosus Willd (family: Asparagaceae) and 
have resulted in the isolation of three constituents, two of which were established to 
be new to the literature. Part 2.2 is further sub-divided into two sections, A and B. In 
section A, structure determination of constituents from the Asparagus racemosus 
has been discussed. The isolates of Asparagus racemosus have been designated as 
designated as AR-I, AR-II and AR-III. Section B includes experimental details and 
spectral data of the constituents isolated from different solvent extracts of Asparagus 
racemosus. Pari 2.3 deals with the chemical investigation of fVUhania somnifera 
Dunal (family: Solenaceae) and have resulted in the isolation of five constituents, 
one of which was established to be new to the literature. Part 2.3 is also sub-divided 
into two sections A and section B. In A section, structure determination of 
constituents from the Withania somnifera has been discussed. The isolates of 
Withania somnifera have been designated as WS-I, WS-II, WS-III, WS-IV and WS-
V. Section B includes experimental details and spectral data of the constituents 
isolated from different solvent extracts of Withania somnifera. 
Chromatography and spectroscopic studies were made for the isolation and structure 
determination of the compounds. Chemical transformations, degradations have also 
been attempted to support the assigned structures. 
Repeated column chromatography of the ethyl acetate extract and n-butanolic 
fraction of the roots of Asparagus racemosus and 95% ethanolic and 50% aqueous 
ethanolic extracts of roots/leaves of Withania somnifera over silica gel resulted in 
the isolation of above mentioned compounds. References to the relevant literature 
have been incorporated at the end of this chapter. 
Part 2.2 
Section A 
AR-I: It was obtained from CHCI3: MeOH (95:5, v/v) fractions by the column 
chromatography of the ethyl acetate extract of Asparagus racemosus. It was 
crystallised from ethyl acetate, m.p. 199 °C, [aj^^-l 1-9 (c 0.0009, MeOH). AR-I a 
new compound, was identified as 2,3,6 trihydroxy-18-nor (25S) spirostan-4-ene, 21-
Ill 
oic acid. It analysed for C26H38O7, [M+H]^  at m/z 463. IR (KBr) spectrum revealed 
characteristic absorption bands for (25S)-spiroketal , hydroxyl groups and carbonyl 
group. 'H N M R (500 MHz, pyridine-ds) displayed proton signals at 6 0.68 and 1.03 
for two methyl groups. 
'^ C NMR (125 MHz, pyridine-ds) revealed the presence of 26 carbon atoms in the 
molecule, the resonance frequencies indicated that all the carbon atoms except three 
are in the state of sp^  hybridisation. On acetylation AR-I yielded triacetate m.p 158-
159°C, indicated the presence of three hydroxyl groups. Triacetate on further 
esterification resulted in the formation of ester indicated the presence of carboxylic 
group. 
HOOC 
AR-I 
AR-II: It was isolated from CHCI3: MeOH (19:1, v/v) fractions by the column 
chromatography of the n-BuOH extract of Asparagus racemosus. It was crystallized 
from MeOH , m.p. 275 °C, [a]^' -90.2° (c 0.50, pyridine). AR-II was established as 
a new compound on the basis of spectral and chemical studies and assigned the 
structure 3 - 0 -[a-L-rhamnopyranosyl (l->2)-a-L-rhamnopyranosyl-(l->4)-0-p-
D-glucopyranosyl]-25(S)- spirostan -3p-ol. It analysed for C45H74O16 [M+H]* ion at 
m/z 871.IR (KBr) spectrum revealed characterstic bands for (25S)-spiroketal and 
hydroxyl groups. In '^ C NMR spectrum (50.23MHz, pyridine-ds) of AR-II, a total of 
IV 
45 absorptions signals were recorded in CPD (complete proton decoupled) spectrum. 
In DEPT 45 and DEFT 135 a total of 41 absorptions signals were recorded. The 
DEFT, HSQC and HMBC spectra indicated the presence of six methyl, twelve 
methylene and twenty three methine. The rest were assigned to quaternary carbons. 
The resonance frequency indicated that all the carbon atoms are in the state of sp'' 
hybridisation. Compound AR-II on acidic hydrolysis resulted in the formation of an 
aglycone identified as sarsasapogenin, m.p 199-200 °C and a mixture of two sugars 
identified as D-glucose and L-rhamnose. Compound AR-II on permethylation with 
methyl iodide and subsequent hydrolysis yielded a mixture of two methylated 
sugars, 3,6-di-O-methyl glucopyranoside and 2,3,4-tri-O-methyl rhamno-pyranoside 
in the 1:2 molar ratio and sarsasapogenin. This established linkage of two a-L-
rhamnose units to glucosyl moiety as l->2 and l->4. 
R'O 
R = a-L-rhmanopyranosyl 
R = a-L-rhmanopyranosyl 
AR-II 
AR-III: It was isolated from CHCI3: MeOH (85:15, v/v) fractions by the column 
chromatography of the n-BuOH extract of Asparagus racemosus. It was crystallized 
from MeOH, m.p. 307-9 "C; [^^f^ -68.6 (c 1.0% pyridine). It analysed for C45H74O17 
[M+H]^  ion at m/z 887. IR(KBr) spectrum revealed characteristic bands for (25S)-
spiroketal and hydroxyl groups. On the bases of melting point and spectral data, AR-
III was observed to be similar to shatavarin IV earlier reported from Asparagus 
racemosus. 
R'O 
OR' 
R' = a-L-rhmanopyranosyl 
R^  = P-D-glucopyranosyl 
AR-III 
Section B 
Plant Material 
Asparagus racemosus Willd (Liliaceae) was supplied by Zandu Pharmaceutical Ltd. 
Bombay. A voucher specimen (RJM/0001) is deposited in the herbarium of 
Regional Research Laboratory, Jammu. 
Extraction, Fractionation and Isolation procedure 
Dried, powdered roots of Asparagus racemosus were extracted successively with 
ethyl acetate and water. Each extract after concentration and drying under reduced 
pressure was screened for immunomodulatory activity, when marked activity was 
VI 
found to be concentrated in the aqueous extract. The aqueous extract was dissolved 
in de-ionized water and the resulting solution was extracted with CHCI3, EtOAc and 
n-BuOH successively. n-BuOH fraction residue was found to be rich in quantity and 
chemical composition and showed significant immunomodulatory activity. Both 
Ethyl acetate extract and n-BuOH fraction were subjected to column chromato-
graphy with solvents of increasing polarity in different proportions. Rf values, 
quantity of each constituent isolated and solvent employed for elution of columns 
have been incorporated in tabular form. 
Part 2.3 
Section A 
WS-1: It was isolated from CHCI3 elute by the column chromatography of the 
chloroform fraction obtained from the leaves of Withania somnifera. It was 
crystallized from MeOH. m.p. 242-43 °C, [a]^ ^^  +70.95 (c 0.002 CDCI3). WS-I was 
established as a new compound on the basis of spectral and chemical studies and 
assigned the structure 6a, 7a-epoxy-5a, 17a, 27-trihydroxy-l-oxo-22R-witha-2, 24-
dienolide. It analyzed for CigHjgOi, [M+H]"*" ion at m/z 486.2624.The UV spectrum 
showed characteristic bands for a, p-imsaturated 8-lactone. IR(KBr)): spectrum 
revealed characteristic bands for hydroxyl groups, a, P-unsaturated 6-lactone and a, 
p-unsaturated ketone. In '^ C NMR spectrum (125 MHz, CDCI3) of WS-I, a total of 
28 absorptions signals were recorded in CPD (complete proton decoupled) spectrum. 
The DEFT experiments (performed at 45° and 135°) were carried out to ascertain the 
nature of the carbon atoms. They showed thirteen positive peaks for four methyl and 
nine methine carbons and seven negative peaks for methylene carbons. The other 
Vll 
eight resonances were due to quaternary carbons. The proposed structure was finally 
confirmed by X-ray diffraction studies. 
WS-I 
WS-II: It was isolated from CHCI3: MeOH (99:1, v/v) fraction by the column 
chromatography of chloroform fraction obtained from the leaves/roots of Withania 
somnifera. It was crystallised from EtOAc, m.p 252.5 °C, [a]?J+125 (c 1.30, 
CHCI3). The UV spectrum showed characteristic bands for a, P-unsaturated 6-
lactone. IR(KBr) spectrum revealed characteristic bands for a, P-unsaturated 6-
lactone and hydroxy! groups. The 'H N M R (50.32 MHz, CDCI3) and '^ C NMR 
(200.13 MHz, CDCl3)of WS-II was observed to be very similar to v t^haferin A 
earlier reported from Withania somnifera. 
WS-II 
WS-IIl: It was isolated from CHCI3: MeOH (98:2, v/v) fractions by the column 
chromatography of the chloroform fraction obtained from the leaves/roots of 
Vlll 
Withania somnifera. It was crystallized from CHCI3: EtOAc, m.p.275-76 °C, 
[a]^^ +81" (c 0.5, CHCI3). The UV spectrum showed characteristic bands for a, p-
unsaturated 5-lactone. IR(KBr) spectrum revealed characteristic bands for a, p-
unsaturated 6-lactone, a, p-unsaturated ketone and hydroxyl groups. The 'H NMR 
(50.32 MHz, CDCI3) and '^ C NMR (200.13 MHz, CDCI3) of WS-III was observed 
to be very similar to withanone earlier reported from Withania somnifera. 
WS-III 
WS-IV: It was isolated from CHCI3: MeOH (97:3, v/v) fractions by the column 
chromatography of the chloroform fraction obtained from the roots of Withania 
somnifera. It was crystallized from CHCI3: EtOAc, m.p.294.3 °C, [a]^+92.3° (c 
1.47, CHCI3). The UV spectrum showed characteristic bands for a, P-unsaturated 5-
lactone. IR(KBr) spectrum revealed characteristic bands for a, P-unsaturated 5-
lactone, a, P-unsaturated ketone and hydroxyl groups. The 'H NMR (50.32 MHz, 
CDCI3) and '^ C NMR (200.13 MHz, CDCI3) of WS-IV was observed to be very 
similar to withanolide A earlier reported from Withan'o somnifera. 
IX 
WS-IV 
WS-V: It was isolated from CHCI3: MeOH (95:5, v/v) fractions by the column 
chromatography of the chloroform fraction obtained from the roots of Withania 
somnifera. It was crystallized from MeOH, m.p. 294.3 °C, [a] ^^+92.3° (c 1.47, 
CHCI3). The UV spectrum showed characteristic bands for a, (J-unsaturated 6-
lactone. IR(KBr) spectrum revealed characteristic bands for a, P-unsaturated 5-
lactone, a, P-unsaturated ketone and hydroxyl groups. The 'H NMR (50.32 MHz, 
CDCI3) and '^ C NMR (200.13 MHz, CDCI3) of WS-IV was observed to be very 
similar to 12-Deoxywithastramonolide earlier reported from Withania somnifera. 
Section B 
Plant Material 
The specimen of Withanla somnifera Dunal was collected from RRL fields and 
deposited in the Herbarium of Regional Research Laboratory, Jammu under 
collection No: 50414 dated 11-06-02. 
Extraction, fractionation and isolation procedure 
Withania somnifera dried powder leaves were extracted by percolation with 95% 
EtOH for 16 hrs and dried powder roots was extracted by agitating with EtOH: H2O 
(1:1, v/v) for 2 hrs at room temperature. Each extract after concentration and drying 
under reduced pressure was subjected to the column chromatography with 
increasing polarity in different proportions. Rf values, quantity of each constituent 
isolated and solvent employed for elution of columns have been incorporated in 
tabular form. 
Chapter-3 
Chemical standardisation of Asparagus racemosus and Withania somnifera on 
the bases of isolated markers by Morden techniques 
Herbal medicines have been used for thousands of years in many parts of the world. 
Today, they appear to be engaging the attention of health authorities even in the 
developed countries. This is attributable to the fact that they offer alternative sources 
of medical therapy that are reasonably effective and least productive of disturbing 
after effects. However, to maximise their ultimate efficacy, we have to ensure that 
preparations derived from medicinal plants are of acceptable quality, safety and 
efficacy. In the present, global market scenario 50% share belongs to People's 
XI 
Republic of China , 20% to Japan followed by Russia with 16%. Unfortunately, 
India's share is only 2.5% although the internal market has crossed Rs. 4500 crore 
per year. The reason is simple lack of quality control and scientific evaluation data 
for Indian products. 
Non-standardized herbal preparations have not found acceptance in the global 
market and therefore need to be chemically standardized on the basis of isolated 
constituents. Presently, formulations standardized on the basis of a maximum 
possible number of biomarkers are accepted readily in the global market. In view of 
the importance of Asparagus racemosus and Withania somnifera in traditional 
Indian medicine and their apparent potential in the global market as a positive health 
promoter the two plants were chemically standardised. 
The chapter 3 includes detailed protocol development for standardisation of these 
two plants on the bases of isolated markers using state of art techniques, High 
Performance Thin Layer Chromatography (HPTLC) in case of Asparagus 
racemosus and High Performance Liquid Chromatography-Ultra Violet (Diode 
Array Detector)- positive ion electrospray ionisation-mass spectrometry [HPLC-
UV(DAD)~positive ion electrospray ionisation-mass spectrometry] in case of 
Withania somnifera. 
Chapter-4 
Synthesis of Some Physilogically Active Nitrogen Heterocyclic Compounds 
The chapter 4 deals in the synthesis of some physiologically active nitrogen 
heterocyclic compound and has been divided into two parts. Part 4.2 deals in the 
synthesis of 3,5-disubstituted-4,5-dihydro-lH-pyrazoles, possessing anti-
inflammatory activity. Though number of results are available in the literature for 
xu 
their synthesis.The present work aimed at ecofriendly synthesis of these molecules 
using microwave irradiations has resulted in the synthesis of twelve (la to 12a ) 
molecules. Wherein the yeilds have been improved significantly and time has been 
reduced drastically in comparion to conventional synthesis. 
,0H 
OMe 
Microwave 
HNH.NHj 
MeO IV- ~^  
1 
H 
OMe 
-^y°" 
MeO 
(la-12a) 
Part 4.2 deals in the synthesis and spectral assignment of some 4-methyl-2-oxo-
(2H)- pyrido [1,2-a] pyrimidine and 2-methyl-4-oxo-(4H)- pyrido[l,2-a] pyrimidine 
derivatives. No Comparative data for the two sets of isomeric compounds with 
respect to '^ C and 'H N M R have been reported so far. In the present work, synthesis 
followed by detailed studies of the 2D NMR spectra of these compounds has shown 
that assignments made for nonprotonated carbon atoms and those reported in the 
literature for similar compounds indicated errors in assignments and needed 
corrections. The unequivocal assignments of these compounds were made on the 
basis of heteronuclear single quantum correlation (HSQC) and heteronuclear 
multiple bond correlation (HMBC) techniques. 
H CH, 
N ^ ^ O 
2-oxo-(2H)-pyrido |l,2-a| pyrimidine 4-oxo-(4H)-pyrido|l,2-al pyrimidine 
Xlll 
A relative assessment of the chemical shifts of C-2, C-4 and C-10 in the '^ C NMR 
spectra indicated that in 4-oxo-compounds C-2 (p to carbonyl is more deshielded 
than C-4 (carbonyl), whereas in 2 - oxo compounds the reverse is true. 
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Summary 
The Thesis embodies the work on the chemical investigation of two plants, 
Asparagus racemosus Willd (Asparagacae) and Withania somnifera Dunal 
(Solanecae). It includes a short review of literature on these plants. It also includes 
synthesis of class of bridgehead nitrogen heterocycles. Manuscript of the thesis 
comprises of four chapters. 
Chapter-1 
Review of literature 
This chapter has been devoted to the summary statement of a review on different 
types of compounds isolated from plants, Asparagus racemosus and Withania 
somnifera. These are presented in tabular form describing the new structures, plant 
source, reference to the isolation and structure elucidation. In addition, a short 
review of pharmacological properties of the constituents of Asparagus racemosus 
and Withania somnifera have also been included. References to the relevant 
literature have been incorporated at the end of this chapter. 
Chapter-2 
Chemical investigation oi Asparagus racemosus Willd and Withania somnifera 
Dunal 
The second chapter of the thesis is divided into two parts. 2.2 deals with the 
chemical investigation of Asparagus racemosus Willd (family; Asparagaceae) and 
have resulted in the isolation of three constituents, two of which were established to 
be new to the literature. Part 2.2 is further sub-divided into two sections, A and B. In 
section A, structure determination of constituents from the Asparagus racemosus 
has been discussed. The isolates of Asparagus racemosus have been designated as 
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designated as AR-I, AR-II and AR-III. Section B includes experimental details and 
spectral data of the constituents isolated from different solvent extracts of Asparagus 
racemosus. Part 2.3 deals with the chemical investigation of Withania somnifera 
Dunal (family: Solenaceae) and have resulted in the isolation of five constituents, 
one of which was established to be new to the literature. Part 2.3 is also sub-divided 
into two sections A and section B. In A section, structure determination of 
constituents from the Withania somnifera has been discussed. The isolates of 
Withania somnifera have been designated as WS-I, WS-II, WS-III, WS-IV and WS-
V. Section B includes experimental details and spectral data of the constituents 
isolated from different solvent extracts of Withania somnifera. 
Chromatography and spectroscopic studies were made for the isolation and structure 
determination of the compounds. Chemical transformations, degradations have also 
been attempted to support the assigned structures. 
Repeated column chromatography of the ethyl acetate extract and n-butanolic 
fraction of the roots of Asparagus racemosus and 95% ethanolic and 50% aqueous 
ethanolic extracts of roots/leaves of Withania somnifera over silica gel resulted in 
the isolation of above mentioned compounds. References to the relevant literature 
have been incorporated at the end of this chapter. 
Part 2.2 
Section A 
AR-I: It was obtained from CHCI3: MeOH (95:5, v/v) fractions by the column 
chromatography of the ethyl acetate extract of Asparagus racemosus. It was 
crystallised from ethyl acetate, m.p. 199 °C, [af^-] 1.9 (c 0.0009, MeOH). AR-I a 
new compound, was identified as 2,3,6 trihydroxy-18-nor (25S) spirostan.4-ene, 21-
Ill 
oic acid. It analysed for C26H38O7, [M+H]^  at m/z 463. IR (KBr) spectrum revealed 
characteristic absorption bands for (25S)-spiroketal , hydroxyl groups and carbonyl 
group. 'H N M R (500 MHz, pyridine-ds) displayed proton signals at 6 0.68 and 1.03 
for two methyl groups. 
'^ C NMR (125 MHz, pyridine-ds) revealed the presence of 26 carbon atoms in the 
molecule, the resonance frequencies indicated that all the carbon atoms except three 
are in the state of sp^  hybridisation. On acetylation AR-I yielded triacetate m.p 158-
159°C, indicated the presence of three hydroxyl groups. Triacetate on further 
esterification resulted in the formation of ester indicated the presence of carboxylic 
group. 
HOOC 
AR-I 
AR-II: It was isolated from CHCI3: MeOH (19:1, v/v) fractions by the column 
chromatography of the n-BuOH extract of Asparagus racemosus. It was crystallized 
from MeOH , m.p. 275 °C, [a]^ -90.2° (c 0.50, pyridine). AR-II was established as 
a new compound on the basis of spectral and chemical studies and assigned the 
structure 3 - 0 -[a-L-rhamnopyranosyl (l->2)-a-L-rhamnopyranosyl-(l-^4)-0-p-
D-glucopyranosyl]-25(S)- spirostan -3p-ol. It analysed for C4SH74O16 [M+H]^  ion at 
m/z 871.IR (KBr) spectrum revealed characterstic bands for (25S)-spiroketal and 
hydroxyl groups. In '^ C NMR spectrum (50.23MHz, pyridine-ds) of AR-II, a total of 
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45 absorptions signals were recorded in CPD (complete proton decoupled) spectrum. 
In DEPT 45 and DEFT 135 a total of 41 absorptions signals were recorded. The 
DEFT, HSQC and HMBC spectra indicated the presence of six methyl, twelve 
methylene and twenty three methine. The rest were assigned to quaternary carbons. 
The resonance frequency indicated that all the carbon atoms are in the state of sp 
hybridisation. Compound AR-II on acidic hydrolysis resulted in the formation of an 
aglycone identified as sarsasapogenin, m.p 199-200 °C and a mixture of two sugars 
identified as D-glucose and L-rhamnose. Compound AR-II on permethylation with 
methyl iodide and subsequent hydrolysis yielded a mixture of two methylated 
sugars, 3,6-di-O-methyl glucopyranoside and 2,3,4-tri-O-methyl rhamno-pyranoside 
in the 1:2 molar ratio and sarsasapogenin. This established linkage of two a-L-
rhamnose units to glucosyl moiety as 1—>2 and 1—>4. 
R>0 
R' = a-L-rhmanopyranosyl 
R = a-L-rhmanopyranosyl 
AR-II 
AR-III: It was isolated from CHCI3: MeOH (85:15, v/v) fractions by the column 
chromatography of the n-BuOH extract of Asparagus racemosus. It was crystallized 
from MeOH, m.p. 307-9 °0, ^^f^ -68.6 (c 1.0% pyridine). It analysed for C45H740,7 
[M+H]^  ion at m/z 887. IR(KBr) spectrum revealed characteristic bands for (25S)-
spiroketal and hydroxyl groups. On the bases of mehing point and spectral data, AR-
III was observed to be similar to shatavarin IV earlier reported from. Asparagus 
racemosus. 
R20 
OR' 
R' = a-L-rhmanopyranosyl 
R^  = p-D-glucopyranosyl 
AR-III 
Section B 
Plant Material 
Asparagus racemosus Willd (Liliaceae) was supplied by Zandu Pharmaceutical Ltd. 
Bombay. A voucher specimen (RJM/OOOl) is deposited in the herbarium of 
Regional Research Laboratory, Jammu. 
Extraction, Fractionation and Isolation procedure 
Dried, powdered roots of Asparagus racemosus were extracted successively with 
ethyl acetate and water. Each extract after concentration and drying under reduced 
pressure was screened for immunomodulatory activity, when marked activity was 
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found to be concentrated in the aqueous extract. The aqueous extract was dissolved 
in de-ionized water and the resulting solution was extracted with CHCI3, EtOAc and 
n-BuOH successively. n-BuOH fraction residue was found to be rich in quantity and 
chemical composition and showed significant immunomodulatory activity. Both 
Ethyl acetate extract and n-BuOH fraction were subjected to column chromato-
graphy with solvents of increasing polarity in different proportions. Rf values, 
quantity of each constituent isolated and solvent employed for elution of columns 
have been incorporated in tabular form. 
Part 2.3 
Section A 
WS-I: It was isolated from CHCI3 elute by the column chromatography of the 
chloroform fraction obtained from the leaves of Withania somnifera. It was 
crystallized from MeOH. m.p. 242-43 °C, [a] ^^+70.95 (c 0.002 CDCI3). WS-I was 
established as a new compound on the basis of spectral and chemical studies and 
assigned the structure 6a, 7a-epoxy-5a, 17a, 27-trihydroxy-l-oxo-22R-witha-2, 24-
dienolide. It analyzed for C2gH3g07, [M+H]^  ion at m/z 486.2624.The UV spectrum 
showed characteristic bands for a, p-unsaturated 8-Iactone. IR(KBr)): spectrum 
revealed characteristic bands for hydroxyl groups, a, p-unsaturated 6-lactone and a, 
P-unsaturated ketone. In '^ C NMR spectrum (125 MHz, CDCI3) of WS-I, a total of 
28 absorptions signals were recorded in CPD (complete proton decoupled) spectrum. 
The DEFT experiments (performed at 45° and 135°) were carried out to ascertain the 
nature of the carbon atoms. They showed thirteen positive peaks for four methyl and 
nine methine carbons and seven negative peaks for methylene carbons. The other 
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eight resonances were due to quaternary carbons. The proposed structure was finally 
confirmed by X-ray diffraction studies. 
WS-I 
WS-II: It was isolated from CHCI3: MeOH (99:1, v/v) fraction by the column 
chromatography of chloroform fraction obtained from the leaves/roots of Withania 
a]j^+125 (c 1.30, 
CHCI3). The UV spectrum showed characteristic bands for a, P-unsaturated 5-
lactone. IR(KBr) spectrum revealed characteristic bands for a, p-unsaturated 5-
lactone and hydroxyl groups. The 'H NMR (50.32 MHz, CDCI3) and '^ C NMR 
(200.13 MHz, CDCl3)of WS-II was observed to be very similar to withaferin A 
earlier reported from Withania somnifera. 
OH 
WS-II 
WS-III: It was isolated from CHCI3: MeOH (98:2, v/v) fractions by the column 
chromatography of the chloroform fraction obtained from the leaves/roots of 
Vlll 
Withania somnifera. It was crystallized from CHCI3: EtOAc, m.p.275-76 °C, 
[a]^^ +81° (c 0.5, CHCI3). The UV spectrum showed characteristic bands for a, p-
unsaturated 6-lactone. IR(KBr) spectrum revealed characteristic bands for a, P-
unsaturated 6-lactone, a, P-unsaturated ketone and hydroxyl groups. The 'H NMR 
(50.32 MHz, CDCI3) and '^ C NMR (200.13 MHz, CDCI3) of WS-III was observed 
to be very similar to withanone earlier reported from Withania somnifera. 
OH '0 
WS-III 
WS-IV: It was isolated from CHCI3: MeOH (97:3, v/v) fractions by the column 
chromatography of the chloroform fraction obtained from the roots of Withania 
somnifera. It was crystallized from CHCI3: EtOAc, m.p.294.3 °C, [a]?J+92.3° (c 
1.47, CHCI3). The UV spectrum showed characteristic bands for a, p-unsaturated 5-
lactone. IR(KBr) spectrum revealed characteristic bands for a, P-unsaturated 5-
lactone, a, p-unsaturated ketone and hydroxyl groups. The 'H NMR (50.32 MHz, 
CDCI3) and '^ C NMR (200.13 MHz, CDCI3) of WS-IV was observed to be very 
similar to withanolide A earlier reported from Withan'a somnifera. 
IX 
OH 'O 
WS-IV 
WS-V: It was isolated from CHCI3: MeOH (95:5, v/v) fractions by the column 
chromatography of the chloroform fraction obtained from the roots of Withania 
somnifera. It was crystallized from MeOH, m.p. 294.3 °C, [a] ^^ +92.3** (c 1.47, 
CHCI3). The UV spectrum showed characteristic bands for a, p-unsaturated 8-
lactone. IR(KBr) spectrum revealed characteristic bands for a, P-unsaturated 5-
lactone, a, P-unsaturated ketone and hydroxyl groups. The 'H N M R (50.32 MHz, 
CDCI3) and '^ C NMR (200.13 MHz, CDCI3) of WS-IV was observed to be very 
similar to 12-Deoxywithastramonolide earlier reported from Withania somnifera. 
Section B 
Plant Material 
The specimen of Withania somnifera Dunal was collected from RRL fields and 
deposited in the Herbarium of Regional Research Laboratory, Jammu under 
collection No: 50414 dated 11-06-02. 
Extraction, fractionation and isolation procedure 
Withania somnifera dried powder leaves were extracted by percolation with 95% 
EtOH for 16 hrs and dried powder roots was extracted by agitating with EtOH: H2O 
(1:1, v/v) for 2 hrs at room temperature. Each extract after concentration and drying 
under reduced pressure was subjected to the column chromatography with 
increasing polarity in different proportions. Rf values, quantity of each constituent 
isolated and solvent employed for elution of columns have been incorporated in 
tabular form. 
Chapter-3 
Chemical standardisation of Asparagus racemosus and Withania somnifera on 
the bases of isolated markers by Morden techniques 
Herbal medicines have been used for thousands of years in many parts of the world. 
Today, they appear to be engaging the attention of health authorities even in the 
developed countries. This is attributable to the fact that they offer alternative sources 
of medical therapy that are reasonably effective and least productive of disturbing 
after effects. However, to maximise their ultimate efficacy, we have to ensure that 
preparations derived from medicinal plants are of acceptable quality, safety and 
efficacy. In the present, global market scenario 50% share belongs to People's 
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Republic of China , 20% to Japan followed by Russia with 16%. Unfortunately, 
India's share is only 2.5% although the internal market has crossed Rs. 4500 crore 
per year. The reason is simple lack of quality control and scientific evaluation data 
for Indian products. 
Non-standardized herbal preparations have not found acceptance in the global 
market and therefore need to be chemically standardized on the basis of isolated 
constituents. Presently, formulations standardized on the basis of a maximum 
possible number of biomarkers are accepted readily in the global market. In view of 
the importance of Asparagus racemosus and Withania somnifera in traditional 
Indian medicine and their apparent potential in the global market as a positive health 
promoter the two plants were chemically standardised. 
The chapter 3 includes detailed protocol development for standardisation of these 
two plants on the bases of isolated markers using state of art techniques, High 
Performance Thin Layer Chromatography (HPTLC) in case of Asparagus 
racemosus and High Performance Liquid Chromatography-Ultra Violet (Diode 
Array Detector)- positive ion electrospray ionisation-mass spectrometry [HPLC-
UV(DAD)-positive ion electrospray ionisation-mass spectrometry] in case of 
Withania somnifera. 
Chapter-4 
Synthesis of Some Physilogically Active Nitrogen Heterocyclic Compounds 
The chapter 4 deals in the synthesis of some physiologically active nitrogen 
heterocyclic compound and has been divided into two parts. Part 4.2 deals in the 
synthesis of 3,5-disubstituted-4,5-dihydro-lH-pyrazoles, possessing anti-
inflammatory activity. Though number of results are available in the literature for 
Xll 
their synthesis.The present work aimed at ecofriendly synthesis of these molecules 
using microwave irradiations has resulted in the synthesis of twelve (la to 12a ) 
molecules. Wherein the yeilds have been improved significantly and time has been 
reduced drastically in comparion to conventional synthesis. 
OH 
OMe 
Microwave 
HNH.NH2 
MeO \ ^ 
1 
H 
OMe 
^y°" 
MeO 
(la-12a) 
Part 4.2 deals in the synthesis and spectral assignment of some 4-methyl-2-oxo-
(2H)- pyrido [1,2-a] pyrimidine and 2-methyl-4-oxo-(4H)- pyrido[l,2-a] pyrimidine 
derivatives. No Comparative data for the two sets of isomeric compounds with 
respect to '^ C and 'H N M R have been reported so far. In the present work, synthesis 
followed by detailed studies of the 2D NMR spectra of these compoimds has shown 
that assignments made for nonprotonated carbon atoms and those reported in the 
literature for similar compounds indicated errors in assignments and needed 
corrections. The unequivocal assignments of these compounds were made on the 
basis of heteronuclear single quantum correlation (HSQC) and heteronuclear 
multiple bond correlation (HMBC) techniques. 
H CH3 
N / ^ - O 
2-oxo-(2H)-pyrido j 1,2-a) pyrimidine 4-oxo-(4H)-pyrido|l,2-aJ pyrimidine 
Xlll 
A relative assessment of the chemical shifts of C-2, C-4 and C-10 in the '^ C NMR 
spectra indicated that in 4-oxo-compounds C-2 (P to carbonyl is more deshielded 
than C-4 (carbonyl), whereas in 2 - oxo compounds the reverse is true. 
CHAPTER I 
Review of Literature 
1.1 General Introduction 
Man's existence on this earth has been made possible only because of the vital role 
by the plant kingdom in sustaining his life. The three important necessities of life-
food, clothing and shelter as well as most of the other useful products are supplied to 
a greater extent by the plant kingdom. The nature has provided a complete 
storehouse of remedies to cure all ailments of mankind. Since the dawn of 
civilization, in addition to food crops, man cultivated herbs for his medicinal needs. 
The knowledge of drugs has accumulated over thousands of years as a result of 
man's inquisitive nature, so that today we possess many effective means of ensuring 
health care'. 
Natural product chemistry stems from the use of nature for medicinal purposes. The 
World Health Organization (WHO) estimates that approximately 80% of the world 
relies on natural sources for primary medical treatment and that the health care 
systems for the remaining 20% of the population also incorporate natural sources in 
their medical treatment^ . In a study of the pharmaceuticals in the market from 1981-
2002, only 43% of the drugs were purely synthetic, while remaining 57% were 
derived from a natural source (Fig. !)•' and used in native form or as a modified 
molecule. The data shown in the (Fig. 1) categorizes in the following way: 
biological - a peptide or protein isolated from an organism or cell line; natural 
product derivative-derived from a natural product usually with some semi-synthetic 
modifications; synthetic drug; synthetic drug with a natural product pharmacophore; 
vaccine\ Natural product chemistry can be defined as the exploration of nature in 
search of novel drugs or drug leads. 
23% 
• Biological 
• Natural PrtxJuct 
• Natural Proouct 
Oettvatlve 
• Synthetic Ooig 
• Synthetic Oug vv/ 
Natural Product 
Pharmacophore 
a Vaccine 
Fig 1: Pharmaceuticals containing natural products (1981-2002). 
Adapted from Newman, Cragg, and Snader (2003) 
Some possible sources of natural products include plants, marine organisms, 
microbes and fungi. Of the approximately 250,000 higher species of plants it is 
estimated that only 5-15% have been investigated for natural products'*. Marine 
organisms are abundant in the oceans, which cover more than 70% of the Earth's 
surface^. Also, research suggests that less than 1% of bacterial species and less than 
5% of fungal are currently known^ Therefore, it is important that natural product 
chemistry continues to explore natural resources in the search of new natural 
products for the welfare of mankind. 
The field of research on 'Natural Product Chemistry' is one of the most fascinating 
area of research. The extensive phytochemical investigations of the indigenous 
plants of medicinal value have always been the attention of inquisitive minds. Much 
progress has already been made, but a lot remains to be done in this field. Hundreds 
of new compounds of various structures are being discovered every year fi"om 
natural sources and many of them are being synthesised. The study of their 
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stereochemistry, physiological activity and biosynthesis is widening the horizons of 
this field. 
The present study focuses on the chemical investigation of two plants namely 
Asparagus racemosus and Withania somnifera which are extensively being used in 
the indigenous system of medicines because of their curative/therapeutic effect in 
the number of aliments. 
1.2 Asparagus racemosus Willd 
Asparagus racemosus Willd is commonly mentioned as a Rasayana in the Ayurveda 
and is mentioned as Shatavari which means "she who has hundred husbands" 
referring to the rejuvenative effect of the herb on the female reproductive organs. A 
study of ancient classical Ayurvedic literature claimed several therapeutic attributes 
for the roots of Asparagus racemosus and has been specially recommended in case 
of threatened abortion and as a galactogogue .^ The plant belongs to the genus 
Asparagus of family Asparagacae. Genus Asparagus has been recently moved from 
the subfamily Asparagae in the family Liliaceae to a newly created family 
Asparagaceae^ The name is taken from the Greek/ Persian "Asparag" referring to 
tender 'short' or stalk that can be consumed*. It is known to have been in cultivation 
since 200 BC. Because of the prickly nature of the foliage, the fronds have been 
used in Greece to stuff up the holes of mice and rats. An old Chinese custom was to 
save the selected roots for family and friends in the belief that it would increase 
feelings of compassion and love'. Aspargus is a highly regarded herb worldwide and 
is considered to be of medicinal importance because of the presence of steroidal 
saponins and sapogenins in the various parts of the plant'°. The name "Asparagus" 
was given by Theophrastus. Genus Asparagus includes about 300 species of erect or 
climbing herbs or shrubs, distributed in the temperate and tropical parts of the world. 
About 22 species are native of India, of which some are most commonly used in 
indigenous medicine". The roots of some species are the source of the drug 
Shatawar . The drug is used in indigenous medicine. Asparagus racemosus has 
been used in Ayurveda for various conditions'^ though Its main use has been as a 
galactogogue to increase the milk secretion during lactation"*. It is also used as 
general tonic'^ and as an aphrodisiac'^. Asparagus racemosus is recommended in 
Ayurvedic text for prevention and treatment of gastric ulcers, dyspepsia and as a 
galactogogue. Asparagus racemosus has also been used successfially by some 
Ayurvedic practitioners for nervous disorders, inflammation, liver diseases and 
certain infectious diseases^. Recently, few reports have come demonstrating 
beneficial effects of alcoholic and water extracts of roots of Asparagus racemosus in 
some clinical conditions and experimentally induced diseases e.g. galactogogue 
effect'^, antihepatotoxic and immunomodulatory activities'*. 
1.2.1 Taxonomical classification 
Kingdom 
Phylum 
Class 
Order 
Family 
Genus 
Plantae (plants) 
Anthophyta 
Moncotyledons 
Liliales 
Liliaceae 
Asparagus 
1.2.2 Distribution 
The plant species Asparagus racemous is chiefly distributed throughout the India, 
tropical and subtropical parts including Andamans, ascending in the Himalayas upto 
an altitude of 1500 m and other Asian and Africa countries. Native to Australia 
through Western Africa to Southern Asia'^. Asparagus racemosus grows wild and is 
also cultivated throughout the tropical and subtropical parts of India. 
1.2,3 Botanical description 
Asparagus racemosus is an ascending, spinous, much branched, perennial climber 
growing upto 2 m in height, with tuberous, short rootstock bearing numerous 
fusiform, succulent tuberous roots 30-100 cm long and 1-2 cm thick, found growing 
wild in tropical and sub-tropical parts of India. Stems woody, whitish gray or brown 
armed with strong, straight or recurved spines 5-13 mm long cladodes more or less 
acicular, 2-6 nate, falcate finely acuminate; leaves reduced to sub-erect or sub-
spines; flowers white, fragrant, small, profuse in simple or branched racemes upto 7 
cm long; berries globose scarlet, trilobed, 4-6 nun in diameter, 1-seeded red. The 
plant is rather variable, three varieties are generally recognized although not 
distinguished in trade''. 
(i) var. racemosus with slightly compressed, acuminate falcate cladodes, 
and longer, decurved spines common in partial shade in plains and 
across upper ghats in Hassan district (Kamataka). 
(ii) var. javanicus Baker syn. Asparagopsis javanica Miq. has very 
slender, flexuous racemes with terminal tufts of cladodes, and 
narrower and liner-oblong perianth, distributed in the Deccan 
geninsula, Kamataka, Saurashtra (Gujarat) and Bhopal (Madhya 
Pradesh). 
(iii) var. subacerosa Bakers distrubuted in Sikkim at an altitudes of 
300-1,200 m. The plant is very common in the upper Gangetic plains 
and the Bihar plateau, flowering after the rains when it becomes 
conspicuous by its masses of white fragrant flowers. The white 
tuberous roots are collected for food and constitute a kind of safed 
musali used medicinally. It is often cultivated in gardens near Dehra 
Dun and is ornamental when in flower. Often the whole plant is seen 
in flower, bearing no cladodes. 
1.2.4 Medicinal uses 
The plant finds use as diuretic, aphrodisiac and as galactagogue^ *^ . The juice of the 
plant is used as demulcent, aphrodisiac, in leucorrhoea, as a uterine tonic, in 
epistaxis, hyperacidity '^. The bark is used in amoebic dysentery .The twigs are used 
in wound healing, dysentery, bacterial, viral, plastic diseases and digestive 
disturbances^ '^^ .^ The fruits are used in eczema '^'. The leaves are used as hair tonic, 
galactogogue, in post delivery complaints, urinary troubles, herpes, as antitussive 
and in scabies^^" '^. The root is used as diuretic, aphrodisiac, antiseptic, 
antidiarrhoeal, antidysentric, galactogogue, antispasmodic, in stomach disorders, 
dysuria, in piles, constipation, tuberculosis, leprosy, epilepsy, night blindness and as 
a laxative and expectorant. It is used in swelling, diarrhea, piles, eye diseases and 
rheumatic complaints ' . The root is also used as fertility enhancer, as a 
antidiabetic, in fever, in haemostatic, in whooping cough, to check excessive 
bleeding during menstruation, in urinary troubles, wormicidal in, cattle in 
gonorrhoea, impotency, leucorrhoea, stool with blood, vomiting, burning 
micturition, post partum complaints, bodyache and as a tonic. The root also finds use 
in infection of umbilicus''^ . The tubers are used as lactagogue, in headache and boils, 
for hasting delivery, as analgesic, antitussive, in menorrhagia''''. The preparation as 
"Shatavari guda" is used in diabetes, jaundice and other urinary disorders^ .^ 
1.2.5 Pharmacology 
Asparagus racemosus has undergone extensive pharmacological investigations. 
The studies demonstrate that plant has significant beneficial effects in dyspepsia, 
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acid-pepsin disease and deficient lactation^^ Pharmacological activities associated 
with plant include. 
Anticancer: An alcoholic extract of the arial parts of Asparagus racemosus 
exhibited anticancer activity in human epidermal carcinoma of the nasopharynx in 
tissue culture . 
Adaptogenic: Aqueous extracts administrated orally to experimental animals, in a 
dose extrapolated from the human dose, protected against a variety of biological, 
physical and chemical stressors. A model of cisplatin-induced alterations in 
gastrointestinal motility was used to test the ability of extract to exert a normalizing 
effect, irrespective of direction of pathological change. The extract reversed the 
effects of cisplatin on gastric emptying and also normalized cisplatin-induced 
intestinal hypermotility . 
Antibacterial: Methanol extract of the roots showed significant in vitro antibacterial 
efficacy against Escherichia coli, Shigella dyenteriate, Shigella sonnei, Bacillus 
subtilis and Staphylococcus aureus . 
Antitussive: Methanolic extract of the root, at a dose of 200 and 400 mg/kg PO, 
showed significant antitussive activity on sulphur dioxide-induced cough in mice. 
The cough inhibition of 40% and 58.5% respectively, was comparable to that of 10-
20 mg/kg of codeine phosphate, where the inhibition observed was 36% and 55.4% 
respectively'' . 
Antiprotozoal: An aqueous solution of the crude alcoholic extract of the roots 
exhibited an inhibitory effect on the growth of E.histolytica in vitro'^\ 
Antiulcer: The powdered dried root of Asparagus racemosus is used in Ayurveda 
for dyspepsia. Oral administration of dried root of Asparagus racemosus has been 
found to promote gastric emptying in healthy volunteers. Its action is reported to be 
comparable with that of the synthetic dopamine antagonist metoclopromide . In 
Ayurveda, Asparagus racemosus has also been mentioned for the treatment of 
ulcerative disorders of stomach and parinama sula, a clinical entity akin to the 
duodenal ulcer diseases. The juice of the fresh root Asparagus racemosus has been 
shown to have definite curative effect in patients of duodenal ulcers. Shatavari 
promptly and persistently relieve the pain and burning sensation as well as other 
dyspeptic symptoms due to duodenal ulcer'*^ . 
Galactogogue: The root extract of Asparagus racemosus is prescribed in Ayurveda 
to increase milk secretion during lactation'*'*. Asparagus racemosus in combination 
with herbal substances in the form of 'Ricalex' tablets has been shown to increase 
milk production in females complaining of deficient milk secretion'''. Systamatic 
administration of the alcoholic extract of Asparagus racemosus in weaning rats 
increased weight of the mammary glands, inhibited involution of lobulo-alveolar 
tissues and maintained milk secretion''^  
Immunomodulatory activities: Immunomodulating property of Asparagus 
racemosus has been shown to protect the rat and mice against experimental induced 
abdominal sepsis. Oral administration of decoction of powdered root of Asparagus 
racemosus has been reported to produce leucocytosis and predominant neutrophilia 
along with enhanced phagocytic activity of the macrophages and polymorphs'*^ "'*^  
Antihepatotoxic: Alcoholic extract of root of Asparagus racemosus have been 
shown to significantly reduce the enhanced levels of alanine transaminase, aspartate 
transaminase and alkaline phosphatase in CCI4 induced hepatic damage in rat'^ 
indicating antihepatotoxic potential of Asparagus racemosus. 
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Antineoplastic: Chloroform / methanol (1:1) extract of fresh root of Asparagus 
racemosus has been reported to reduce tumor incidence in female rats treated with 
DMBA (7,21 dimethyl benz (a) anthracene''^  
Molluscicidal: Aqueous and ethanolic extract of Asparagus racemosus exhibited a 
high mortality rate (100%) against Biomphalaria pfeifferi and Lymnaea natalensis'*'^. 
Cardiovascular effects: Alcoholic extract of the root of Asparagus racemosus has 
been reported to produce positive ionotropic and chronotropic effect on frog's heart 
with lower doses and cardiac arrest with higher doses. The extract was found to 
produce hypotension in cats which was blocked by atropine, indicating cholinergic 
mechanism of action. The extract also produces congestion and complete stasis of 
blood flow in mesenteric vessels of mice and rats. Slight increase in the bleeding 
time and no effect on clotting time was observed on I.V administration of the extract 
in rabbits^°. 
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1.2.6 Chemical Constituents: Chemical constituents isolated from 
different parts of Asparagus racemosus along with their structures 
and references are given below: 
Plant Chemical Constituents References 
Asparagus racemosus Proteins, saponins, carbohydrates, 51 
crude fibre, inorganic matter, mucilage 
quercetin, rutin, Hyperoside 52 
(1) (2) 
Glycosides of quercetin, Hyperoside, rutin 
Cyanidin-3-galactoside, 
(3) 
Cyanidin-3-glucorhamnoside 
(4) 
Diosgenin 53 
(5) 
3-0-P-D-glucopyranosyl-D-mannopyranose 54 
(6) 
D-glucose, D-mannose, Sitosterol, 55 
(7) (8) (9) 
Stigmasterol, sarsasapogenin 
(10) (11) 
Shatavarin-IV 56 
(12) 
Shatavarin-I 57 
(13) 
4,6-dihydroxy-2-0-(2'-hydroxyisobutyl) 58 
benzaldehyde 
(14) 
Undecanyl cetanoate 59 
(15) 
Asparagamine A 60 
(16) 
9,10-dihydrophenanthrene derivative 61 
(17) 
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8-methoxy-5,6,4'-trihydroxyisoflavone 62 
7-0- (J-D-glucopyranoside 
(18) 
Racemofuran 63 
(19) 
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1.3 Withania somnifera Dunal 
Withania somnifera Dunal is also known by the names Ashwagandha, Winter 
Cherry, Indian Ginseng, and Withania. Incidentally, it has been frequently called 
"Indian ginseng" a term denoting its level of respect and multiple tonic-like 
application in Ayurvedic traditional medicine. However, Ashwagandha is not related 
to true ginseng {Panax spp.) as it belongs to Solanaceae, the nightshade family, 
while Panax is in the Aralizceae family^ '*. But Ashwaganda in India is similar to 
"Ginseng" in other parts of the Orient. Both herbs are touted for their longevity 
enhancing and sexually stimulating properties, however Ashwaghanda is considered 
to be milder and less stimulating than Ginseng^^ 
Withania somnifera (Aswaganda, Indian ginseng) is widely used in Ayurvedic 
medicines and in traditional Indian medicines for 4000 years. Historically, the plant 
has been used as an aphrodisiac, liver tonic, anti-inflammatory agent, astringent, and 
more recently to treat bronchitis, asthma, ulcers, emaciation, insomnia, and 
seniledementia^*. Clinical trials and animal research support the use of Ashwaganda 
for anxiety, cognitive and neurological disorders, inflammation, and Parkinson's 
disease^ . Ashwaganda's chemopreventive properties make it a potentially useful 
adjunct for patients undergoing radiation and chemotherapy. The plant also holds a 
great promise in the treatment of cancer as adjuvant in radiation therapy^^ 
Ashwaganda is also used therapeutically as an adaptogen for patients with nervous 
exhaustion, insomnia, and debility due to stress, and as an immune stimulant in 
patients with low white blood cell counts. Recent reports have shown that the leaf 
extracts of the plant possess excellent selective COX-2 inhibitory and antioxidant 
effects '^-'o. 
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The major medicinal properties of this herb are confined to roots. The shoots and 
seeds are also used as food, and to thicken milk. Ashwaghanda is an important herb 
used in Ayurveda. The name comes from the peculiar odour of this herb, a smell 
similar to that of a sweaty horse. Methanolic or aqueous extracts of the root alone or 
in combination with other herbal materials is used in many commercial herbal 
formulation under various trade names such as Mentat, Griforte, Pepcaps, 30-plus, 
stresscom, ashwagandha-risht '^ etc. Plant extracts have also been reported to possess 
antimicrobial activity . 
1.3.1 Taxonomical Classification 
Kingdom 
Sub kingdom 
Super division 
Division 
Class 
Sub class 
Order 
Family 
Genus 
Plantae (plants) 
Tracheaobionta (vascular plant) 
Spermatophyta (seed plants) 
Magnoliophyta (flowering plants) 
Magnoliopsida (Dicotyledone) 
Asteridae 
Solanales 
Solanaceae 
Withania 
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1.3.2 Distribution 
Withania somnifera is a shrubby bush, which grows in dry arid soil of subtropical 
region. It is widespread from Southern Mediterranean area to Canary Island and to 
Southern and East Africa, covering Afghanistan, Iran, Iraq, Sudan, Egypt, Pakistan 
and Baluchistan between 600-1200 m altitude. In India plant grows well in semi 
temperate, subtropical region including states of Maharashtra and Manhasa district 
in Madhya Pradesh, which is the main cultivation zone. Rajasthan, Uttar Pradesh, 
Haryana, Himachal Pradesh and Jammu & Kashmir are also the region of 
cultivation^^ 
1.3.3 Botanical Description 
Withania somnifera grows well in sandy loam or light red soil, having pH 7.5-8.0 
with good drainage. Plants are usually erect, branched, shrubby, upto 1.25 m in 
height, leaves are simple, petiolate, elliptic-ovate to broadly ovate, entire, 
exstipulate, acute, cuneate or oblique, glabrous and upto 10 cm long. Leaves on 
vegetative shoots alternate and large; those on floral branches opposite, arranged 
somewhat laterally in pairs of one large and one small leaf, having in their axil a 
cymose cluster of 5-25 inconspicuous pale green flowers. Flowers shortly 
pedicellate, 4-6 mm in diameter. Calyx gamosepalous: enlarged and inflated in fruit; 
sepals 5-partite, persistent, lobes linear, acute. Corolla 5-lobed gamopetalous: lobes 
spreading or recurved, acute, pubescent and greenish-yellow. Stamens 5, attached 
near the base of the corolla, epipetalous; anthers oblong, dehiscing longitudinally, 
filaments linear, slender. Gynoecium syncarpous, composed of minute swollen 
ovary subtended by a long slender style; stigmas shortly 2-fid. Berry globose, 
enclosed in the green persistent calyx, 5 mm in diameter, green when unripe, orange 
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red when mature, containing numerous small, smooth, discoid seeds'"*. The various 
forms of Ashwagandha are different varieties of same species, since polymorphism 
is usual phenomena in Solanaceae'^ There is extreme degree of variability in 
Withania somnifera with respect to growth, habit and morphological characteristics 
of plants found in different parts of the India. Also the cultivated plants are 
morphologically different from wild plants not only in their thereapeutic properties 
but also in a in a variety of morphological characters. The family Solanaceae 
comprises of about 90 genera and 3000 species occurring specially in tropics. It was 
Pauquy who created the genus Withania in year (1825). Today the genus Withania 
includes 26 species of which only two occur in India. These are readily 
distinguishable as Withania somnifera and Withania coagulans '. 
1.3.4 Medicinal Uses 
Ashwagandha has been an adaptogenic tonic in India for 3000-4000 years. 
According to Ayurveda, the root is bitter, acrid, aphrodisiac, tonic, alternative and 
useful in treatment of inflammations, psoriasis, bronchitis, asthma, constipation, 
ulcers, scabies, marasmus of children, insomnia, senile debility. It is pungent, 
astringent and recommended in cough, rheumatism dropsy in sexual debility^ .^ It is 
said to work mainly on reproductive nervous system coupled with rejuvenating 
qualities'^. It is commonly used to increase vitality, recover from chronic illness and 
pain management for arthritic conditions. It also helps to control blood sugar''. It is 
a promising alternative for cancer treatment, relaxing nervine, post-partum tonic, 
immunomodulant, astringent, diuretic, thermogenic and seems to show positive 
effect on endocrine cardio and central nervous system'*'". It is the only known herb 
that can help your body to produce its own thyroid hormone^ .^ Leaves are used 
internally for fever and externally for wounds, hemorrhoids, tumors, tuberculosis 
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glands, anthrax pustules, syphilitic scores and in ophthalmitis . Fruits are used 
externally in ringworm. 
1.3.5 Pharmacology 
Wilhunia somnifera has got a wide range of applications in the treatment of 
various physiological disorders: 
Adaptogen: The traditional use of Ashwagandha as a Rasayana has been 
validated by scientific investigation*^ Wistar rats treated with an extract of 
Withania somnifera showed better stress tolerance in cold-water swimming 
tests^^ 
Anti-inflammatory: A methanol extract of the aerial parts of Withania 
somnifera had anti-inflammatory activities*^ Withania somnifera displayed 
significant anti-inflammatory activity on carrageenan-induced paw edema*''. 
Antioxidant: An aqueous suspension of root extract of Ashvaganda prevented 
the rise of experimentally induced lipid peroxidation in rabbits and mice. An 
extract of Withania somnifera, consisting of equimolar concentrations of 
withaferin A, induced an increase in the levels of superoxide dismutase, catalase 
and glutathione peroxide in rat brain, consistent with other research reports an 
antioxidant, immunomodulant and anti-inflammatory activity* .^ 
Antitumor properties: Several animal studies are suggestive of antitumor activity 
as well as enhancement of the effects of radiation by Withania somnifera^^. The 
growth inhibitory effect of Withania somnifera was observed in Sarcoma 180 (S-
180), a transplantable mouse tumor. Ethanol extract of Withania somnofera root 
(400 mg/kg and up, daily for ISdays) after intra-dermal inoculation of 5 x 105 cells 
21 
of S-180 in BALB/c mice produced complete regression of tumor after the initial 
growth. A 55% complete regression was obtained at 1000 mg/kg, however, it was 
found to be a lethal dose in some cases. Withania somnifera was also found to act as 
a radio and heat sensitizer in mouse S-180 and in Ehrlich ascites carinoma '^. 
Antistress: Several animal studies have found that Withania somnifera induces a 
state of nonspecific increased resistance to stress, as measured by an increase in the 
length of time the animals were able to exercise, reduced stress-induced increases in 
blood urea nitrogen, blood lactic acid and adrenal hypertrophy, and reduced anabolic 
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activity (promotes assimulation of nutritive matter) . 
Immunomodulatory: Laboratory studies have found that a root extract of Withania 
somnifera stimulates hemolytic antibody responses (creating an immune response in 
the red blood cells) toward human erythrocytes (red blood cells) indicating 
immunostimulatory activity* .^ 
Hemopoetic effect: Administration of extract Withania somnifera was found to 
significantly reduce leukopenia (a condition in which the number of leukocytes 
circulating in the blood is abnormally low) induced by cyclophophamide treatment 
in mice. The major activity of Withania somnifera may be the stimulation of stem 
cell proliferation^ .^ 
Rejuvenating effect: In one of the few human studies, children were given Withania 
somnifera for 60 days to test its growth-promoting effect. Hemoglobin, packed cell 
volume, mean corpuscular volume, serum iron, bodyweight, and hand grip were all 
evaluated. The findings suggest that Withania somnifera may be useful as a growth 
promoter and hemotonic (an agent that tends to stimulate blood cell formation or to 
increase the hemoglobin in the blood) in growing children^'. 
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Nervous system effects: Studies have found that a total alkaloid extract 
(ashwagandholine, AG) of Withania somnifera roots exhibited taming and mild 
depressant effects on the central nervous system of monkeys, cats, dogs, albino rats, 
and mice. The results were consistent with the use of Withania somnifera to produce 
relaxation'^ . Effects of sitoindosides VII-X and withaferin isolated from aqueous 
methanol extract of roots of cultivated varieties of Withania somnifera were studied 
on brain cholinergic, glutamatergic and GABAergic receptors in male Wistar rats'^. 
Effects on the endocrine system: Root extract of Withania somnifera were given 
mice (1.4 gm/kg by gavage, daily for 20 days). The treatment significantly increased 
the serum levels of 3, 3',5-triiodothyronine (T3) and tetraiodothyronine (T4), while 
the heptic concentrations of glucose 6-phosphatase activity and hepatic iodothronine 
5'-monodeiodinase activity did not change significantly. Withania somnifera 
significantly reduced hepatic lipid peroxidation and increased the activity of 
superoxide dismutase and catalase. The results suggest Withania somnifera throidal 
activity and also promotes hepatic antioxidant activity '^'. 
Effects on the cardiopulmonary system: The pharmacological actions of the total 
extract of Withania somnifera roots on the cardiovascular and respiratory systems 
appeared to be due to its alkaloid content. The total alkaloids were found to be more 
than twice as active as the 70-percent alcohol extract of Withania somnifera root. 
These studies were found to be consistent with the use of Withania somnifera as a 
tranquilizing agent'"\ 
Antibacterial activity: Aqueous as well as alcoholic extracts of Withania somnifera 
(roots as well as leaves) were found to possesses strong antibacterial activity against 
a range of bacteria as revealed by in vitro agar well diffusion method'^ . 
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1.3.6 Chemical Constituents: Chemical constituents isolated from 
different parts of Withania somnifera along with their structures and 
references are given below: 
Plant Chemical Constituents References 
Withenia Somnifera Nicotine, Somniferine, Somniferinine, 97 
Somnine, Withanine, Pseudo-withanine, 
Withananinine 
Tropine, Pseudotropine, 98 
(20) 
dl-isopelletierine, Anaferine, Anahygrine 99 
(21) (22) (23) 
Cuscohygrine, 3-Tropyl tigloate 100 
(24) (25) 
Withasomnine 101 
(26) 
Visamine 102 
Withaferin 103 
(27) 
Withaferin A, Withanolide D 104 
(28) (29) 
4p-hydroxy-l-0X0-5p, 6p-epoxy 
witha-2,24-dienolide. 
(30) 
4P-20a (R) dihydroxy-1-0X0-5p, 6p-epoxy-
with-2-enolide. 
(31) 
5 and 4p-hydroxy-l-oxo-5p, 6p-epoxy-
with-2-enolide. 
(32) 
Dihydrowithaferin A 105 
(33) 
27-desoxy-14a-hydroxy-withaferin A 106 
(34) 
27-deoxywithaferin A, 107 
(35) 
27-deoxy-17 a- hydroxyl-withaferin A 
(36) 
Withanolide N, Withanolide O, Withanolide P 
(37) (38) (39) 
27-hydroxywithanolide D 
(40) 
14a-hydroxywithanolide, 17a-hydroxywithanolide 
(41) (42) 
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Withanolide E, Withanolide F, Withanolide S 108 
(43) (44) (45) 
Withanolide G, Withanolide H,Withanolide I 109 
(46) (47) (48) 
Withanolide J, Withanolide K, Withanolide L 
(49) (50) (51) 
Withanolide M 
(52) 
la, 3p, 20aF, 27-trihydroxy-20R, 22R-witha- 110 
5-24-dienolide. 
(53) 
1-0X0-14, 20aF,27-trihydroxy-20R, 22R-witha-
3,5,24-trienoUde. 
(54) 
5a-ethoxy-l-oxo-6|3-14a, 17p, 20aF-tetra 
hydroxy-20S, 22R-with a-2, 24-dienolide. 
(55) 
A"^ withanolide 111 
(56) 
17-Isowithanolide E 112 
(57) 
Withanolide C 113 
(58) 
Wilhanonc, 5a, 17a-dihydroxy-l-oxo- 114 
(59) 22R-with a-2,6,24-trienolide. 
(60) 
5a, 27-dihydroxy-1 -oxo-6a,7a-epoxy 
-22R-with a-2,24-dienolide. 
(61) 
4p, 17a-dihydroxy-l-0X0-5p, 6P-epoxy-22R-
witha-2, 24-dienolide. 
(62) 
17a, 27-dihydroxy-l-oxo-22R-with a-2,5, 
24-trienolide. 
(63) 
7a, 27-dihydroxy-l-oxo-22R-with a-2, 5, 
24-trienolide. 
(64) 
4p-hydroxy-5p, 6P-epoxy-l -oxo-22R-witha-
2,14-24-trienolide. 
(65) 
la, 3P, 5a-trihydroxy-6a, 7a-epoxy, 22R-with-
24-enolide 
(66) 
3a-methoxy-2, 3-dihydro-27-deoxywithaferin A 115 
Withanolide Q, Withanolide R 116 
(67) (68) 
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Withanolide T, Withanolide U 117 
(69) (70) 
14P- hydroxywithanone, 14a- hydroxywithanone 118 
(71) 
2,4,6-trien-1 -one, 6P-7P-Epoxywithanone 
(72) (73) 
Withanolide Y 119 
(74) 
6a-chloro-4p, 5p, 20aF-trihydroxy-1 -oxo-22R- 120 
witha-2, 24-dienolide 
(75) 
4p, 20a-dihydroxy-1 -oxo-5 p, 6p-epoxy-20R, 22R- 121 
witha-24-enolide. 
(76) 
20a-hydroxy-l, 4-dioxo-5p, 6p-epoxy-20R, 22R-
witha-2-enolide. 
(77) 
5-Dehydroxywithanolide R, Withasomniferin A 122 
(78) (79) 
Sominone, Sominolide 123 
(80) (81) 
Withasomidienone 124 
(82) 
14,17,20-trihydroxy-5P, 6P-epoxy-l-oxo-witha- 125 
2,24-dienolide. 
4, 14,17,20-terahydroxy-5p, 6P-epoxy-l-oxo-witha-
2, 24-dienolide. 
Dihydroxyoxowithatetraenolide 126 
(83) 
5, 20a (R)-dihydroxy-6a, 7a -epoxy-1 -oxo- 127 
(5a)-with a-2,24-dienolide 
(84) 
Lycium substance B, Withasomniferol A 128 
(85) (86) 
Withasomniferol B, Withasomniferol C 
(87) (88) 
Withanolide-WS I 129 
(89) 
Sitoindoside VII, Sitoindoside VIII 130 
(90) (91) 
Stoindoside IX, Sitoindoside X 131 
(92) (93) 
6, 8-dihydroxykaempferol, 3-0- 132 
rutinoside 
(94) 
Quercetin, Quercetin, 3-0-rutinoside 
(1) (95) 
3 -O-rutinoside-7-O-glucoside 
(96) 
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Quinic acid, 4-0-caffeoylquinic acid 
(97) (98) 
4, 5-0-dicaffeoylquinic acid 
(99) 
Sitosterol, Stigmasterol 133 
(9) (10) 
Campesterol, 24-ethylidene cholesterol 
(100) (101) 
24-Methylene cholesterol 
(102) 
28-Isofucosterol, 
(103) 
24-Methylcholesta-5,24(25)-Dien-3p-ol 
(104) 
WS-1 (Long chain aliphatic ketone), 134 
WS-2 (Long chain of aliphatic ester) 
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CHAPTER 2 
Chemical Investigation of 
Asparagus racemosus Willd and 
Withania somnifera Dunal 
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2.1 Object of the present study 
Significant research has been done to explore the healing potential of extracts from 
Asparagus racemosus and Withania somnifera. Research indicates that extracts from 
Asparagus racemosus and Withania somnifera have anticancer'' antioxytocic , 
immunomodulatory'*'^ , antiulcerogenic ,^ antioxidant^ *'', antistress', anti-inflammatory'°, 
antibacterial"''^, galactogogue'^ , adaptogenic''*"'^ , antitiussive'^, antiprotozoal'^ , 
molluscicidal , activities, no adverse effects due to the use of the root powder of these 
plants have been reported and the plants are also consumed as food. The majority of 
compound isolated from Asparagus racemosus are terpenoids, steroids and saponins 
whereas from Withania somnifera are alkaloids, steroidal lactones and iron. Continued 
research on these plants may result in the isolation of novel compounds with important 
medicinal properties. 
In the present study, chemical investigation on Asparagus racemosus and Withania 
somnifera has been carried out and are detailed in Part 2.2 and Part 2.3. 
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2.2 Isolation and structure elucidation of the constituents of Asparagus 
racemosus Willd (Family Asparagaceae) 
The Ayurvedic crude drug, Shatavari of commerce comprises of dried decorticated 
roots of Asparagus racemosus Willd'^ . Several therapeutic attributes have been 
mentioned, in the classical Ayurvedic literature for this drug, to mention a few, it is 
useful in cases of threatened abortion and as a galactogogue^*'"^ ', as a powerful 
Rasayana drug capable of improving memory, intelligence, physical strength and 
maintaining youthfulness and as a reputed drug for diseases caused by the morbidity 
of Vata, Pita and Kapha^ .^ The volatiles of Asparagus racemosus showed excellent 
inhibition of spore germination in some of the fungi . Chemical constituents 
reported from the plant material include steroidal glycosides^ "*, a novel polycyclic 
cage type pyrrolizidine alkaloid, asparagamine A^ ^ and a 9,10-dihydro-
phenanthrene^^ derivative. 
In the present work, phytochemical investigation on ethyl acetate and n- butanol 
extracts of the roots of the plant have resulted in the isolation and characterization of 
three compounds, two of which have been established to be new to the literature and 
third one, is a known compound. 
The two new compounds which have been designated as AR-I and AR-II and 
identified as 2,3,6-trihydroxy-18-nor (25S) spirostan-4-ene,21-oic acid and 3-0-[ a-
L-rhamnopyranosl- (1 ->2)a-L-rhamnopyranosyl(l ^4)-0-p-glucopyranosyl]25(S)-
spirostan-3p-ol respectively. The known compound designated as AR-III is 
identified as shatavarin IV. 
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Air-dried plant material (4.0 Kg) of Asparagus racemosus was ground to a coarse 
powder. The coarse powder was extracted with ethyl acetate in a Soxhlet apparatus 
for 48 hrs .The extract was freed from solvent on a wiped film evaporator at 50 ± 5 
°C to get EtOAc extract residue (12 gm) .The marc was then extracted with 
deionised water at 98 °C for 2 hrs. Extraction process was repeated thrice using total 
water (28+16+16 L, three extractions) in 1:15 ratio w/v with respect to the plant 
material. The pooled aqueous extract was centrifliged, clear supernatant was 
evaporated to dryness on a wiped film evaporator at 50 ± 5 °C, residue (1.48 Kg). 
The crude extracts were screened for immunomodulatory activity, when marked 
activity was found to be concentrated in the aqueous extract, and this was fiirther 
fractionated to identify the bioactive fraction. The aqueous extract (1.48 Kg) was 
dissolved in deionized water (8.0 L) and the resulting solution was extracted with 
CHCI3, EtOAc and n-BuOH (6 x 2 L each) successively. CHCI3 and EtOAc 
fractions residue were 0.8 and 1.2 gm respectively whereas n-BuOH fraction residue 
(160 gm) was found to be rich in quantity and chemical composition. It showed 
significant immunomodulatory activity. 
Thin layer chromatography of ethyl acetate extract and n-butanol fraction in various 
solvent systems revealed the presence of a number of constituents. Both the extracts 
were subjected to column chromatography individually. Different solvent mixtures 
with increasing polarity were used for elution of the columns. Repeated column 
chromatography of resulting fractions from previous columns followed by 
crystallization resulted in the isolation of pure constituents. The isolation procedure 
and characterization data of each isolate has been discussed separately. 
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Section A 
2.2A.1: Structure determination of AR-I as 2,3,6-trihydroxy-18-nor (25S) 
spirostan-4-ene, 21-oic acid. A new compound from Asparagus 
racemosus. 
AR-I was isolated from CHCI3: MeOH (95:5, v/v) fraction by the column 
chromatography of the ethyl acetate extract of^ Asparagus racemosus over silica gel. 
It was crystallized from ethyl acetate as a colourless crystals. m.p.l99 °C, [a]p^ 
.11.9° (c 0.0009, MeOH). 
The FABMS spectrum of AR-I gave a [M+Na]^  ion at m/z 485 and [M+H]*at 463 
indicating its molecular weight to be 462 and suggested the molecular composition 
to be C26H38O7, in combination with its elemental analysis as indicated by its high 
resolution FABMS, where [M+H]"*" showed m/z 463.2707 which corresponds to 
C26H39O7. 
IR(KBr)) spectrum of AR-I displayed a band at 3500-3300 cm"' which suggested the 
presence of hydroxyl groups, a band at 2850-1710 cm'' for carbonyl group and 
characteristic absorption bands for (25S)-spiroketal^ ^ at 919 and 896 cm'' with the 
absorption at 919 cm"' being of greater intensity then 896 cm"'. In addition 25(S)-
spiroketal skeleton of a sarsasapogenin AR-I was also suggested by the occurrence 
of typical C-22 resonance at 5 109.10 in '^ C NMR spectrum. 
The 'H NMR spectrum (500 MHz, pyridine-ds) of AR-I showed (Table 1) protons 
signals attributed to C-27 and C-19 methyl groups at 5 0.68 (d, 3H, J = 6.41 Hz) and 
6 1.03 (s, 3H) respectively. Absence of proton signal between 6 0.68 and 0.91 
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indicated clearly the absence of C-18 methyl which is further supported by the '"'C 
NMR. 
The '•*€ NMR spectrum (125 MHz, pyridine-ds) of AR-I, a total of 26 absorptions 
signals (Table 1) were recorded in CPD (complete proton decoupled) spectrum. In 
DEPT 45 and DEPT 135 a total of 22 absorptions were recorded. The DEPT, HSQC 
and HMBC spectra indicated the presence of two methyl, eight methylene and 
twelve methine .The rest were assigned to quaternary carbons. The resonance 
frequency indicated that all the carbon atoms except three are in the state of sp 
hybridisation. 
The compound on acetylation at room temperature yielded triacetate (AR-Ia), 
suggesting the presence of three hydroxyl group. The triacetate on further 
esterification with MeOH and a drop of sulphuric acid resulted in the formation of 
ester (AR-Ib) suggesting the presence of carboxylic group. This was also supported 
by the occurrence of resonance in '^ C NMR at 6 175.13 (acid carbonyl). 
The downfield value due to double bond at 5 123.01 and 5 142.95 in '^ C NMR 
suggested that the double bond can be assigned a position where it is allylic to two 
hydroxyls the geminal protons of which appear exceptionally downfield at 5.00 and 
5.06 in 'H NMR, Biosynthetically presence of hydroxyl at position three cannot be 
ruled out , so keeping in view the '•'C NMR resonance for double bond, the other 
hydroxyl can only be placed at position 6. Out of three hydroxyls, one is vicinal 
because the compound readily forms an acetonide (AR-Ic) whereas it does not form 
lactone suggesting that none of the hydroxyl is in the vicinity of C-21 carboxylic 
acid. Based on the above data, the structure of Compound AR-I, was established as 
2,3,6- trihydroxy-18-nor (25S) spirostan-4-ene, 21-oic acid, a new chemical entity . 
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Table 1: 'H- *^C- NMR data of 2,3,6 trihydroxy-18-nor (25S) spirostan-4-ene 
21-oic acid (5values: 500MHz, 125 MHz pyridine-ds, TMS as internal 
standards). 
C ''C(5) 'H(8)* C ''€(5) 'mr C ''C(5) 'H(5)* 
1 37.23 10 20.84 19 17.33 1.03 s 
2 74.58 11 23.57 20 41.21 
3 69.73 5.00 m 12 39.94 21 175.13 
4 123.01 13 37.64 22 109.10 
5 142.95 14 58.96 23 32.76 
6 72.52 5.06 d 15 34.70 24 29.33 
(J = 2.44 Hz) 
7 34.25 16 83.19 25 30.8 
8 30.50 17 54.16 26 67.24 
9 54.64 27 15.17 0.68 d 
(J = 6.41Hz) 
* 'H NMR of sp^  methylene and methine proton appears as overlapped envelope 
between 61.5- 2.2 (complete 'H NMR values are given in section 2.2B.3, Page No. 
82-83). 
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Acetylation of compound AR-I 
Acetylation of AR-I with AC2O-C5H5N by heating on a steam bath for 2 hrs under 
anhydrous conditions gave a triacetate, AR-Ia, m.p. 158-159 "C. The [M+H]^ in MS 
at m/z 588 and elemental analysis established its molecular formula as C32H44O10, 
Moreover in 'H N M R (CDCI3) signal at 6 3.54, 5.00, 5.06 due to proton at C-2, C-3 
and C-6 got shifted at 5 4.54, 5.38 and 5.63 respectively. 
The 'H NMR (200.13 MHz, CDCI3), along with assignments of AR-Ia are tabulated 
in Table 2 . 
Table 2: ' H NMR (200.13 MHz, CDCI3) data of AR-la 
Chemical shift No. of Multiplicity J-value Proton 
(6-ppm) protons assignment 
6.41Hz C-27, -CH3 
C-19, -CH3 
C-2 , OCOCH3 
C-3,OCOCH3 
C-6,OCOCH3 
Proton a to C - 2 
Proton a to C - 3 
Proton a to C - 6 
0.68 
1.03 
2.03 
2.07 
2.09 
4.54 
5.38 
5.63 
3 
3 
3 
3 
3 
1 
1 
1 
d 
s 
s 
s 
s 
br.s 
br.s 
br.s 
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Methylation of AR-Ia 
AR-Ia on methylating with ethereal solution of diazomethane yielded AR-Ib, m.p. 
117-118 °C. The [M+ H]* in MS at m/z 602 and elemental analysis established its 
molecular formula as C33H46O10. 
IR(KBr) spectrum of AR-Ib showed absorption at 1730 cm"' indicating the presence 
of an ester function and in '•'C NMR signal due to acid carbonyl at 6 175.13 got 
shifted to 6 169.22. 
Acetonide of AR-I 
AR-I on treatment with dry Me2C0 and two drops of HCl at room temperature for 
24 hrs yielded AR-Ic gummy, which could not be crystallised. The [M+H]"^  in MS at 
m/z 590 and elemental analysis established its molecular formula as C29H42O7. 
Formation of acetonide clearly indicates that two out of three hydroxyls are vicinal. 
Probable mass fragmentation of AR-I is given in chart I. 
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HoCOCO 
H,COCO 
HOOC 
OCOCH, 
AR- I AR-la 
OCOCH, 
AR-lb AR-lc 
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Chart I: Probable mass fragmentation of AR-I 
m/z 382 m/z 390 
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2.2A.2: Structure determination of AR-II as 3-0-[a-L-rhamnopyranosyl 
(1 ->2)-a-L-rhamnopyranosyl-(I ->4)-0-P-D-glucopyranosyl]-25(S)-
spirostan -3P-ol. A new saponin from Asparagus racemosus Willd. 
AR-II was isolated from CHCI3: MeOH (19:l,v/v) fractions by the column 
chromatography of the n-BuOH extract of Asparagus racemosus over silica gel. It 
was crystallized from MeOH as amorphous powder, which responded positively to 
Liebermann-Burchard^^ Molisch's tests^ "^^ ", m.p.275 °C, [a]^-90.2° (c 0.50, 
pyridine). 
Compound AR-II was hydrolysed with acid to afford glucose, rhamnose and an 
aglycone which was established as sarsasapogenin. Elemental analysis and FAB 
mass spectrum of AR-II gave a [M+Na]^  ion at m/z 893 and [M+H]"^  at m/z 871 
indicating its molecular weight to be 870 and suggested the molecular composition 
as C45H74O16. 
IR(KBr) AR-II spectrum of displayed a band at 3400-3350 cm"' which suggested the 
presence of hydroxyl groups and characteristic absorption bands for (25S)-
spiroketal^ ^ at 919 and 896 cm'' with the absorption at 919 cm"' being of greater 
intensity than at 896 cm'. In additions, 25(S)-spirostane skelton of AR-II was also 
suggested by the occurrence of C-22 resonance at 5 109.85 in '^ C NMR spectrum. 
The 'H NMR spectrum (200.13 MHz, pyridine-ds) of AR-II showed (Table 3) 
protons signals attributed to the C-18 and C-19 methyl groups at 0.77 and 0.98, the 
C-21 and C-27 methyls at 1.01 (3H, d, J = 6.0 Hz) and 1.09 (3H, d, J = 7.2 Hz), 
three anomeric proton signals at 4.87 (IH, d, J = 7.7 Hz), 5.73 (IH, br.s and 6.40 
(lH,br.s). 
In '^ C NMR spectrum (50.32 MHz, pyridine-ds) of AR-II, a total of 45 absorptions 
signals (Table 3) were recorded in CPD spectrum. In DEPT 45 and DEFT 135 a 
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total of 41 absorptions signals were recorded. The DEPT, HSQC and HMBC spectra 
indicated the presence of six methyl, twelve methylene and twenty three methine 
The rest were assigned to quaternary carbons. The resonance frequency indicated 
that all the carbon atoms are in the state of sp^  hybridisation. Out of twenty three 
methine, three anomeric C-atoms at 6 101.60, 102.23 and 103.01 indicating that 
AR- II contained one glucosyl and two rhamnosyl units in the oligosaccharide 
function. The anomeric configuration of the glucosyl unit was indicated to be p 
based on Ji, 2 (7.7 Hz). The anomeric configuration of two rhamnosyl tmits was 
assigned as a based on their C-5 chemcial shifts at 5 69.52 and 70.57 respectively '^. 
A comparison of '"'C chemical shifts of the sugar units with those reported for 
methyl glucopyranosides"", revealed glycosylation shifts by 6 + 4.66 for C-2 and + 
5.80 for C-4 of glucose unit thus indicating the presence of one 2,4-disubstituted 
glucose unit. These data indicated that 2-rhamnose units are linked to glucose 
moiety at position 2 and 4. Further proof to the site of interlinkage amongst sugar 
units and the sapogenin was provided by the hydrolysis of permethylated compound 
AR-II. Acid catalysed hydrolysis of permethylated compound AR-II yielded 3,6-di-
0-methyl glucopyranoside and 2,3,4-tri-O- methyl rhamnose. This established 
linkage of two a-L-rhamnose units to glucosyl moiety as l->2 and 1-^4. Based on 
the above data, the structure of Compound AR-II, was established as 3-0-[a -L-
rhamnopyranosyl-( 1->2)-a-L-rhamnopyranosyl-( 1->4)-0-P-glucopyranosyl]-25(S)-
spirostan-3P-ol, a new chemical entity. Shvets et al. isolated neotigogenin''^  (3P, 5a, 
25S) derivative and characterised as 3-0-[a-L-rhamnopyranosyl-(l-^2)-a-L-
rhamnopyranosyl-(1^4)-0-p-D-glucopyranosyl]-25(S)-5a-spirostan-3p-ol 
whereas compound is derivative of sarasasapogenin (3p, 5p, 25S). 
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Table 3: *H-"C-NMR data of 3-0-Ia-L-rhamnopyranosyl-(l->2)-a-L-
rhamno- pyranosyl-(l-»4)-0-P-gluco-pyranosyll-25(S)-spirostan-3P-
ol (6values: 200.13 MHz, 50.32 MHz, pyridine-ds, TMS as internal 
standards). 
c 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
1 
2 
3 
4 
5 
6 
'•'C(5) 
31.13 
27.71 
63.03 
32.35 
37.32 
26.60 
27.00 
35.81 
40.60 
'H(5)* 
3.84 m 
Glue (sugar) 
101.60 
79.46 
78.30 
77.20 
76.79 
61.65 
4:87 d 
(7.7) 
4.28 
4.23 
4.40 
3.68 
4.09 
4.24 
C 
10 
11 
12 
13 
14 
15 
16 
17 
18 
''C(5) 
35.49 
21.40 
32.35 
41.18 
56.86 
40.69 
81.59 
60.79 
16.94 
Rhm^ 
'H(5)* 
4.40 q 
(7.1) 
0.77 s 
(Sugar) 
102.23 6.40 (br.s) 
72.22 
72.60 
73.81 
69.52 
18.60 
4.86 
4.68 
4.36 
4.97 
1.72 
C 
19 
20 
21 
22 
23 
24 
25 
26 
27 
''C(6) 
24.05 
42.70 
15.12 
109.85 
27.0 
26.39 
27.0 
65.42 
' H ( 5 ) * 
0.98 s 
1.01 d 
(6.0) 
3.39bd,3.58 dd 
(11.0)(11.0&2.0) 
16.58 
Rhm" 
103.01 
72.43 
72.70 
73.97 
70.57 
18.80 
1.09 d 
(7.2) 
(Sugar) 
5.73 (br.s) 
4.70 
4.62 
4.34 
4.95 
1.59 
Glue = P-D-glucopyranosyl; Rhm^ = a-L-rhmanopyranosyl connected with 2-position of 
glu; Rhm*= a-L-rhamnopyranosyl connected with 4-position of glue. 
* H signal of sp' methylenes and methines appeared as a broad envelope (singal), between 
1.5-2.2 
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Acidic hydrolysis of AR-II 
Compound AR-II on acidic hydrolysis with methanolic H2SO4 and dioxane, under 
nitrogen reflux for 4 hrs, resulted in the formation of an aglycone AR-IIa. m.p 199-
200 °C (lit '^.m.p.200 °C) and a mixture of two sugars identified as D-glucose and L-
rhamnose by paper chromatography (BuOH: AcOH: H2O; 4: 1: 5, v/v) by 
comparison with reference sugar samples. 
The molecular ion peak at m/z in mass spectrum and elemental analysis of the 
aglycone suggested its molecular formula as C27H48O8. 
IR(KBr) spectrum of AR-IIb exhibited strong absorption at 3400 cm"' (-0H), 1065 
cm''(-CO), 910,892 and 847 cm"'(spiroketal), 
Permethylation and hydrolysis of AR-II 
Compound AR-II on permethylation with methyl iodide in presence of NaH and 
DMSO by Hakomori method'''' and subsequent hydrolysis yielded a mixture of 
methylated sugars and a compound AR-IIb. m.p 199-200 "C (lit '^.m.p.200 °C). From 
IR and 'H N M R spectra, this compound has been identified as sarsasapo-genin. 
Compound AR-IIb has been found identical with in AR-IIa in respect of co-TLC, 
m.p, m.m.p. and spectral data. These data lead to the determination of the position 
sugar moiety in AR- II at C-3. 
The reaction mixture containing methylated sugars was neutralised by passing 
through ion exchange resin (OH) column. The column chromatography of the 
neutralised mixture over silca gel yielded two methylated sugars, 3,6-di-O-methyl 
glucopyranoside and 2,3,4-tri-O-methyl rhamnopyranoside in the 1:2 molar ratio. 
This established linkage of two a-L-rhamnose units to glucosyl moiety as l->2 and 
1^4. Probable mass fragmentation of AR-II is given in Chart II. 
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AR-II 
Acidic 
hydrolysis 
AR-lla 
Me 
HO 
HO 
0 OH 
HO 
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MeO 
MeO 
MeO 
OMe 
AR-II b 
Acidic 
hydrolysis 
AR-II 0 
iVIeO 
MeO 
Me 
O OH 
MeO 
HO 
MeO 
CHjOMe 
HO 
Chart II: Probable mass fragmentation pattern of AR-II 
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Me 
H O ^ ^ O H \ 
HO 
Me 
m/z 578 
74 
m/z 417 
[(M+H)* - 472] 
m/z 398 
[(M+H)^  - 542] 
m/z 329 
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2.2A.3 Structure determination of AR-III as 3-0-[a-L-rhamnopyranosyl-
(l-^2)-p-D-glucopyranosyl(l->4)-0-p-D-glucopyranosyl]-25(S)-
spirostan -3p-ol from Asparagus racemosus Willd. 
AR-III was isolated from CHCI3: MeOH (85:15,v/v) fractions by the column 
chromatography of the n-BuOH extract oi Asparagus racemosus over silica gel. It 
[ l O 1 
" • I D 
-68.6° (cl.0%, pyridine). 
Elemental analysis and FAB-MS spectrum of AR-III gave a [M+Na]"^  ion at 909 and 
[M+H]"^  at m/z 887 indicating its molecular weight as 886, and suggested the 
molecular composition as C45H74O17. 
The IR (KBr) spectrum of compound AR-III displayed a band at 3450-3500 cm'' 
which suggested the presence of hydroxyl groups and bands at 990, 925, 900 and 
855 cm"' expected to be spirostanol^ ,^ indicating that the spirostanol structure is a 
primary saponin and does not arise from a secondary cyclization of a furastanol 
during acid hydrolysis. Furthermore, since the 925 cm'' absorption is more intense 
than that at 900 cm''. 
The 'H NMR and '^ C NMR data (Table 4) of compound AR-III well compared with 
the reported data of a known compound Shatavarin IV '^*. The identity of the 
compound AR-III was further supported by the MS, optical rotation, m.p. and IR 
data which were in agreement with the literature values '^'. 
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R20 
CH,OH 
I'll,I H 
R'= a-L-rhm (pyr) 
R^=p-D-gluc(pyr) 
AR-III 
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Table 4: ' H - * ' C - N M R data of 3-0-[a-L-rhamnopyranosyl-(1^2)-p-D-gIuco-
pyranosyl(l->4)-0-P-D-glucopyranosyl]-25(S)-spirostan-3p-oI 
(6values:200.13 MHz, 50.32 MHz, pyridine-ds, TMS as internal 
standards) 
c 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
1 
2 
3 
4 
5 
6 
"'C(5) 
32.10 
28.45 
64.49 
(6.0) 
32.32 
37.01 
26.13 
28.53 
32.61 
41.72 
Glue 
'H(5)* 
2.97 m 
(sugar) 
101.284:07d 
76.19 
74.39 
69.78 
65.74 
61.45 
(7.7) 
3.66 
3.02 
3.85 
3.3S 
4.02 
4.00 
C 
10 
11 
\2 
13 
14 
15 
16 
17 
18 
•'C(5) 
36.49 
21.30 
34.16 
45.12 
55.31 
37.19 
72.29 
62.13 
15.43 
Rhm^ 
95.98 
73.21 
72.54 
67.31 
59.81 
17.91 
'H(6)* 
3.73 q 
(7.1) 
0.64 s 
(Sugar) 
5.90(br.s) 
4.46 
3.79 
3.68 
4.57 
1.52 
C 
19 
20 
21 
22 
23 
24 
25 
26 
27 
"C(6) 
20.13 
39.90 
14.12 
111.17 
28.01 
25.91 
27.02 
65.39 
'H (6)* 
1.06 s 
1.04 d 
3.32bd,3.13dd 
(10.0)(10.0&2.0) 
15.91 
Glue' 
97.54 
75.12 
70.01 
74.12 
69.59 
62.13 
1.09 d 
(7.2) 
(sugar) 
4.03 (br.s) 
3.63 
2.98 
3.74 
3.24 
3.93 
4.02 
Glue = P-D-glucopyranosyl; Glue'' = P-D-glucopyranosyl connected with 4-position of 
glue; Rhm = a-L-rhamnopyranosyl connected with 2-position of glucr-^r 'A^ri, ; 
* H signal of sp methylenes and methines appeared as a broad epv l^epe-(signal)7l5Slwe6^ 
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2.2A.4 Bioevaluation 
The immunophararmacological evaluation of aqueous extract of Asparagus 
racemosus has shown a highly significant immunorestorative activity in different 
doses (25-200 mg/kg p.o. x 5 days) against specific antigen SRBC with optimum 
immunostimulatory response being achieved at (100 mg/kg x 5 days) in 
immunocompromised (cyclophosphamide) treated animals (Humoral antibody 
synthesis and delayed type hypersensitivity reaction DTH)'' . Strong 
immunorestorative activity of aqueous extract has been accounted for by pure 
chemical entities i.e., AR-II and AR-III isolated. The sarasasopagenin glycoside AR-
11 revealed significant immunostimulatory activity, whereas sarasasopagenin 
glycoside AR-lII showed significant immunomodulatory activity on immune 
response in experimental animals (both Humoral as well as Cell -mediated) against 
specific T-dependent antigen in immune compromised animals in doses (0.0062 to 
0.0125 mg/kg) and (0.037 to 0.30 mg/kg) respectively corresponding to their 
concentrations in the extract. AR-III (0.15 mg/kg) elicited optimum response on 
both the limbs responsible in the regulation of immune system (Table 5). 
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Table 5: Effect of Aqueous Extract of Asparagus racemosus , AR-II and AR-
III. on Humoral and Cell mediated immune response in 
Immunocompromised mice 
Treatment 
Normal control 
Cyclophosphamide 
CY 
LEV 
Aq. Extract+ CY 
Aq. Extract+ CY 
Aq. Extract+ CY 
AR-II+ CY 
AR-II+ CY 
AR-III + CY 
AR-III + CY 
AR-III + CY 
AR-III + CY 
Dose 
mg/kg p.o. 
-
250 
2.5 
50 
100 
200 
0.0006 
0.0125 
0.0375 
0.075 
0.15 
0.30 
Antibody 
Titre 
Mean+ S.E. 
6.50±0.50 
3.60±0.21 
7.01±0.22 
5.5±0.26 
7.5±0.26 
8.0±0.26 
5.60+0.33 
6.41±0.16 
8.50±0.34 
8.6010.21 
6.8010.16 
5.7010.28 
% Change 
compared to 
control 
-
45* i 
go** 'J^  
48** t 
102*** t 
116*** t 
56*** t 
78 *** t 
131 *** t 
J34 *** f 
85 **t 
55**t 
DTH 
Mean! 
S.E. 
0.78+0.04 
0.6810.22 
1.80+0.24 
1.610.15 
1.810.37 
1.710.33 
0.8010.14 
0.9110.42 
1.1610.17 
1.2410.17 
1.2610.04 
0.9310.05 
% 
Change 
compared 
to control 
-
21*1 
130**1 
100** t 
125*** t 
112*** t 
48**t 
76**t 
48**t 
76**t 
85**t 
36**t 
Lev : Levamisole ; DTH : Delayed type hypersensitivity 
Number of observations = 12 
*p < 0.05, **P<0.01, ***P<0.001 
Treatment Schedule 
0 day = Sensitization with 0.2 mL of 5 x 10^  SRBC/mL i.p. 
0-4 day = Drug treatment 
4 day = Challenge with 20 |al of 5 x 10^  SRBC/mL into right hind foot pad for 
DTH reaction only. 
5 day = Measurement of foot thickness/Haemagglutination antibody 
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Section 6 
2.2B Experimental 
2.2B,1 General 
Melting points were determined with a Buchi melting point apparatus (Model B-
545) and are uncorrected. Infrared spectra were obtained on a Hitachi 270-30 
spectrophotometer in KBr pellets. 'HNMR (200.13 MHz), '^ CNMR (50.32 MHz) 
and 2D NMR spectra were determined on a Bruker DPX-200 and Bruker DPX-500 
spectrometers. Chemical shifts are shown in 6 values (ppm) with tetramethylsilane 
(TMS) as an internal reference. FAB-MS was recorded on a JEOL SX 102/DA-6000 
mass spectrometer. Optical rotation was obtained on a Perkin Elmer 241 
polarimeter. Elemental analytical data was recorded on Carlo Erba, Model 1106, 
elemental analyzer. Column chromatography was carried out using SiOi gel (60-120 
mesh, Merck). Spots on TLC were visualised by spraying with 1% cerricammonium 
sulphate in 30% aqueous H2SO4 followed by heating the plate at 105 "C for 15 min. 
2.2B.2 Plant material 
Asparagus racemosus Willd (Liliaceae) was supplied by Zandu Pharmaceutical Ltd. 
Bombay. A voucher specimen (RJM/0001) is deposited in the herbarium of 
Regional Research Laboratory, Jammu (RRL, J). 
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2.2B.3 Extraction, fractionation and isolation procedure 
The air dried (under shade) roots of Asparagus racemosus (4.0 Kg) were powdered 
and defatted by continuous extraction with ethyl acetate in a Soxhlet for 48 hrs. The 
defatted roots were extracted thrice with deionised water at 98 °C for 6 hrs. 
The ethyl acetate and aqueous extract were concentrated by distillation under 
reduced pressure and finally vacuum dried. The crude extracts were also screened 
for immunomodulatory activity, marked activity was found to be present in the 
aqueous extract, and this was further fractionated to identify the bioactive fraction. 
A portion of the aqueous extract (1.48 Kg) was dissolved in deionized water (8.0 L) 
and the resulting solution was extracted with CHCI3, EtOAc and n-BuOH (6 x 2 L 
each) successively. CHCI3 and EtOAc fractions were 0.8 and 1.2 gm respectively 
whereas n-BuOH fraction residue (160 gm) found to be rich in quantity, chemical 
composition and showed significant immunomodulatory activity and was therefore 
subjected to further chemical investigation. 
Portions of both the ethyl acetate extract (12 gm) and n-BuOH fraction (150 gm) 
were subjected to column chromatography over silica gel. The columns were eluted 
with solvents of increasing polarity in different proportions. Each fraction of 200 mL 
was collected and elutes were monitored on TLC. Fractions showing identical TLC 
pattern were pooled as details given in the (Table 6). 
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Table 6: Fractions eluted from roots of Asparagus racentosus. 
Fraction No Eluent Fractions Extract/ Fraction 
48-64 
35-54 
74-84 
CHClj -.MeOH 
95 : 5 
CHCI3: MeOH 
95 : 5 
CHCI3 :MeOH 
85 : 15 
Fraction A 
Fraction B 
Fraction C 
Ethyl acetate extract 
n-Butanol fraction 
n-Butanol fraction 
Isolation and identification of A R - I 
Fraction A: This fraction sliowed a number of spots on TLC (CHCI3: MeOH; 
19: 1, v/v) with one spot as the major one. It was subjected to column 
chromatography over siHca gel and eluted successively with CHCI3, CHCI3: MeOH. 
Each fraction of 50 mL was collected. Elution with CHCI3: MeOH; 19: 1, v/v 
(fractions 48-64 on concentration under reduced pressure and repeated 
crystallization from EtOAc) yielded a colourless crystalline compound, 
homogeneous on TLC. This compound was designated as AR-I, m.p.l99 °C, \af^ 
.11.9° (c 0.0009, MeOH). [M+H]" in MS at m/z 463, Found: C, 67.51; H, 8.28% 
calculated for C26H39O7: C, 67.61; H, 8.34%. 
IR(KBr) cm-': 3500-3300 (-0H), 2850-1710 (C=0), 919 - 896 (25S)-spiroketal. 
' H N M R (Pyridine - ds, 500 MHz): 5 0.68 (d, 3H, J = 6.41 Hz, 27CH3), 1.03 (s, 3H, 
CH3), 1.97 (t, IH, J = 4.63Hz, H-11), 1.99 (d, IH, J = 9.87, H-11), 3.51 (t, IH, J = 
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10.83, H-26 axial), 3.56 (dd, IH, J = 4.21 and 10.78 Hz, H-26 eq), 4.56 (q, IH, H-2), 
4.66 (dq, IH, H-16), 5.00 (d, IH, J = 2.44 Hz, H-3), 5.06 (m, IH, H-6). 
'•'C NMR (Pyridine - ds, 500 MHz): The resonance frequencies of 26 carbon atoms 
in the molecule are given in Table 1. 
FABMS: m/z 463 [M+H]\ 485 [M+Na]^ 444 [M+H- HzO]^ 426 [M+H- 2xH20]^ 
382 [M+H- 2XH2O+ C02l^ 390 [M+H- CsHgOr, 318 [M+H- CeHioOal 
Acetyiation of AR-1 
AR-1 (50 mg) was dissolved in dry pyridine (2 mL). To this solution acetic 
anhydride (3 mL) was added. The reaction mixture was heated on steam for one 
hour under dry conditions. The reaction mixture was allowed to stand for overnight. 
After the completion of reaction, as monitored on TLC, the solvent was removed 
under reduced pressure. The residue was crystallised and recrystallised from ethyl 
acetate to give AR-Ia. Light yellow crystals (55 mg) m.pl58-159 °C. The purity was 
checked on TLC (System: CHCI3: MeOH; 97: 3). [M]^ in MS at m/z 588, Found: 
C, 64.79; H, 7.37% calculated for C32H44O10: C, 65.10; H, 7.48%. 
'H NMR (125 MHz, pyridine-ds): 6 0.68 (d, 3H, J = 6.41 Hz, 27CH3) and 1.03 (s, 
3H, I9CH3), 2.03 (s, 3H, - OAc), 2.07 (s, 3H, - OAc), 2.07 (s, 3H, - OAc), 4.54 (s, 
IH, H-2), 5.38 (s, IH, H-3), 5.63 (s, IH, H-6). 
Methylation of AR-Ia 
AR-Ia (55mg) and ethereal solution of diazomethane was left overnight at 0 °C 
under dry condition. Progress of the reaction was monitored on TLC. After reaction 
was found complete, solvent was removed under reduced pressure to yield AR-Ib 
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(65 mg) as colourless crystals, m.p. 117-118 °C TLC (System: CHCI3: MeOH; 96:4, 
v/v). 
[M]* in MS at m/z 602, Found: C, 65.76; H, 7.69% calculated for C33H46O10: C, 
65.89; H, 7.87%. 
Acetonide of AR-I 
AR-I (20 mg) was dissolved in dry Me2C0. To this 2 drops of HCl were added. The 
reaction mixture was kept at room temperature overnight under moisture protected 
conditions. Solvent was removed under reduced pressure and residue AR-Ic could 
not be crystallised. [M]"" in MS at m/z 502. Found: C, 70.69; H, 9.89% calculated for 
C29H42O7: C, 76.66; H, 10.00%. 
Isolation and identification of AR-II 
Fraction B: This fraction showed three spots on TLC (EtOAc: MeOH: H2O; 75: 
13.5: 10, v/v), with one spot as the major one. It was subjected to column 
chromatography over silica gel and eluted successively with CHC13, CHCI3: 
MeOH. Each fraction of 50 mL was collected. Elution with CHCI3: MeOH; 19: 1, 
v/v (fractions 32-54 on concentration under reduced pressure and repeated 
crystallization from MeOH) yielded a colourless amorphous powder, homogeneous 
on TLC. This compound was designated as AR-II, m.p.275 °C, [(^f^ -90.2° (c 0.50, 
pyridine). [M+H]* in MS at m/z 871, Found: C, 61.94; H, 8.39% calculated for 
C45H74O16: C, 62.06 ; H, 8.50%. 
IR (KBr) cm-': 3400-3350 cm"' (-0H), 919-896 cm"' (25S)-spiroketal. 
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'H NMR (Pyridine - dj, 200.13 MHz): 5 0.77 (s, 3H, CH3 H-18), 0.98 (s, 3H, CH3, 
H-19) ,1.01 (3H, d, J = 6.0 Hz, CHj, H-21) 1.09 (3H, d, J = 7.2 Hz, CH3, H-27) , 
3.84 (m, IH), 4.40 (q , J = 7.1 Hz, H-16), 3.39 (IH, bs, J = 11.0 Hz, H-3), 3.58 (IH, 
dd, J = 11.0 Hz and J = 2.0 Hz, 26-H). 
3-0-Sugar 
Glucose signal ( 'H NMR) observed as given below: 
6 4.87 (d, J = 7.7 Hz, H-1), 4.28 (H-2), 4.23 (H-3), 4.40 (H-4), 3.68 (H-5), 4.09,4.24 
(H-6). 
^Rhamanose signal ( 'H NMR) observed as given below: 
6 6.40 (br.s, H-2), 4.68 (H-3), 4.36 (H-4), 4.97 (H-5), 1.72 (CH3) 
''Rhamanose signal ( 'H NMR) observed as given below: 
5 5.73 (H-2), 4.70 (H-2), 4.62 (H-3), 4.34 (H-4), 4.95 (H-5), 1.59 (CH3) 
'^ C NMR (Pyridine - ds, 200.13 MHz): The resonance frequencies of 45 carbon 
atoms in the molecule are summarized in Table 2. 
FABMS: m/z 871 [M+H]\ 893 [M+Na]^ 734 [(M+H)^-146], 578 [(M+H)^-292], 
417 [(M+H)^  - 454], 398 [(M+H)^  - 472], 329 [(M+H)^  - 542]. 
Acidic hydrolysis 
AR-II (20 mg) in 2N-H2SO4 (5 mL) and dioxane (3 mL) was refluxed under 
nitrogen for 4 hrs. The reaction mixture was cooled, diluted with H2O (15 mL) and 
extracted with benzene (3x10 mL). The benzene extract was washed with H2O (3 x 
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10 mL), brine and dried over anhy. Na2S04. Solvent removal furnished a residue, 
which was crystallised from acetone to get pure AR-IIa (6 mg), m.p. 199-200 °C 
was thus identified as sarsaspogenin (lit^'. m.p. 200 °C), [M+H]"^  in MS at m/z 417, 
Found: C, 77.73; H, 10.51% calculated for C26H39O7: C, 77.83; H, 10.65%. 
IR(KBr): 3400 cm"' (-0H) 1065, 985, 910, 892, 847 cm'' (25S)-spiroketal. 
The aqueous phase from the above workup was neutralized by passing through a bed 
of anion exchange resin (IR-400, OH form), and then freed of water under reduced 
pressure to get sugars (7 mg). Paper chromatography (BuOH: AcOH: H2O; 4:1:5, 
v/v, upper layer, spray reagent: aniline hydrogen phthalate followed by heating at 
120 °C) showed two spots identified by reference to authentic samples as D-glucose 
and L-rhamnose. A portion (5 mg) of the total sugars was treated with dry pyridine 
(0.5 mL), trimethylsilyl chloride (0.2 mL) and hexamethyldisilazane (0.4 mL). The 
reaction mixture was shaken for 10 min and then freed of pyridine etc. at 55 °C on a 
rotavapour under reduced pressure. Residue was extracted with pet. ether. The pet. 
ether residue was analysed by GLC (6' column, 10% SE-30 on chromosorb-W, 190°, 
80 mL/min.) and individual sugars i.e., D-glucose and L-rhamnose were found to be 
in 1: 2 molar ratio. 
Permethylation of AR-II 
AR-II (20 mg) was dissolved in DMSO (1 mL, dried by distillation over CaH2) and 
added to the stirred suspension of NaH (50% dispersion in paraffin 40 mg; washed 
with pet. ether before use) in DMSO. The mixture was stirred for half an hour under 
Nitrogen. Reaction mixture was cooled and Mel (2 mL) was added. After stirring for 
another 1 hr. at room temperature water (10 mL) was added and the product taken 
up in ether (20 mL x 4). The combined ether extract was washed with water (10 mL 
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X 4), brine and dried over anhy. Na2S04. Solvent removal gave a AR-IIb. Progress 
of the methylation reaction was monitored by IR and the product was remethylated 
(as above) till IR indicated the absence of hydroxyl groups. Final product (18 mg) 
was obtained after crystallization. 
Methanolysis of permethyl AR-II 
Permethyl AR-II (18 mg) was refluxed with 5% HCl-MeOH (15 mL) for 5 hrs. 
Methanol was removed under reduced pressure, dry methanol (25 mL) added and 
again removed under reduced pressure. The material was treated with water (20 
mL), filtered to remove aglycone, the filtrate neutralized by anion exchange resin 
(IR-400, OH form) and freed of water to get a residue (10 mg). It was 
chromatographed over Si02 gel (100-200 mesh) 1.5 gm, (column dia. 1 cm). Elution 
with CHCI3 and 1% MeOH in CHCI3 yielded 2,3,4-tri-O-methyl rhamnopyranoside 
and 3,6-di-O-methyl glucopyranoside. 
Isolation and identiflcation of AR-III 
Fraction C: This fraction showed a single spot on TLC (EtOAc: MeOH: H2O; 75: 
13.5: 10, v/v). It was subjected to column chromatography over silica gel and eluted 
successively with CHCI3, CHCI3: MeOH. Each fraction of 50 ml was collected. 
Elution with CHCI3: MeOH; 17:3, v/v (fractions 64 - 84 on concentration under 
reduced pressure and repeated crystallization from MeOH) yielded a colourless 
amorphous powder, homogeneous on TLC. This compound was designated as AR-
III, m.p.275 °C, [a]p -68.6° (c 1.0, pyridine). [M+H]* in MS at m/z 887, Found: C, 
67.51; H, 8.28% calculated for C45H74O17: C, 67.61; H, 8.34%. 
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Bioevaluation 
The immunopharmocological evaluations of the aqueous extract of the plant showed 
optimum stimulatory response at (100 mg/kg p.o x 5 days) in immunocompromised 
animals (Cyclophosphamide). The two sarsasapogenin glycosides, viz, AR-III and 
AR-II showed significant immunomodulation activity against a specific T dependent 
antigen in immimocompromised animals, in doses corresponding to their 
concentration in the aqueous extract, i.e. 0.15 mg/kg p.o. for AR-III and 0.006 
mg/kg p.o. AR-II (Table 5). 
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2.3 Structure elucidation of the constituents of Withania sommfera{ family 
Solanaceae) 
Withania somnifera (Aswagandha, Indian ginseng) is widely used in Ayurvedic 
medicine (traditional system of medicine in India). It is an ingredient of many 
formulations prescribed for variety of musculoskeletal conditions, and as a general 
health tonic for elderly persons and lactating mothers^ '^^ .^ To authenticate its use as 
a multipurpose medicinal plant, a battery of pharmacological investigations has been 
reported^^ The plant is also used in traditional system of medicine by several 
countries as narcotic, anti-epileptic, against female sterility, hypotonic, for 
stomachache, ulcers, colds, rashes, gonorrhea, sedative and for its antiseptic 
properties''^ "'". The fruit of the plant has been used in folk medicine as febrifuge, 
diuretic and antirheumatic under the name "Morgan" in Egypt'". Genuine interest 
arose in Withanolides when it was found that they show antitumour activity in a 
number of animal studies'*^ "'*''. In addition, cytotoxicity, immunosuppressive'*'', 
antimicrobial, hepatoprotective, insect antifeedant''^  and anti-inflammatory 
properties were observed'* .^ The primary chemical constituents of this herb include 
alkaloids, steroidal lactones, iron and compounds knovm as withanolides are 
believed to account for the multiple medicinal applications of this herb. 
In the present work, phytochemical investigation on chloroform extracts, of leaves 
and roots of the plant have resulted in the isolation and characterization of five 
compounds, one of which has been established to be new to the literature and the 
rest were known compounds. 
The new compound has been designated as WS-I and identified as 6a, 7a-epoxy-
5a, 17a, 27-trihydroxy-l-oxo-22R-witha-2, 24-dienolide. The known compounds 
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have been designated as WS-II, WS-III, WS-IV and WS-V and were identified as 
Withaferian A, Withanone, Withanolide A, 12-Deoxywitiiastramonolide, 
respectively. 
Withania somnifera dried leaves powder (1 Kg) was extracted by percolation with 
95% EtOH and dried roots powder (1 Kg) was extracted by agitating with EtOH: 
H2O (1:1, v/v) at room temperature. Each extract was concentrated under reduced 
pressure. Residues from the extracts were partitioned independently between water 
and chloroform. The chloroform fraction obtained from each residue was dried 
under reduced pressure. Thin layer chromatography of CHCI3 fraction obtained from 
each extract in various solvent systems revealed the presence of a number of 
constituents. A portion of each dried extract (15 gm) was subjected to column 
chromatography over silica gel. Different solvent mixtures with increasing polarity 
were used for elution of the columns. Repeated column chromatography of resulting 
fractions from previous columns followed by crystallization resulted in the isolation 
of pure constituents. The isolation procedure and characterization data of each 
isolate has been discussed separately. 
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Section A 
2.3A.1 Structure determination of WS-I as 6a, 7a - epoxy -5a, 17a, 27-
trihydroxy-l-oxo-22R-witha-2,24-dienolide. A new withanolide from 
Withania somnifera. 
WS-I was isolated from CHCI3 elute by the column chromatography of the 
chloroform fraction obtained from the leaves of Withania somnifera over silica gel. 
It was crystallized from methanol as fine needles, m.p.242-43 °C, [a]?! "'"^ 0.95° 
(c 0.002, CDCI3). 
The molecular formula was established as C28H38O7 by analysis of the positive high-
resolution fast atom bombardment mass spectrometry (HRFAB-MS). 
The UV spectrum showed an absorption Xm&\ 225 nm (e 16,000) in MeOH which is 
characteristic for the overlapping two chromophores, the a, P-unsaturated carbonyl 
in ring A and the unsaturated 6-lactone system, present in withanolides''^ . 
IR(KBr)) spectrum of WS-I displayed a band at 3400 cm'' which suggested the 
presence of hydroxyl groups and a band at 1680 cm"' was assigned to a, p-
unsaturated 5-lactone. The other band at 1670 cm"' was assigned a, p-unsaturated 
ketone'* .^ 
The 'H N M R spectrum (500 MHz, CDCI3) of the compound WS-I (Table 7) was 
characteristic of the steroidal structure for the withanolide class"*'. Three singlets at 5 
0.84, 1.16 and 2.1 were attributed to 18, 19, 28-methyl groups respectively and the 
spectrum was found to be very close to that of withanone"^ (WS-III). The major 
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difference was the absence of singlet for C-27 methyl and furthermore, an additional 
oxygen has to be present in WS-I as shown by the [M+Na]"^  at m/z 509.2462. 
^ ^CHjOH 
' OH 'O 
WS-I WS-III 
Accordingly a hydroxyl group was placed at C-27. The vinylic hydrogen signals at 
55.83 (IH, dd, J = 10.14 and 2.61 Hz) and 6.58 (IH, ddd, J = 10.4,4.9 and 2.4 Hz) 
were attributed to H-2 and H-3 protons respectively in a steroidal A^-l-one system. 
The multiplicity of the 2-H and 3-H signals indicated that position C-4 was 
unsubstituted, and through double irradiation the two geminal protons could be 
identified: the axial 4a-H at 2.64 (IH, bd, J = 18.82 Hz) and the equatorial 4p-H at 
2.5 (IH, dd, J = 18.82 and 4.9 Hz). A doublet resonating at 3.16 (J = 4.0 Hz) was 
due to the C-6 methine proton and double of doublets centered at 3.30 (J = 4.0 and 
1.0 Hz) was assigned to C-7 methine proton'*^ . The chemical shift of the H-6 and H-
7 protons indicated the presence of 6a, 7a-epoxy-5a-hydroxy steroid^". The 21-Me 
signal appears as a doublet at 1.03 (J = 7.0 Hz) and H-20 is clearly seen as a 
multiplet at 2.32. The 17a-0H position of the tertiary OH in WS-I was supported by 
low field position of the H-22 (6 4.65), which is similar to that given for other 17a-
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hydroxy withanolides" .^ Two doublets at 4.85 (J =11.82 Hz) and 4.89 (J =11.82 
Hz) appeared for H-27. 
In '^ C NMR spectral (125 MHz, CDClj) data of compound WS-I (Table 7), all the 
signals for the carbon atoms of rings A and B have values similar to those of 
withanolides having 6a, 7a-epoxy-5a-OH substitution''^ Also the signals for carbon 
atoms of rings C, D and side chain have values similar to those of withanone except 
for appearance of an oxymetylene signal at 57.37 indicated that compound WS-I 
contained 27-hydroxyl group. 
The DEPT experiments (performed at 45" and 135°) were carried out to ascertain the 
nature of the carbon atoms. They showed thirteen positive peaks for four methyl and 
nine methine carbons and seven negative peaks for methylene carbons. The other 
eight resonances were due to quaternary carbons. 
Further confirmation for the structure of WS-I, was deduced from its fragmentation 
in the positive high resolution fast atom bombardment mass spectrum (HRFAB-MS) 
which showed the [M+Na]* at m/z 509.2462 and [M+H]^ peak at m/z 486.2624. 
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Table 7: ' H - '^C- N M R data of 6a, 7a-epoxy-5a, 17a, 27-trihydroxy-l-oxo-22R-
witha- 2, 24-dienoIide (6 values: 500MHz, 125 MHz, CDCI3, TMS as 
internal standards). 
C '^ C(5) 'H(8)* C "C(5) 'H(8)* C ''C(6) 'H(5)* 
1 201.36 10 50.99 19 15.09 1.16 s 
2 128.94 5.83 dd 11 21.67 20 42.95 2.32 m 
(10.14&2.16) 
3 139.84 6.58 ddd 12 32.43 21 09.47 1.03 d 
(10.14 & 4.9,2.61) 
4 36.79 13 48.72 22 79.32 4.65 dd 
(7.0 & 2.61) 
5 73.31 14 45.93 23 32.95 
6 56.31 15 22.87 24 154.62 
7 57.13 16 36.81 25 125.11 
8 36.00 17 84.45 26 167.19 
9 32.25 18 14.72 0.84 s 27 57.37 4.89 d 
(11.82) 
28 20.01 2.1 s 
'H NMR signals for sp methylenes and methines appeared as broad multiplet 
(envelope) between 1.5 - 2.25. 
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Finally the structure of WS-I was confirmed by X-ray crystallography analysis. 
Compound WS-I crystallized in form of a monohydrate in the chiral monoclinic 
space group P2i. An Ortep-Plot of the structure showing the sterochemistry with 
labeling scheme is presented in (Fig. 1 and Fig. 2) and crystal data are listed in 
(Table 8). 
Fig 1: Ortep - Plot (SOVo) with labeling scheme, view A 
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Fig 2: Ortep - Plot (50%) with labeling scheme, view B 
Table 8: Crystal data of compound WS-1 
Chirality Check 
Flack Parameter (standard deviation) 
Twin Basf (standard deviation) 
wR2-value (with Flack Parameter) 
Chirality 
Correct structure 
-0.01 (0.16) 
0.00(0.16) 
0.1013 
S(C1);S(C2);S(C5); 
S(C6);R(C11);S(C12); 
S(C13);S(C14);S(C15); 
R(C18);R(C19) 
Inverted structure 
1.01(0.16) 
0.99(0.16) 
0.1015 
R(C1);R(C2);R(C5); 
R(C6);S(C11);R(C12); 
R(C13);R(C14);R(C15); 
S(C18);S(C19) 
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Although the chiral natural product does not contain heavy heteroatoms, yet it was 
possible to determine the absolute configuration of WS-I maintaining the conditions 
of credibleness fixed by Flack en Bemardly '^. In all four measured crystals the same 
configuration with a Flack parameter of zero could be determined obtaining values 
of the standard deviations close to 0.1. The mean value calculated for the Flack 
parameter including all four crystals is 0.06 with a standard deviation of 0.06. The 
complete list of obtained values is shown in Table 9. Additionally full matrix least 
square refinement of the Flack parameter using the procedure of the TWIN/BASF 
instructions was performed leading to same values and confirming the 
stereochemistry. The inverted structures were also included in the calculations 
leading to values for the Flack parameters as expected close to WS-I. The values 
obtained using TWIN/BASF and inverting the stereochemistry of the structure each 
shown in (Table 10). 
The stereochemistry of the stereogenic centers for the novel compound WS-I were 
defmitly proved as: S(C1), S(C2), S(C5), S(C6), R(Cll), S(C12), S(C13), S(C14), 
S(C15),R(C18)andR(C19). 
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Table 9: Bond lengths [ A"] and angles [" ] for WS-I 
C(l)-0(2) 
C(l)-C(18) 
C(1)-C(I7) 
C(l)-C(2) 
C(2)-C(3) 
C(2)-C(28) 
C(2)-C(15) 
C(3)-C(4) 
C(4)-C(5) 
C(5)-C(14) 
C(5)-C(6) 
C(6)-C(7) 
C(6)-C(27) 
C(6)-C(ll) 
C(7)-0(3) 
C(7)-C(8) 
C(8)-C(9) 
C(9)-C(10) 
C(10)-C(ll) 
C(ll)-0(8) 
C(n)-C(i2) 
1.4381(5) 
1.5464(5) 
1.5639(5) 
1.5696(5) 
1.5337(4) 
1.5404(5) 
1.5456(5) 
1.5429(5) 
1.5435(5) 
1.5492(4) 
1.5518(5) 
1.5315(4) 
1.5443(5) 
1.5635(4) 
1.2215(5) 
1.4809(5) 
1.3395(7) 
1.4955(5) 
1.5313(5) 
1.4281(4) 
1.5255(4) 
C(12)-0(4) 
C(12)-C(13) 
C(13)-0(4) 
C(13)-C(14) 
C(14)-C(15) 
C(15)-C(16) 
C(16)-C(17) 
C(18)-C(29) 
C(18)-C(19) 
C(19)-0(l) 
C(19)-C(20) 
C(20)-C(2l) 
C(21)-C(22) 
C(21)-C(25) 
C(22)-C(23) 
C(22)-C(24) 
C(23)-0(6) 
C(23)-0(l) 
0(7)-C(24) 
0(2)-C(l)-C(18) 
0(2)-C(l)-C(17) 
1.4530(5) 
1.4649(5) 
1.4588(4) 
1.4997(5) 
1.5275(5) 
1.5297(4) 
1.5512(6) 
1.5334(7) 
1.5378(6) 
1.4646(4) 
1.5137(7) 
1.4996(6) 
1.3532(5) 
1.4956(7) 
1.4807(6) 
1.5105(6) 
1.2234(4) 
1.3431(5) 
1.4308(6) 
105.71(3) 
110.71(3) 
C(18)-C(l)-C(17) 
0(2)-C(l)-C(2) 
C(18)-C(l)-C(2) 
C(17)-C(l)-C(2) 
C(3)-C(2)-C(28) 
C(3)-C(2)-C(15) 
C(28)-C(2)-C(15) 
C(3)-C(2)-C(l) 
C(28)-C(2)-C(l) 
C(15)-C(2)-C(l) 
C(2)-C(3)-C(4) 
C(3)-C(4)-C(5) 
C(4)-C(5)-C(14) 
C(4)-C(5)-C(6) 
C(14)-C(5)-C(6) 
C(7)-C(6)-C(27) 
C(7)-C(6)-C(5) 
C(27)-C(6)-C(5) 
C(7)-C(6)-C(n) 
C(27)-C(6)-C(ll) 
C(5)-C(6)-C(ll) 
Contd. 
11.88(3) 
10.71(3) 
115.98(3) 
102.24(3) 
110.42(3) 
107.70(2) 
111.46(3) 
117.37(3) 
109.44(3) 
100.00(3) 
12.54(3) 
112.89(3) 
107.31(2) 
116.56(2) 
110.41(3) 
106.73(2) 
114.28(3) 
110,99(2) 
104.03(2) 
111.74(3) 
108.90(2) 
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Table 9: Bond lengths [ A"] and angles [" 1 for WS-I 
0(3)-C(7)-C(8) 
0(3)-C(7)-C(6) 
C(8)-C(7)-C(6) 
C(9)-C(8)-C(7) 
C(8)-C(9)-C(10) 
C(9)-C(10)-C(n) 
0(8)-C(ll)-C(12) 
O(8)-C(ll)-C(10) 
c(i2)-c(n)-c(io) 
0(8)-C(ll)-C(6) 
C(12)-C(ll)-C(6) 
C(10)-C(ll)-C(6) 
0(4)-C(12)-C(13) 
0(4)-C(12)-C(lI) 
C(13)-C(12)-C(ll) 
0(4)-C(13)-C(12) 
0(4)-C(13)-C(14) 
C(13)-C(12)-C(14) 
C(13)-C(14)-C(15) 
C(13)-C(14)-C(5) 
C(15)-C(I4)-C(5) 
119.73(3) 
123.67(3) 
116.57(3) 
121.82(3) 
122.43(4) 
111.47(4) 
109.36(3) 
106.11(3) 
109.27(3) 
108.90(3) 
112.32(2) 
110.68(3) 
59.99(2) 
113.58(3) 
121.15(3) 
59.60(2) 
115.40(3) 
121.13(2) 
111.97(3) 
114.48(2) 
107.97(3) 
C(14)-C(15)-C(16) 
C(14)-C(15)-C(2) 
C(16)-C(15)-C(2) 
C(15)-C(16)-C(17) 
C(16)-C(17)-C(l) 
C(29)-C(18)-C(19) 
C(29)-C(18)-C(l) 
C(19)-C(18)-C(l) 
O(l)-C(19)-C(20) 
0(1)-C(19)-C(I8) 
C(20)-C(19)-C(18) 
C(21)-C(20)-C(19) 
C(22)-C(21)-C(25) 
C(22)-C(21)-C(20) 
C(25)-C(21)-C(20) 
C(21)-C(22)-C(23) 
C(2l)-C(22)-C(24) 
C(23)-C(22)-C(24) 
0(6)-C(23)-C(l) 
0(6)-C(23)-C(22) 
C(23)-0(l)-C(19) 
119.24(3) 
112.49(2) 
104.23(3) 
103.50(3) 
107.48(3) 
111.36(4) 
114.77(3) 
110.78(3) 
109.38(4) 
105.23(3) 
117.83(3) 
110.73(3) 
123.89(4) 
120.14(4) 
115.89(3) 
119.30(3) 
122.43(4) 
117.59(3) 
117.49(4) 
119.03(3) 
118.59(3) 
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Table 10: Torsion lengths [ A°] and angles ["] for WS-I 
0(2)-C(l)-C(2)-C(3) 
C(18)-C(l)-C(2)-C(3) 
C(17)-C(l)-C(2)-C(3) 
0(2)-C(l)-C(2)-C(28) 
C(18)-C(l)-C(2)-C(28) 
C(17)-C(l)-C(2)-C(28) 
0(2)-C(l)-C(2)-C(15) 
C(18)-C(])-C(2)-C(15) 
C(17)-C(I)-C(2)-C(15) 
C(28)-C(2)-C(3)-C(4) 
C(15)-C(2)-C(3)-C(4) 
C(l)-C(2)-C(3)-C(4) 
C(2)-C(3)-C(4)-C(5) 
C(3)-C(4)-C(5)-C(14) 
C(3)-C(4)-C(5)-C(6) 
C(4)-C(5)-C(6)-C(7) 
C(14)-C(5)-C(6)-C(7) 
C(4)-C(5)-C(6)-C(27) 
C(14)-C(5)-C(6)-C(27) 
C(4)-C(5)-C(6)-C(ll) 
C(14)-C(5)-C(6)-C(n) 
-39.49(4) 
80.85(4) 
-157.15(3) 
-166.31(3) 
-45.98 (4) 
76.03(3) 
76.54(3) 
-163.12(3) 
-41.11(3) 
-69.82(4) 
52.09(4) 
163.83(3) 
-54.58(4) 
57.40(4) 
-178.26(3) 
57.22(4) 
179.97(2) 
-63.53(3) 
59.21(3) 
173.05(3) 
-64.21(3) 
C(27)-C(6)-C(7)-0(3) 
C(5)-C(6)-C(7)-0(3) 
C(ll)-C(6)-C(7)-0(3) 
C(27)-C(6)-C(7)-C(8) 
C(5)-C(6)-C(7)-C(8) 
C(n)-C(6)-C(7)-C(8) 
0(3)-C(7)-C(8)-C(9) 
C(6)-C(7)-C(8)-C(9) 
C(7)-C(8)-C(9)-C(I0) 
C(8)-C(9)-C(10)-C(ll) 
C(9)-C(10)-C(ll)-O(8) 
C(9)-C(10)-C(ll)-C(12) 
C(9)-C(10)-C(ll)-C(6) 
C(7)-C(6)-C(ll)-0(8) 
C(27)-C(6)-C( 10-0(8) 
C(5)-C(6)-C(l 0-0(8) 
C(7)-C(6)-C(ll)-C(12) 
C(27)-C(6)-C(ll)-C(10) 
C(5)-C(6)-C(1I)-C(12) 
C(7)-C(6)-C(ll)-C(10) 
C(27)-C(6)-C(ll)-C(10) 
106.68(4) 
-16.41(5) 
-135.04(4) 
-71.26(4) 
165.64(3) 
47.02(4) 
164.96(4) 
-17.02(6) 
0.17(7) 
-17.69(6) 
-66.90(4) 
175.29(3) 
51.09(4) 
52.00(3) 
166.78(2) 
-70.25(3) 
173.28(3) 
-71.94(4) 
51.03(4) 
-64.28(3) 
50.50(3) 
Contd. 
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Table 10: Torsion lengths [ A°] and angles ["] for WS-I 
C(5)-C(6)-C(ll)-C(10) 
0(5)-C(ll)-C(12)-0(4) 
C(10)-C(ll)-C(12)-O(4) 
C(6)-C(n)-C(12)-0(4) 
0(8)-C(ll)-C(12)-C(13) 
C(10)-C(ll)-C(12)-C(13) 
C(6)-C(ll)-C(12)-C(13) 
C(ll)-C(12)-C(13)-0(4) 
0(4)-C(12)-C(l3)-C(14) 
C(11)-C(I2)-C(I3)-C(14) 
0(4)-C(13)-C(14)-C(15) 
C(12)-C(13)-C(14)-C(15) 
0(4)-C(13)-C(14)-C(5) 
C(I2)-C(13)-C(14)-C(5) 
C(4)-C(5)-C(14)-C(13) 
C(6)-C(5)-C(14)-C(13) 
C(4)-C(5)-C(14)-C(15) 
C(6)-C(5)-C(14)-C(15) 
C(13)-C(I4)-C(15)-C(16) 
C(5)-C(14)-C(15)-C(16) 
C(13)-C(14)-C(I5)-C(2) 
173.47(3) 
32.09(4) 
147.84(3) 
-88.93(3) 
100.14(4) 
-144.11(3) 
-20.88(5) 
-101.00(4) 
103.10(4) 
2.10(5) 
-69.40(3) 
-137.82(3) 
53.90(4) 
-14.52(5) 
173.59(13) 
45.59(4) 
-60.98(3) 
171.02(2) 
-45.97(4) 
-172.87(3) 
-168.43(2) 
C(5)-C(14)-C(15)-C(2) 
C(3)-C(2)-C(15)-C(14) 
C(28)-C(2)-C(15)-C(I4) 
C(l)-C(2)-C(15)-C(14) 
C(3)-C(2)-C(15)-C(16) 
C(28)-C(2)-C(15)-C(16) 
C(l)-C(2)-C(15)-C(16) 
C(14)-C(15)-C(16)-C(17) 
C(2)-C(15)-C(16)-C(17) 
C(15)-C(16)-C(17)-C(l) 
0(2)-C(l)-C(17)-C(16) 
C(18)-C(l)-C(17)-C(16) 
C(2)-C(l)-C(17)-C(16) 
0(2)-C(l)-C(18)-C(29) 
C(17)-C(l)-C(18)-C(29) 
C(2)-C(l)-C(18)-C(29) 
0(2)-C(l)-C(18)-C(19) 
C(17)-C(l)-C(18)-C(19) 
C(2)-C(l)-C(18)-C(19) 
C(29)-C(18)-C(19)-0(I) 
C(l)-C(18)-C(19)-0(1) 
64.67(3) 
-58.75(4) 
62.52(3) 
178.14(2) 
170.68(3) 
-68.05(3) 
47.56(3) 
-160.81(3) 
-34.36(4) 
7.61(4) 
-96.57(4) 
145.93(3) 
21.17(4) 
66.76(5) 
-172.91(4) 
-56.18(5) 
-60.40(4) 
59.92(5) 
176.65(3) 
81.23(4) 
-149.74(3) 
Contd. 
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Table 10: Torsion lengths [ A"] and angles [" ] for WS-I 
C(21)-C(22)-C(23)-0(l) 12.04(6) 
C(24)-C(22)-C(23)-0( 1) -177.15(4) 
0(6)-C(23)-0(l)-C(19) -165.99(4) 
C(22)-C(23)-0(l)-C(19) 17.18(6) 
C(20)-C(19)-O(l)-C(23) -49.02(5) 
C(18)-C(19)-0(l)-C(23) -175.73(4) 
C(ll)-C(12)-0(4)-C(13) 113.56(3) 
C(14)-C(13)-0(4)-C(12) -112.64(3) 
C(21)-C(22)-C(24)-0(7) 65.85(5) 
C(23)-C(22)-C(24)-0(7) -104.66(4) 
C(29)-C(18)-C(19)-C(20) 
C(l)-C(18)-C(19)-C(20) 
O(l)-C(19)-C(20)-C(21) 
C(18)-C(19)-C(20)-C(21) 
C(19)-C(20)-C(21)-C(22) 
C(19)-C(20)-C(21)-C(25) 
C(25)-C(21)-C(22)-C(23) 
C(20)-C(21)-C(22)-C(23) 
C(25)-C(21)-C(22)-C(24) 
C(20)-C(21)-C(22)-C(24) 
C(21)-C(22)-C(23)-0(6) 
C(24)-C(22)-C(23)-0(6) 
-40.53(5) 
88.50(5) 
51.58(5) 
171.16(4) 
-26.49(6) 
156.69(4) 
170.80(4) 
-5.75(6) 
0.46(7) 
-176.10(4) 
-164.60(4) 
6.21(6) 
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2.3A.2 Structure determination of WS-II as 5p,6p-epoxy-4p,27-dihydroxy-l-
oxo-witha-2,24-dienolide (Withaferin A), WS-II . A known compound 
from Withania somnifera. 
WS-II was isolated from CHCI3: MeOH (99:1, v/v) fractions by the column 
chromatography of the chloroform fraction obtained from the leaves/roots of 
Withania somnifera over silica gel. It was crystallized from ethyl acetate as 
colourless crystals, m.p. 252.5 °C, [a]p + 125° (c 1.30, CHCI3). 
The HRFAB mass spectrum of compound WS-II gave a molecular ion formed as 
sodium adduct of m/z 492.832, which corresponds to the molecular formula 
CigHsgOfi+Na. 
The UV spectrum (MeOH) showed ^ax at 223 nm (e 14,000) for enone and a, P-
unsaturated 5-lactone ''^ . 
IR(KBr) spectrum of WS-II displayed a band at 3500 cm'' which suggested the 
presence hydroxyl groups and a band at 1684 cm'' was assigned to a,P-unsaturated 
8-lactone. The other band at 1664 cm"' was assigned to a, P-unsaturated ketone. 
The 'H N M R and '^ C NMR data (Table 11) of compound WS-II compared well 
with the reported data of a known compound Withaferin A^.The identity of the 
compound WS-II was further supported by the MS, optical rotation, m.p., UV, and 
IR data which were in agreement with the literature values^ .^ 
104 
OH 
WS-II 
105 
Table 11: ' H - '^C- N M R data of 5p,6p-epoxy-4p,27dihydroxy-l-oxo-witha-2,24 
dienolide (5values: 200.13 MHz, 50.32 MHz, CDCI3, TMS as 
internal standards). 
C '^ C(8) 'H(5)* C '^C(5) 'H(6)* C '^C(5) 'H(6)* 
1 202.0 10 48.1 19 16.81 1.16 s 
2 132.6 5.83 dd 11 21.30 20 38.85 2.32 m 
(10.14&2.16) 
3 143.2 6.58 ddd 12 40.03 21 13.31 1.03 d 
(10.14 &4.9,2.61) 
4 73.0 13 43.30 22 78.82 4.65 dd 
(7.0 & 2.61) 
5 64.1 14 54.50 23 29.80 
6 61.2 15 23.90 24 153.52 
7 31.2 16 27.41 25 125.21 
8 29.00 17 52.31 26 167.01 
9 44.20 18 14.12 0.84 s 27 57.21 4.89 d 
(11.82) 
28 20.1 2.1 s 
* 'H NMR signals for sp^ methylene and methine protons appeared as a broad 
multiplet between 1.4 to 2.25. 
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2.3A.3 Structure determination of WS-III as 6a,7a-epoxy-5,17-dihydroxy-l-
oxo-witha-2,24-dienolidc (Withanone), WS-III. A known compound 
from Withania somnifera. 
WS-III was isolated from CHCI3: MeOH (98:2, v/v) fractions by the column 
chromatography of the chloroform fraction obtained from the leaves/roots of 
Withania somnifera over silica gel. It was crystallized from CHCI3: EtOAc as a 
colourless solid, freely soluble in CHCI3. m.p.275-76°C, [a]^ + 81° (c 0.5, CHCI3). 
The HRFAB mass spectrum of compound WS-III gave a molecular ion formed as 
sodium adduct of m/z 492.832, which corresponds to the molecular formula 
C28H3806+Na. 
The UV spectrum (MeOH) showed Xmax at 225 nm (e 12,000) for enone and a, p-
unsaturated 6-lactone''^ . 
IR(KBr) spectrum of WS-III displayed a band at 3400 cm"' which suggested the 
presence of hydroxyl groups and a band at 1690 cm'' was assigned to a,P-
unsaturated 5-lactone. Other bands at 2950 cm"' and at 1665 cm'' were assigned to 
C-H stretching and a, P-unsaturated ketone respectively. 
The 'H N M R and '^ C NMR data (Table 12) of compound WS-III compared well 
with the reported data of a known compound Withanone''*. The identity of the 
compound WS- III was further supported by the MS, optical rotation, m.p., UV and 
IR data which were in agreement with the literature values ^^. 
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Table 12: ' H - '^C- N M R data of 6a, 7a-epoxy-5,17-dihydroxy-l-oxo-witha-
2,24- dienolide (5values: 200.13 MHz, 50.3 MHz, CDCb, TMS as 
internal standards). 
C '^ C(5) 'H(8)* C '^ C(5) 'H(5)* C "C(d) 'H(5)* 
1 203.7 10 51.3 19 13.6 1.16s 
2 129.3 5.83 dd 11 22.0 20 43.3 2.32 m 
(10.14&2.16) 
3 140.3 6.58 ddd 12 32.8 21 9.9 1.03 d 
(10.14 &4.9,2.61) 
4 37.13 13 49.4 22 79.2 4.65 dd 
(7.0 & 2.61) 
5 73.6 14 46.2 23 33.1 
6 57.5 15 23.2 24 151.0 
7 57.7 16 37.1 25 121.7 
8 36.7 17 83.1 26 167.5 
9 51.3 18 12.7 0.84 s 27 12.2 4.89 d 
(11.82) 
28 20.9 2.1 s 
* 'H NMR signals for sp^ methylene and methine protons appeared as a broad 
multiplet between 1.4 to 2.25. 
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2.3A.4 Structure determination of WS-IV as 6a,7a-epoxy-5a,20a-(R)-
dihydroxy-l-oxo-witha-2,24-dienoIide (Withanolide A), WS-IV. A 
known compound from Withania somnifera. 
WS-IV was isolated from CHCI3: MeOH (97:3, v/v) fractions by the column 
chromatography of the chloroform fraction obtained from the roots of Withania 
somnifera over silica gel. It was crystallized from CHCI3: EtOAc as a colourless 
solid, freely soluble in CHCI3. m.p. 294.3 °C, [ot]^ + 92.3° (c 1.47, CHCI3). 
The HRFAB mass spectrum of compound WS-IV gave a molecular ion formed as 
sodium adduct of m/z 492.832, which corresponds to the molecular formula 
C28H3806+Na. 
The UV spectrum (MeOH) showed Xmax at 220 nm (e 17,900) for enone and a, p-
unsaturated S-lactone"*^ . 
IR(KBr) spectrum of WS-IV displayed a band at 3300 cm'' which suggested the 
presence hydroxyl groups and a band at 1674 cm"' was assigned to a,P-unsaturated 
6-lactone. The other band at 1662 cm'' was assigned to a, P-unsaturated ketone. 
The 'H N M R and '^ C NMR data (Table 13) of compound WS-IV compared well 
with the reported data of a known compound Withanolide A^.The identity of the 
compound WS-IV was further supported by the MS, optical rotation, m.p., UV and 
IR data which were in agreement with the literature values^ .^ 
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Table 13: ' H - " C - N M R data of of 6a, 7a-epoxy-5a, 20a-(R) -dlhydroxy-1-
oxo-with a-2,24 dienolide (6values: 200.13 MHz, 50.32 MHz, 
CDCI3, TMS as internal standards). 
C "C(5) 'H(6)* C ''C(5) 'H(5)* C '^ C(5) 'H(5)* 
1 203.7 10 51.32 19 14.63 1.16 s 
2 129.3 5.83 dd 11 22.06 20 75.23 2.32 m 
(10.14&2.16) 
3 140.31 6.58 ddd 12 32.86 21 21.01 1.03 d 
(10.14&4.9,2.61) 
4 37.13 13 49.41 22 81.02 4.65 dd 
(7.0 & 2.61) 
5 73.64 14 46.23 23 31.72 
6 57.51 15 23.61 24 148.76 
7 57.71 16 21.94 25 122.15 
8 36.71 17 54.73 26 166.01 
9 51.32 18 13.82 0.84 s 27 12.54 4.89 d 
(11.82) 
28 20.51 2.1s 
H NMR signals for sp^ methylene and methine protons appeared as a broad 
multiplet between 1.4 to 2.25. 
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2.3A.5 Structure determination of WS-V as 12-deoxywithastramonoIide, WS-V. 
A known compound from Withania somnifera. 
WS-V was isolated from CHCI3: MeOH (95:5, v/v) fractions by the column 
chromatography of the chloroform fraction obtained from the roots of Withania 
somnifera over silica gel. It was crystallized from methanol as a microcrystalline 
solid, m.p. 294.3 °C, [a]^ + 92.3° (c 1.47, CHCI3). 
The HRFAB mass spectrum of compound WS-V gave a molecular ion formed as a 
sodium adduct of m/z 492.832, which corresponds to the molecular formula 
C28H3806+Na. 
The UV spectrum (MeOH) showed Xi^ax at 222 nm (e 12,000) for enone and a, (3-
unsaturated 5-lactone''^ . 
IR(KBr) spectrum of WS-V displayed a band at 3300-3450 cm"' which suggested the 
presence of hydroxyl groups and a band at 1740 cm'' was assigned to a,p-
unsaturated 6-lactone. The other band at 1652 cm'' was assigned to a, P-unsaturated 
ketone. 
The 'H NMR and '^ C NMR data (Table 14) of compound WS-V well compared 
with the reported data of a known compound 12-Deoxywithastramonolide '^*. The 
identity of the compound WS-V was further supported by the MS, optical rotation, 
m.p., UV and IR data which were in agreement with the literature values '^'. 
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Table 14: 'H- '•*€- NMR data of 12-deoxywithastramonolide (5values: 200.13 
MHz, 50.32 MHz, CDCI3, TMS as internal standards). 
C "C(8) 'H(5)* C ''C(5) 'H(5)* C "C(5) 'H(5)* 
1 203.4 10 48.82 19 15.76 1.16 s 
2 128.4 5.83 dd 11 21.43 20 37.82 2.32 m 
(10.14 & 2.16) 
3 139.61 6.58 ddd 12 38.56 21 13.01 1.03 d 
(10.14 &4.9,2.61) 
4 37.4 13 43.12 22 78.32 4.65 dd 
(7.0 & 2.61) 
5 73.4 14 53.87 23 28.80 
6 57.32 15 23.65 24 152.12 
7 56.12 16 27.21 25 125.36 
8 32.06 17 51.83 26 166.21 
9 41.32 18 11.12 0.84 s 27 56.41 4.89 d 
(11.82) 
28 18.91 2.1 s 
* 'H NMR signals for sp^  methylene and methine protons appeared as a broad 
multiplet between 1.4 to 2.25. 
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Section B 
2.3B Experimental 
2.3B.1 General 
All melting points were measured on a Buchi Melting point apparatus (Model B-
545) and are uncorrected. UV spectra were recorded on a Shimadzu UV-265 
spectrometer in MeOH and IR spectra on a Hitachi 270-30 spectrophotometer in 
KBr pellets. 'H N M R (500 MHz), '^ C NMR (50.32 MHz) and 2 DNMR spectra 
were determined on a Bruker DPX-500 and DPX-200 spectrometers in CDCI3. 
Chemical shifts are shown in 5 values (ppm) with tetramethylsilane (TMS) as an 
internal reference. FAB and HRFAB-MS were measured with a JMS-HX-110 
spectrometer. Elemental analytical data was recorded on Carlo Erba, Model 1106, 
elemental analyzer. Crystal structure determination was carried out using a Bruker-
Nonius diffractometer equipped with a APPEX 2 4K CCD area detector, a FR591 
rotating anode with MoKa radiation, Montel mirrors as monochromator and a 
Kryoflex low temperature device (T = 100 K). Fullsphere data collection omega and 
phi scans. Programs used: Data collection Apex 2.V.1.22 (Bruker-Nonius 2004), 
data reduction Saint+Version 6.22 (Bruker-Nonius 2001) and absorption correction 
SADABS V. 2.10 (2003). Crystal structure solution was achieved using direct 
methods as implemented in SHELXTL Version 6.10 [Sheldrick, Universtitat 
Gottingen (Germany), 2000] and visualized using XP program. Missing atoms were 
subsequently located from difference Fourier synthesis and added to the atom list. 
Least-squares refinement on F2 using all measured intensities was carried out using 
the program SHELXTL Version 6.10. All non hydrogen atoms were refined 
including an isotropic displacement parameters. Column chromatography: Silica gel 
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(Merck, 60-120 mesh). TLC zones were visualized either by exposure to vanillin 
sulphuric acid, iodine vapour, or under UV light. All evaporations were done in 
vacuo on a rotary evaporator. 
2.3B.2 Plant material 
The specimen of Withania somnifera Dunal was collected from REL fields and 
deposited in the Herbarium of RRL, J under collection No : 50414 dated 11-06-02. 
2.3B.3 Extraction, fractionation and isolation procedure 
Withania somnifera dried leaves powder (1 Kg) was extracted by percolation with 
95% EtOH for 16 hrs and dried roots powder (1 Kg) was extracted by agitating with 
EtOH: H2O (1:1, v/v) for 2 hrs at room temperature. The extraction process for each 
was repeated four times under similar condition. The pooled extract of each was 
concentrated under reduced pressure to get residue (140 gm) and (120 gm) 
respectively. 
Each of the residue, 140 gm from leaves and 120 gm from roots was partitioned 
between CHCI3 and H2O to get a polar along with a moderately polar (CHCI3 
miscible) fraction. Thin layer chromatography of nonpolar fraction from each extract 
in various solvent systems revealed the presence of number of compounds. A 
portion of each dried nonpolar fraction was subjected to column chromatography 
over silica gel. The columns were eluted with solvents of increasing polarity in 
different proportions. Each fraction of 200 mL was collected and monitored on TLC. 
Fractions showing identical TLC pattern were pooled as details given in the 
(Table 15). 
Table 15: Fractions eluted from leaves/roots of 
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Fraction No Eluent Fractions Extract/ Fraction 
20-38 CHCb: MeOH Fraction A Chloroform fraction of leaves 
100:0 
39-46 CHCIj: MeOH Fraction B 
99: 1 
Chloroform fraction of leaves/roots 
47-61 CHCI3; MeOH Fraction C 
98:2 
Chloroform fraction of leaves/roots 
67-72 CHCI3: MeOH Fraction D 
9 7:3 
Chloroform fraction of roots 
80-98 CHCI3: MeOH Fraction E 
95:5 
Chloroform fraction of roots 
Isolation and identification of WS-I 
Fraction A: This fraction showed a number of spots on TLC (CHCI3: MeOH; 19: 
1, v/v) with one spot as the major one. It was subjected to column chromatography 
over silica gel and eluted successively with CHCI3, CHCI3: MeOH. Each fraction of 
50 mL was collected. Elution with CHCI3 (fractions 20 - 38 on concentration under 
reduced pressure and repeated crystallization from MeOH) yielded a fine crystalline 
compound, homogeneous on TLC. This compound was designated as WS-1, 
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m.p.242-43 °C, [a]^ +70.95° (c 0.002, CDCI3). [M+H]"" in MS at m/z 486.2624 
Found: C, 69.11; H, 7.87% calculated for C28H38O7: C, 69.14; H, 7.98%. 
UV X„,ax (MeOH) nm (e): 225 (16,000). 
IR(KBr) cm'': 3400 (-0H), 1680 (a, p-unsaturated 5-lactone), 1670 (a, p-
unsaturated ketone). 
'H NMR (500 MHz, CDCI3): 6 5.83 (dd, IH J = 10.14 and 2.61 Hz, H-2), 6.58 (ddd, 
IH, 10.14, 4.9 and 2.61 Hz, H-3), 2.64 (d, IH, J = 18.82 Hz, H-4a), 2.55 (dd, IH, J 
= 18.82 and 4.9 Hz, H-4p), 3.16 (d, IH, J = 4.0 Hz, H-6P), 3.30 (dd, 1H,J = 4.0 and 
l.O Hz, H-7p), 2.32 (m, IH, H-20), 4.65 (dd, J = 7.0 and 2.61 Hz IH, H-22), 4.85 
and 4.89 (d, 2H, J = 11.82 Hz, H-27), 0.84 (s, 3H, CH3-I8), 1.16 (s, 3H, CH3-I9), 
1.03 (d, 3 H, J = 7.0 Hz, CH3-2I), 2.1 (s, 3H, CH3-28). 
'^ C NMR (500 MHz, CDCI3): The resonance frequencies of 28 carbon atoms in the 
molecule are given in Table 7. 
The structure of the compound was finally confirmed by X-ray crystallography. 
Isolation and identification of WS-II 
Fraction B: This fraction showed one major spot along with number of minor 
compounds on TLC (CHCI3: MeOH; 97: 3, v/v). It was subjected to column 
chromatography over silica gel and eluted successively with CHCI3, CHCI3: MeOH. 
Each fraction of 50 mL was collected. Elution with CHCI3: MeOH; 99: 1, v/v 
(fractions 39-46 on concentration under reduced pressure and repeated 
crystallization from MeOH) yielded a colourless crystalline compound, 
homogeneous on TLC. This compound was designated as WS-II, m.p.252-253 °C, 
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[a]2^+I25° (c 1.30,CDCl3). [M+H]^  in MS at m/z 470, Found: C, 71.46; H, 8.14 % 
calculated for CzgHsgOs C, 71.34; H, 8.06%. 
UV \rnax (McOH) nm (8): 223 (14,000) 
IR(KBr) cm'': 3500 (-0H), 1684 (a, p-unsaturated 8-lactone), 1664 (a, p-unsaturated 
ketone) 
'H N M R (500 MHz, CDCI3): 6 6.52 (dd, IH J = 10.14 and 2.61 Hz, H-2), 6.76 (ddd, 
IH, 10.14, 4.9 and 2.61 Hz, H-3), 5.25 (d, IH, J = 18.82 Hz, H-4), 2.86 (d, IH, J = 
4.0 Hz, H-6), 2.23 (m, IH, H-20), 3.98 (dd, J = 7.0 and 2.61 Hz IH, H-22), 4.34 (d, 
2H, J = 11.82 Hz, H-27), 1.16 (s, 3H, CH3-I8), 1.21 (s, 3H, CH3-I9), 1.06 (d, 3H,J = 
7.0 Hz, CH3-2I), 1.71 (s, 3H, CH3-28). 
'^ C NMR (500 MHz, CDClj)-. The resonance frequencies of 28 carbon atoms in the 
molecule are given in Table 11. 
Isolation and identification of WS-III 
Fraction C: This fraction showed number of spots on TLC (CHCI3: MeOH; 97: 3, 
v/v) with one spot as the major one. It was subjected to column chromatography 
over silica gel and eluted successively with CHCI3, CHCI3: MeOH. Each fraction of 
50 mL was collected. Elution with CHCI3: MeOH; 98: 2,v/v (fractions 47-61 on 
concentration under reduced pressure and repeated crystallization from CHCI3: 
EtOAc) yielded a colourless crystalline compound, homogeneous on TLC. This 
compound was designated as WS-III, m.p.275-76 °C, [a]^+81° (c 0.5, CDCI3). 
[M+H]^  in MS at m/z 471, Found: C, 71.46; H, 8.14 % calculated for C28H38O6: C, 
71.34; H, 8.06%. 
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UV \max (MeOH) nm (s): 225 (12,000). 
IR(KBr) cm"': 3400 (-0H), 1690 (a, p-unsaturated 6-lactone), 1665 (a, p-unsaturated 
ketone), 2950 cm'" (C-H stretching). 
'H NMR (500 MHz, CDCI3): 6 5.81 (dq, IH J = 10.3 and IHz, H-2), 6.60 (dq, IH, 
10 and 4.5 Hz, H-3), 3.06 (dd, IH, J = 4.0 Hz, H-6), 3.34 (d, IH, J = 4.0 and 1 Hz, 
H-7), 4.63 (dt, J = 8.5 and 3 Hz IH, H-22), 1.09 (27 and 28H), 0.85 (s, 3H, CH3-I8), 
1.21 (s, 3H, CH3-I9), 1.04 (d, 3H, J = 7.0 Hz, CH3-2I), 1.18 (s, 3H, CH3-28). 
'•'C NMR (500 MHz, CDCI3): The resonance frequencies of 28 carbon atoms in the 
molecule are given in Table 12. 
Isolation and identification of WS- IV 
Fraction D: This fraction showed four spots on TLC (CHCI3: MeOH; 97: 3, v/v), 
with one spot as the major one. It was subjected to column chromatography over 
silica gel and eluted successively with CHCI3, CHCI3; MeOH. Each fraction of 50 
mL was collected. Elution with CHCI3: MeOH; 97: 3, v/v (fractions 67-72 on 
concentration under reduced pressure and repeated crystallization from CHCI3: 
EtOAc) yielded a colourless crystalline compound, homogeneous on TLC. This 
compound was designated as WS-IV, m.p.294.3 °C, [ct]^ + 92.3° (c 1.47,CDCl3). 
[M+H]^  in MS at m/z 470, Found: C, 71.46; H, 8.14 % calculated for C28H38O6: C, 
71.34; H, 8.06%. 
UV X^^ (MeOH) nm (e): 220 (17900). 
IR(KBr) cm"': 3300 (-0H), 1674 (a, p-unsaturated 6-lactone), 1662 (a, P-unsaturated 
ketone). 
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'H NMR (500 MHz, CDCI3): 6 6.07 (dq, IH J = 10.3 and 1 Hz, H-2), 6.57 (dq, IH, 
10 and 4.5 Hz, H-3), 2.94 (dd, IH, J = 4.0 Hz, H-6), 2.86 (d, IH, J = 4.0 and IHz, H-
7), 4.06 (dt, J = 8.5 and 3 Hz IH, H-22), 1.93 (s, 3H, CH3-27), 1.16 (s, 3H, CH3-I8), 
1.31 (s, 3H, CH3-I9), 1.21 (d, 3H, J = 7.0 Hz, CH3-2I), 1.71 (s, 3H, CH3-28). 
'^ C NMR (500 MHz, CDCI3): The resonance frequencies of 28 carbon atoms in the 
molecule are given in Table 13. 
Isolation and identification of WS- V 
Fraction E: This fraction showed three minor spots on TLC (CHCI3: MeOH; 97: 3, 
v/v), with one spot as the major one. It was subjected to column chromatography 
over silica gel and eluted successively with CHCI3, CHCI3: MeOH. Each fraction of 
50 mL was collected. Elution with CHCI3: MeOH; 95: 5, v/v (fractions 80-98 on 
concentration under reduced pressure and repeated crystallization from MeOH) 
yielded a microcrystalline compound, homogeneous on TLC. This compound was 
designated as WS-V, m.p.292-294 °C, [a.]^ + 92.3° (c 1.47,CDCl3). [M+H]^  in MS 
at m/z 471, Found: C, 71.46; H, 8.14 % calculated for C28H38O6: C, 71.34; H, 
8.06%. 
UV >^ ax (MeOH) nm (e): 222 (12,000). 
IR(KBr) cm-': 3300-3450 (-0H) 1740 (a, p-unsaturated 5-lactone), 1652 (a, P-
unsaturated ketone). 
'H NMR (500 MHz, CDCI3): 5 5.97 (ddd, IH J = 9.5 and 2.61 Hz H-2), 6.32 (ddd, 
IH, 9.5 and 4.3 Hz, H-3), 5.81 (dt, IH, J = 10.5 Hz, H-22), 4.32 (s, 2H, H.27), 3.25 
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(dd, IH, J = 3.25 and IHz, H-7), 3.02 (d, IH, J = 3.9 Hz, H-6), 0.75 (s, 3H, CH3-I8), 
1.18 (s, 3H, CH3-I9), 1.06 (d, 3H, J = 6.8 Hz, CH3-2I), 2.04 (s, 3H, CH3-28). 
'•'C NMR (500 MHz, CDCI3): The resonance frequencies of 28 carbon atoms in the 
molecule are summarized in Table 14. 
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CHAPTERS 
Chemical Standardisation of 
Asparagus racemosus and 
Withania somnifera on the Bases of 
Isolated Markers by Morden 
Techniques. 
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3.1 Introduction 
The medical establishment has become a threat to health, wrote Ivan lUich, an 
eminent researcher, in his book "Limits to Medicine". These words grimly describe 
the state in which modem medicine finds itself today. The modem allopathic system 
of medicine stakes no claim to its ability to fully cure several difficuh to treat 
chronic diseases. There is a distinct possibility that the curative properties required 
to treat them successfully may lie within the ken of herbal medicinal systems. 
Herbal medicines have been used for thousands of years in many parts of the world. 
Today, they appear to be engaging the attention of health authorities even in the 
developed countries. This is attributable to the fact that they offer alternative sources 
of medical therapy that are reasonably effective and least productive of disturbing 
after effects. However, to maximise their ultimate efficacy, we have to ensure that 
preparations derived from medicinal plants are of acceptable quality, safety and 
efficacy'. 
Global market for herbal dmgs in the year 2000 accounted for over 60 billion US 
dollars and it is expected to touch four trillion US dollars by 2010 if the present 
trend continues, and this has to be so undoubtedly. In the present, global market 
scenario 50% share belongs to People's Republic oJ' China, 20% to Japan followed 
by Russia with 16%. Unfortunately, India's share is only 2.5% although the internal 
market has crossed Rs. 4500 crore per year. The reason is simple lack of quality 
control and scientific evaluation data for Indian products. The question of quality 
therefore acquires greater relevance today than ever before. Regulatory agencies and 
consumer groups on one hand and increasingly stringent quality norms for global 
positioning of the products on the other hand, demaiid that raw materials and herbal 
products there from, used for medicinal, nutritional and cosmetic purposes should be 
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of consistent reproducibility, scientifically (chemically and biologically) validated 
and supplemented by data on documented evidence of efficacy and safety through 
limited human clinical trials^. 
Non-standardized herbal preparations have not found acceptance in the global 
market and therefore need to be chemically standardized on the basis of isolated 
constituents, preferably bioactive ones. Presently, formulations standardized on the 
basis of a maximum possible number of biomarkers are accepted readily in the 
global market. In view of the importance of Asparagus racemosus and Withania 
somnifera in traditional Indian medicine and their apparent potential in the global 
market as a positive health promoter, it was decided to carry out work on the 
chemical profiling of these two plants on the bases of bioactive molecules. 
Quantitative testing of botanicals has all along been a difficult and controversial 
subject due to the complex nature of active constituents of the botanicals found wild 
or cultivated in various regions of the world. However with rapid strides in the field 
of instrumentation where LOD and LOQ have been routinely upgraded from 
milli-»micro->nano->pico->femto->atto levels, things are rapidly coming into 
grips, so much so that the instrumental chemical standardization (HPTLC, HPLC, 
LC/MS) of herbal products has become more credible than biological evaluation of 
late^ 
In the present work, the Asparagus racemosus extract has been chemically 
standardised using two isolated saponins (AR-II and AR-III) by High performance 
thin layer chromatography (HPTLC) and Withania somnifera extract has been 
standardised using four isolated withanolides (WS-II, WS-III, WS-IV and WS-V) by 
HPLC-UV(DAD)-Positive ion electrospray ionisation-mass spectrometry. 
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3.2 Standardisation of Asparagus racemosus on the bases of sarsasapogenin 
glycosides by High performance thin layer chromatography 
3.2.1 Results and Discussion 
To enrich the aqueous extract with the sarsasapogenin glycosides i.e., AR-III and 
AR-II, three batches (2 gm each) of the aqueous extract was dissolved in 20 mL of 
demineralised water and the resulting solutions were extracted with n-BuOH (3 x 
10 mL). The n-BuOH extracts (0.219, 0.195 and 0.220 gm) were dissolved in 
methanol (5 mg/mL, HPLC grade) in case of AR-III and 15 mg/2mL in case of AR-
II. 10 jaL solution of the each extract was applied on precoated Si02 gel plate 
(Merck) of 0.25 mm thickness with the help of CAMAG Linomat IV alongwith the 
standards which were also dissolved in MeOH (HPLC grade, 1 mg/2mL). The 
standards were applied on the precoated silica gel plates having (0.25 mm thichness) 
in concentration 1 to 5 |ig alongwith the n-BuOH extracts solution 5 mg/mL in case 
of AR-III and 15 mg/mL in case of AR-II in triplicate. The method described 
utilizes precoated silica gel plates as stationary phase and EtOAc: MeOH: H2O; 75: 
13.5: 10, v/v as mobile phase which gives good separation for both the standards in 
the extracts. The method was found accurate, precise sensitive and suitable for 
application to routine quality control analysis and quantitative determination of AR-
III and AR-II in the n-BuOH as well as aqueous extract of the plant and its 
pharmaceutical preparations. 
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AR-II (R=-CH3) 
AR-III (R=-CH20H) 
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3.2.2 Experimental 
Plant material and isolation of markers are mentioned in chapter 2, page no. 81-88. 
3.2.2.1 Sample preparation 
Aqueous extract (2 gm) in each experiment was dissolved in deionised water (20 
mL) and extracted with n-BuOH (3 x 10 mL). Each extract was concentrated on 
rotavapour at 60 ± 5 "C. Residue obtained were 0.219, 0.195 and 0.022 gm 
respectively. For standardisation, each residue was dissolved in methanol (HPLC 
grade). 5 mg/mL in case of AR-III and 15 mg/2 mL in case of AR-II. AR-III (1 mg) 
was dissolved in 2 mL MeOH (HPLC grade). 
3.2.2.2 Standard preparation 
AR-II (1 mg) was dissolved in 2 mL MeOH (HPLC grade). 
3.2.2.3 HPTLC Standardisation analysis 
10 ]xL solution of each extract was applied on precoated silica gel plate (Merck) of 
0.25 mm thickness with the help of CAMAG Linomat IV along with the standards 
(1 ixg-5 \ig). The plates were developed with mobile phase consisting of EtOAc: 
MeOH: H2O (75: 13.5:10, v/v). The developed plates were visualized by immersing 
the plate in the solution of 1% cerricammunium sulphate in 30% aqueous sulphuric 
acid and heating the chromatograms at 110 °C for 20 min. Developed plates were 
covered with glass plates and sealed from all sides. The plates were scarmed by 
flying spots scanning densitometer (CS-9301PC, Shimadzu) at 450 nm by linear 
(Scan) reflection (Photo) mode. The concentration of the markers compounds as 
estimated by HPTLC (Table 1) i.e AR-III (Fig. 1) and AR-II (Fig. 1) in the extract 
was determined by using the standard curves generated for the compounds. 
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Fig. 1: HPTLC profile of AR-III 
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3.3 Identification and standardisation of Withania somnifera extract by 
HPLC-UV(DAD)-Positive ion electrospray ionisation-mass spectro-
metrometry on the bases of four markers. 
3.3.1 Results and Discussion 
Nowadays, mass spectrometric detection in combination with HPLC has become an 
effective and convenient technique for the quantification of the individual 
constituents in the plant extracts. A literature survey indicates that a number of 
methods for the simultaneous detection and quantitation of two/three withanolides 
by HPLC are available but simultaneous separation and quantification of four 
withanolides by HPLC-MS has not been reported to date. The present work 
describes the development of a sensitive and selective method for the determination 
of four withanolides [withaferin A (WS-II), withanone (WS-III), withanolide A 
(WS-IV) and 12-deoxywithastramonolide (WS-V)] in Withania somnifera by High 
Performance Liquid Chromatography in combination with Electrospray Ionization 
Mass Spectrometry (EIMS). 
OH '0 
WS-III 
OH 
OH '0 
WS-V 
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Optimisation of the LC-MS method required a thorough evaluation of the 
withanolide ionisation. A robust LC chromatographic separation method was 
developed which was compatible with LC-MS ionisation conditions. The efficiency 
of the method was checked by comparing the electrospray technique both in the 
positive as well as in the negative ion mode and it was found that the positive 
electrospray ionisation mode is best suited for the developed LC conditions. In order 
to evaluate the separation of withanolides, an artificial mixture of four isolated 
compounds was used. The separation of withanolides was achieved on a RP-18 
column using MeOH: H2O (60:40, v/v) at a flow rate of 0.5 mL/min .The reasonable 
difference in retention times of the marker compounds facilitated quantification of 
withanolides in samples. The retention times were 21.35(WS-II), 31.01(WS-III), 
28.40 (WS-IV) and 25.24 (WS-V) min. respectively. No ion suppression was 
observed and intense [ M+Na]"*" ions were recorded for all the four withanolides. No 
significant enhancement of ionisation was observed on addition of volatile buffers 
such as formic or acetic acid. Under the optimised conditions, first analyses were 
performed in full scan mode m/z (100-900) to estimate the qualitatively the content 
of withanolides in H2O: EtOH (1:1, v/v) extract of leaves, roots and stems of the 
plant. The extracts showed other peaks besides those corresponding to the isolated 
withanolides. The results of the analysis are detailed in Table 2. 
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Table 2: Amounts of withanoIides( WS-II, WS-III, WS-IV, WS-V) in different 
germplasms of Withania somnifera obtained during the quantitative 
LC-MS experiments. 
S.No. 
1. 
2. 
3. 
4. 
4. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
Code of the 
sample 
WSL-1 
WSS-1 
WSR-1 
WSL-2 
WSS-2 
WSR-2 
WSL-3 
WSS-3 
WSR-3 
WSL-4 
WSS-4 
WSR-4 
WSL-5 
WSS-5 
WSR-5 
WS-II 
0.317 
0.095 
0.007 
0.329 
0.024 
0.194 
0.478 
0.100 
0.005 
0.567 
0.148 
0.044 
0.862 
0.161 
0.135 
%age of Withanolides 
WS-III 
0.025 
0.023 
0.117 
0.004 
0.010 
0.117 
0.001 
0.009 
0.145 
0.005 
0.003 
0.015 
0.009 
0.006 
0.046 
WS-IV 
0.226 
0.089 
0.005 
0.016 
0.009 
0.008 
0.223 
0.019 
0.092 
-
-
-
-
-
0.007 
WS-V 
0.085 
0.010 
0.003 
0.012 
0.014 
0.0008 
0.003 
0.007 
0.004 
0.004 
0.004 
0.009 
0.008 
0.005 
0.019 
Extractions were carried out in EtOH : H2O; 1:1, v/v (r.t.). 
Stock solutions were prepared in MeOH : H2O; 1 :1 , v/v. 
WSL = Withania somnifera leaves. 
WSR = Withania somnifera roots. 
WSS = Withania somnifera stem. 
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3.3.2 Experimental 
3.3.2.1 General 
The HPLC system consisted of an Agilent series 1100 instrument equipped with a 
binary pump, an autosampler, an automatic electronic degasser, an automatic 
thermostatic column oven, a diode array detector and a computer with chemstation 
software for data analysis. HPLC was used in combination with Quadrupole Ion 
Trap Mass Spectrometer (Esquire 3000) from Bruker, Bremen (Germany) equipped 
with an Atmospheric Pressure Ionization (API) electrospray interphase. High purity 
nitrogen from a nitrogen generator was used as a carrier gas. 
3.3.2.2 Solvents 
All the solvents used in the study were of HPLC grade and water was prepared with 
milli-Q water purification system. All the four withanolides were isolated from a 
95% ethanol and 50% aq. alcoholic extract of roots/ leaves of the plant purity > 98% 
mentioned in the chapter 2, page no. 123-128. 
3.3.2.3 Sample preparation 
Accurately weighed quantities of the dried 95% alcoholic and 50% aq. alcoholic 
extracts were dissolved in a known volume of HPLC grade MeOH: H2O (1:1, v/v). 
The solutions were filtered through a millipore filter (0.45 [im) before injection into 
the HPLC system. 
3.3.2.4 Preparation of stock solutions and samples 
Stock solutions of the reference compounds (WS-II, WS-III, WS-IV and WS-V) 
were prepared in HPLC grade methanol and stored in refrigerator at 4 °C. From the 
stock solutions, working solutions for these reference compounds, in concentration 
range of 7.5 ng to 325 ng/mL were prepared by dilution with HPLC grade methanol. 
An artificial mixture of four withanolides was prepared by mixing the solutions to 
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give a final concentration in the range of 1.5 ng-6.5 ng/|xL. 2-20 |iL 
(n = 6) of the mixture was injected on to the column for LC-ES-MS studies for 
preparation of standard curves. 
3.3.2.5 Liquid chromatography- electrospray mass spectrometry analysis 
The LC separation were achieved using RP-18, Merck (4.6 x 250 mm, 5 ^m) 
column. This mobile phase consisted of MeOH: H2O (60:40, v/v) delivered at a flow 
rate of 0.5 mL/min. The samples were analyzed at 30 "C to provide efficiency to the 
peaks. The UV chromatograms were recorded at 237 nm. All the interphase 
parameter were optimized by injecting standard solutions of the withanolides during 
the LC-MS experiments. The conditions for mass spectrum analysis during the LC-
MS studies were set at dry gas flow of llL/min, nebulizer pressure 35 psi, and 
drying gas temperature was at 320 °C. The mass range was from 100-900 m/z, ICC 
target value 8000, while the maximum accumulation time was 200 min. 
3.3.2.6 LC-UV (DAD) - MS analysis 
Using the above conditions good results were obtained in the positive mode ES-MS. 
(Fig. 4) shows the LC-UV (DAD) chromatogram (237 nm) and the Total Ion 
Current (TIC) traces in the positive mode of four markers. LC- ES- MS spectra of 
the four withanolides (Fig. 5, Fig. 6, Fig. 7 and Fig. 8) showed that all the four 
compounds exhibited identical ion mass spectra at m/z 492.8 [M+Na]^ along with 
some of the digonastic fragments attributable to the parent compounds (Table 3). 
(Fig. 9) shows the LC-UV (DAD) and the Total Ion Current (TIC) trace of a sample 
where the presence of two major withanolides, i.e WS-II and WS-V has been 
observed. 
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35 TimtMn) 
Fig 4: Total Ion Current (TIC) trace (A) of four withanolides in the positive mode 
under ESI and LC-UV(DAD) chromatogram (237 nm) of same withanolides (B). 
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Table 3: Retention times, molecular ion peaks, and some of the diagnostic 
fragments of the marker compounds (withanolides) in the LC-ES-
MS. 
Compound Retention 
time (min) 
Molecular ion 
(m/z) 
Diagnostic fragments 
WS-II 
WS-III 
WS-IV 
ws-v 
21.35 
31.01 
28.40 
25.24 
492.8 [M+Na]^ 
492.8 [M+Na]^  
492.8 [M+Na]^  
492.8 [M+Na]^  
470.8,434.9, 398.3, 340.8, 289.7 
470.7, 280.8,252.6 
452.8,416.7,262.7 
470.7,434.8,416.8,289.8 
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3.3.2,7 HPLC Analysis 
For quantification of withanolides in various accessions of plant extracts, calibration 
curves were established by injecting six concentrations each of the isolated standards 
in the concentration range of 1.5 ng to 6.5 ng/|aL. Quantification of the four 
withanolides was carried out using selective ion monitoring (SIM) detection of their 
respective [M+Na]"^  ions at different concentration of all the four withanolides. In 
order to avoid source contamination, as no compound of interest was eluting before 
18 min, the switching off and on of the LC outflow from the diode detector was 
monitored. The LC outflow was diverted to the MS detector between 18 to 35 min. 
Excellent calibration curves were obtained for the withanolides within the 
concentration range of 1.5 ng to 6.5 ng/pL (R2=curve co-efficient 0.999849, 
0.999842, 0.999783 and 0.999759 were obtained respectively for WS-II, WS-III, 
WS-IV and WS-V n= 6). The recovery studies were within the concentration range 
147 
of the calibration curves. The recovery of the method was estimated by spiking the 
same extracts with 5 ixg/gm each of the withanolides WS-III, WS-IV and WS-V, 
whereas in case of withanolides WS-II the recovery of the method was estimated by 
spiking the extracts with 5 ng/lOOmg. The data from recovery studies revealed that 
the recovery of the method was in the range of 99.4 to 101.2%. 
A simple and reliable LC-ES-MS method has been developed for the quantitative 
analysis of withanolides in Withania somnifera extract. 
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CHAPTER 4 
Synthesis of Some Physiologically 
Active Nitrogen Heterocyclic 
Compounds 
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4.1 Introduction 
Heterocyclic compounds have a cyclic structure with atleast one different atom in 
place of carbon. Hetereocycles are the largest of the classical divisions of the 
organic chemistry and are of immense importance biologically, industrially, and 
indeed to the functioning of any developed human society. Heterocyclic compounds 
are widely distributed in nature and are essential to life; they play a vital role in the 
metabolism of all living cells. There are a vast number of pharmacologically active 
heterocyclic compounds, many of which are in regular clinical use. Majority of 
biologically active compounds including agrochemical are heterocyclic. 
Heterocyclic compounds are also being used as additives and modifiers in industries: 
as varied as cosmetics, reprography, information storage, dyestuffs, photographic 
sensitizers etc., and many are valuable intermediates in synthesis. The successful 
application of the heterocyclic compounds in these and many other ways, and their 
appeal as materials in the applied chemistry and more fundamental and theoretical 
studies ensures a virtually limitless series of structurally novel compounds with a 
wide range of physical, chemical and biological properties'. 
Justification of much of the chemistry directed to the synthesis of the compounds, 
possessing nitrogen at the ring fusion is due to the applications of compounds 
having interesting biological properties in the field of medicinal chemistry. 
The present work has been divided into two parts. First part 4.2 deals with the 
solvent free, microwave assisted synthesis of 3,5-disubstituted-4,5-dihydro-lH-
pyrazoles, the compounds have been synthesised for the first time by microwave 
assisted technique, wherein the time required for the synthesis has been reduced 
drastically and yields have improved significantly. Whereas second part 4.3 deals 
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with synthesis of some 4-methyl-2 oxo-(2H)-pyrido[l,2-a]pyrimidine and 2-methyl-
4-oxo-(4H)-pyrido[l ,2-a]pyrimidine derivatives. 
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4.2 Microwave assisted synthesis of 3,5-disubstitituted-4,5-dihydro-lH-
pyrazoles. 
4.2.1 Results and Discussion 
From the last twenty years the pyrazole ring has attracted continued attention, as it 
has become fairly accessible and shows diverse biological attributes. In particular, 
they are used as antitumor ,^ antibacterial, anti-fungal, antiparasitic, anti-tubercular, 
and insecticidal agents^ "^ . Some of these compounds have also COX-2 inhibitory , 
anti-inflammatory, anti-diabetic, anaesthetic and analgesic properties '^ 
Conventional synthesis of anti-inflammatory 3,5-disubstitituted-4,5-dihydro-lII-
pyrazoles has already been reported by the condensation of a-P unsaturated ketones 
with hydrazine and methyl hydrazine to yield two sets of pyrazolmes . 
Formation of non-steroidal anti-inflammatory compounds and useful pharmaco-
logical activities associated with these pyrazolines have developed much interest 
from medicinal chemist to synthesise more of these compounds in a shorter time and 
in a better yield. 
Ecofriendly microwave-assisted synthesis in general is likely to have a large impact 
on synthetic organic chemistry, particularly in the fields of medicinal and 
combinatorial chemistry. Compared to traditional processing of organic synthesis, 
microwave-enhanced chemistry saves significant time and very often improves 
yields. It has also been demonstrated in a number of examples that previously 
practically impossible transformations are successfully completed using microwave 
irradiation. The short reaction times open up new approaches for rapid testing of 
ideas and fast iterations in protocol developments .^ 
Considering that microwave irradiations (MW) using commercial domestic ovens 
has been recently used to accelerate organic reactions, the high heating efficiency 
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giving remarkable rate enhancement and dramatic reduction in reaction times and 
better yield ,^ this work was undertaken to demonstrate the advantages obtained by 
the use of microwave irradiations in the synthesis of 3,5-disubstituted 4,5-dihydro-
IH-Pyrazoles over the conventional methods, using the same precursors but no 
solvents of the conventional method. 
The synthesis of 3,5-disubstituted-4, 5 dihydro IH-Pyrazoles (Scheme 1) was 
carried out by the microwave irradiation of a,P-unsaturated ketones with hydrazines 
and its differently substituted methyl, phenyl derivatives in molar ratios [1:1] for 2 
minutes at 400 Watt. Some simple compounds la to 12a of the 3,5-disubstituted-4, 5 
dihydro 1 H-pyrazoles were synthesised. 
The synthetics prepared by use of microwave and classical method on comparison 
(Table 1) gave surprise results. The result shows that in microwave the formation of 
pyrazolines can be achieved in significant shorter time and in better yields. It was 
observed that the average reaction time between the two methods is 1: 90 for the 
synthesis of 3,5-disubstituted 4,5-dihydro-l H-pyrazoles in favour to the microwave 
method. 
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+ R'NH.NHZ 
Scheme 1 
1a-12a 
OMe 
OH 
S.No 
1. 
2. 
3.-
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
Compound 
la 
2a 
3a 
4a 
5a 
6a 
7a 
8a 
9a 
10a 
11a 
12a 
MeO^ 
MeO-
MeO. 
MeO" 
M e O ^ 
M e O ' ' 
Me^ 
Me 
Me 
M e O ^ 
M e C ^ 
MeO^ 
R 
CC" 
tX"" 
xx°" 
5. 
d. 
fS. 
a°" 
a°" 
a" 
a" 
ex"" 
a" 
R' 
H 
CH3 
Ph 
H 
CH3 
Ph 
H 
CH3 
Ph 
H 
CH3 
Ph 
m.p."C 
166.2 
138.5 
194.7 
175.0 
126.0 
113.6 
148.6 
173.2 
99.3 
175.0 
139.2 
136.5 
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Table 1: Comparison of reaction time and yield of 3,5-disubstiuted-4,5-dihydro-
IH-pyrazoles by microwave and conventional methods 
Compound 
No. 
la 
2a 
3a 
4a 
5a 
6a 
7a 
8a 
9a 
10a 
11a 
12a 
Molecular 
formula 
C,7H,8N204 
C18H20N2O4 
C23H22N2O4 
C,7H,8N204 
C,8H2oN204 
C23H22N2O4 
C,7H,8N203 
C,8H20N2O3 
C23H22N2O3 
C,7H,gN204 
C,8H2oN204 
C23H22N2O4 
Time taken 
Conventional 
3hrs 
3 hrs 
3hrs 
3 hrs 
3 hrs 
3 hrs 
3 hrs 
3 hrs 
3 hrs 
3 hrs 
3 hrs 
3 hrs 
Microwave 
2 min 
2 min 
2 min 
2 min 
2 min 
2 min 
2 min 
2 min 
2 min 
2 min 
2 min 
2 min 
Yield % 
Conventional 
68.83 
58.24 
65.58 
89.82 
45.78 
63.54 
66.87 
66.86 
65.58 
47.34 
54.67 
45.67 
Microwave 
90.12 
81.24 
90.41 
90.12 
86.34 
86.27 
89.34 
80.34 
90.41 
80.67 
81.26 
82.57 
The identification of the compounds was done by 'H NMR, '^C N M R (Table 2: 
Page No. 155-170), X-ray analysis ( Table 2a and 2b: Page No 167-168) MS 
(Table 3 : Page No: 171) and elemental analysis (Tables 4: Page No: 172). 
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Table 2: 3,5-Disubstiuted-4,S-dihydro-lH-pyrazoIes and its derivatives 
S.No. Compound Structure Molecular 
formula 
1. la Cl7H,8N204 
HXO 
"C NMR data 
Carbon No. 
C-3 
C-4 
C-5 
c-r 
C-2' 
C-3' 
C-4' 
C-5' 
C-6' 
146.43 
40.69 
74.71 
114.53 
153.51 
108.47 
166.59 
113.92 
135.54 
Carbon No. 
C-1" 
C-2" 
C-3" 
C-4" 
C-5" 
C-6" 
-OCH3 
-OCH3 
128.56 
114.12 
148.31 
140.18 
116.32 
121.59 
55.96 
55.35 
H^ NMR data 
3.12 (dd, IH, J = 10.4 and 10.4 Hz, Ha-4) 
3.43 (dd, IH, J = 10.4 and 10.4 Hz, Hb-4) 
3.93(dd, lH,J=10.4Hz,H-5) 
3.73 (s, 3H, -OCH3) 
3.71 (s, 3H, -OCH3) 
6.94 (m, 6H, Ar-H) 
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S.No. Compound Structure Molecular 
formula 
2a C18H20N2O4 
H3CO 
' X NMR data 
Carbon No. 
C-3 
C-4 
C-5 
c-r 
C-2' 
C-3' 
C-4' 
C-5' 
C-6' 
146.51 
40.52 
72.82 
116.12 
155.56 
109.12 
166.53 
113.64 
134.96 
Carbon No. 
C-1" 
C-2" 
C-3" 
C-4" 
C-5" 
C-6" 
-OCH3 
-OCH3 
NCH3 
128.51 
114.14 
148.43 
140.21 
116.30 
121.92 
55.98 
55.39 
43.58 
'H NMR data 
3.08 (dd, IH, J = 10.4 and 10.4 Hz, Ha-4) 
3.23 (dd, IH, J = 10.4 and 10.4 Hz, Hb-4) 
3.54(dd, lH,J = 10.4Hz,H-5) 
3.62 (s, 3H, -OCH3) 
3.71 (s, 3H, -OCH3) 
2.78 (s, 3H, NCH3 
6.91(m,6H,Ar-H) 
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S.No. Compound Structure Molecular 
formula 
3a C23H22N2O4 
MeO 
' X NMR data 
Carbon No. 
C-3 
C-4 
C-5 
c-r 
C-2' 
C-3' 
C-4' 
C-5' 
C-6' 
C-1" 
C-2" 
C-3" 
146.32 
40.39 
76.71 
115.01 
153.51 
108.52 
166.51 
113.19 
135.56 
128.53 
114.83 
148.90 
Carbon No. 
C-4" 
C-5" 
C-6" 
C-1'" 
C-2"' 
C-3"' 
C-4"' 
C-5"' 
C-6"' 
-OCH3 
-OCH3 
140.45 
116.31 
121.83 
143.74 
113.17 
129.93 
116.62 
129.93 
113.17 
55.99 
55.39 
'H NMR data 
3.10 (dd, IH, J= 10.4 and 10.4 Hz, Ha-4) 
3. 41(dd, IH, J = 10.4 and 10.4 Hz, Hb-4) 
3.54(dd, lH,J=10.4Hz,H-5) 
3.91(s,3H,-OCH3) 
3.73(s, 3H, -OCH3) 
6.12(bs,2H,H-3',H-5') 
7.01(m,3H,H-6',H-4",H-5") 
6.58 (m, 2H, H-2", H-4'") 
6.92 (m, 2H, H-2"', H-6"') 
7.21(m,2H,H-3'",H-5"') 
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S.No. Compound Structure Molecular 
formula 
4a C,7H,8N204 
MeO 
'^ C NMR data 
Carbon No 
C-3 159.52 
C-4 43.54 
C-5 72.27 
C-r 131.24 
C-2' 101.23 
C-3' 153.52 
C-4' 114.30 
C-5' 161.53 
C-6' 120.95 
Carbon No. 
C-1" 
C-2" 
C-3" 
C-4" 
C-5" 
C-6" 
-OCH3 
-OCH3 
109.92 
128.16 
146.88 
145.51 
106.15 
109.17 
55.31 
55.94 
'H NMR data 
2.93 (dd, IH, J = 14.5 and 14.5 Hz, Ha-4) 
3.48 (dd, IH, J = 14.5 and 14.5 Hz, Hb-4) 
3.67(dd, lH,J=14.5Hz,H-5) 
3.80(s,3H,-OCH3) 
3.93(s, 3H, -OCH3) 
6.84 (m, 6H, Ar-H) 
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S.No. Compound Structure Molecular 
formula 
5a C,8H20N2O4 
MeO 
' X NMR data 
Carbon No 
C-3 
C-4 
C-5 
c-r 
C-2' 
C-3' 
C-4' 
C-5' 
C-6' 
159.52 
43.54 
72.27 
131.27 
101.28 
153.03 
114.27 
161.53 
120.96 
Carbon No. 
C-1" 
C-2" 
C-3" 
C-4" 
C-5" 
C-6" 
-OCH3 
-OCH3 
-NCH3 
109.92 
128.18 
146.87 
145.50 
106.16 
109.17 
55.33 
55.95 
41.89 
' H NMR data 
2.96 (dd, IH, J = 14.5 and 14.5 Hz, Ha-4) 
3.48 (dd, IH, J = 14.5 and 14.5 Hz, Hb-4) 
3.69(dd, lH,J=14.5Hz,H-5) 
3.84 (s, 3H, -OCH3) 
3.93(s, 3H, -OCH3) 
2.78 (s, 3H, NCH3) 
5.64(s, lH,Ar-OH) 
6.44 (dd, IH, J = 2.51 and 2.51 Hz, H-4') 
6.71(bs,2H,H-2',H-6') 
6.55(d, IH,J = 2.47Hz,H-2") 
7.03 (m, 2H, J = 8.56 Hz, H-4", H-5") 
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S.No. Compound Structure Molecular 
formula 
6. 6a C23H22N2O4 
MeO OMe 
"C NMR data 
Carbon No 
C-3 
C-4 
C-5 
c-r 
C-2' 
C-3' 
C-4' 
C-5' 
C-6' 
C-1" 
C-2" 
C-3" 
159.32 
43.52 
72.17 
131.48 
101.25 
153.58 
114.29 
161.50 
120.96 
109.91 
128.29 
146.74 
Carbon No. 
C-4" 
C-5" 
C-6" 
C-1'" 
C-2'" 
C-3'" 
C-4'" 
C-5'" 
C-6'" 
-OCH3 
-OCH3 
145.32 
106.15 
109.14 
144.01 
112.23 
129.13 
116.90 
129.13 
112.23 
55.31 
55.94 
'H NMR data 
2.91 (dd, IH, J = 14.5 and 14.5 Hz, Ha-4) 
3.48 (dd, IH, J = 14.5 and 14.5 Hz, Hb-4) 
3.62(dd, IH,J=14.5Hz,H-5) 
3.82 (s, 3H, -OCH3) 
3.93 (s. 3H, -OCH3) 
5.64(s, lH,Ar-OH) 
6.41 (dd, IH, J = 2.51 and 2.51 Hz, H-4') 
6.62 (bs, 2H, H-2', H-6') 
6.43(m, lH,J = 2.47Hz,H-2") 
7.03 (m, 2H, J = 8.56 Hz, H-4", H-5") 
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S.No. Compound Structure Molecular 
formula 
7a Cl7H,8N203 
Ha 
^ O M e 
'^C NMR data 
Carbon No. 
C-3 
C-4 
C-5 
c-r 
C-2' 
C-3' 
C-4' 
C-5' 
C-6' 
145.43 
41.79 
62.74 
114.55 
155.53 
108.58 
119.47 
133.84 
127.82 
Carbon No. 
C-1" 
C-2" 
C-3" 
C-4" 
C-5" 
C-6" 
-CHj 
-OCH3 
128.09 
13,1.12 
154.55 
146.88 
116.32 
119.47 
20.49 
55.97 
'H NMR data 
3.08 (dd, IH, J = 10.5 and 10.5 Hz, Ha-4) 
3.51 (dd, IH, J = 10.5 and 10.5 Hz, Hb-4) 
3.95(dd, lH,J=10.5Hz,H-5) 
2.26 (s, 3H, -CH3) 
3.86 (s, 3H, -OCH3) 
6.95 (m, 6H, Ar-H) 
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S.No. Compound Structure Molecular 
formula 
8a CnHigNzOs 
"C NMR data 
Carbon No. 
C-3 
C-4 
C-5 
c-r 
C-2' 
C-3' 
C-4' 
C-5' 
C-6' 
145.52 
41.66 
72.28 
116.10 
155.59 
109.10 
114.33 
131.27 
127.42 
Carbon No. 
C-1" 
C-2" 
C-3" 
C-4" 
C-5" 
C-6" 
-CH3 
-OCH3 
-NCH3 
128.03 
130.92 
152.77 
146.90 
116.30 
120.91 
20.50 
55.98 
43.46 
'H NMR data 
3.00 (dd, IH, J = 10.5 and 10.5 Hz, Ha-4) 
3.51 (dd, IH, J = 10.5 and 10.5 Hz, Hb-4) 
3.71(dd, lH,J=10.5Hz,H-5) 
2.26 (s, 3H, -CH3) 
2.79 (s, 3H, NCH3) 
3.90 (s, 3H, -OCH3) 
6.91 (m, 6H, Ar-H) 
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S.No. Compound Structure Molecular 
formula 
9. 9a C23H22N2O3 
' X NMR data 
Carbon No. 
C-3 
C-4 
C-5 
c-r 
C-2' 
c-3' 
c-4' 
C-5' 
C-6' 
C-1" 
C-2" 
C-3" 
145.00 
40.39 
61.74 
117.03 
154.83 
110.71 
119.86 
132.67 
127.64 
128.04 
130.83 
154.32 
Carbon No. 
C-4" 
C-5" 
C-6" 
C-l"' 
C-2"' 
C-3"' 
C-4"' 
C-5"' 
C-6"' 
-CH3 
-OCH3 
146.63 
116.31 
120.74 
143.71 
112.41 
129.62 
117.01 
129.62 
112.41 
20.52 
55.95 
'H NMR data 
3.06 (dd, IH, J = 10.5 and 10.5 Hz, Ha-4) 
3. 45 (dd, IH, J = 10.5 and 10.5 Hz, Hb-4) 
3.90(dd, lH,J=10.5Hz,H-5) 
2.24 (s, 3H, -CH3) 
3.84 (s, 3H, -OCH3) 
6.66(d, lH,H-3') 
7.21 (m, 3H, H-4', H-6', H-5") 
6.45 (m, 2H, H-2", H-4'") 
6.41 (m, 2H, H-2'", H-6'") 
7.02 (m, 2H, H.3'", H-5'") 
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S.No. Compound Structure Molecular 
formula 
10. 10a Cj7Hi8N204 
MeO 
"C NMR data 
Carbon No 
C-3 145.56 
C-4 41.86 
C-5 62.93 
C-y 116.24 
C-2' 152.33 
C-3' 114.59 
C-4' 117.09 
C-5' 154.06 
C-6' 119.57 
Carbon No. 
C-1" 
C-2" 
C-3" 
C-4" 
C-5" 
C-6" 
-OCH3 
-OCH3 
112.66 
133.76 
151.97 
146.93 
116.60 
108.62 
55.97 
56.03 
'H NMR data 
3.07 (dd, IH, J = 9.46 and 9.46 Hz, Ha-4) 
3. 50 (dd, IH, J = 9.46 and 9.46 Hz, Hb-4) 
3.91(dd, lH,J = 9.46Hz,H-5) 
3.76 (s, 3H, -OCH3) 
3.87 (s, 3H, -OCH3) 
4.84(s, 1H,0H) 
6.82 (m, 6H, Ar-H) 
Compound 10a was taken as a representative sample for confirmation of its structure 
by X-ray analysis. The molecular structure ORTEP drawing of 10a is illustrated in 
(Fig. 1 and Fig. 2) and its atomic coordinates, bond lengths for carbon, oxygen and 
nitrogen are listed in Table 2a and 2b. 
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Fig 1: 50% Thermal ellipsoid plot of the 10a compound. H atoms are shown as 
small spheres of arbitrary radii. The broken line shows the 0-H...N 
intramolecular hydrogen bond. 
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Fig 2: Packing diagrams viewed down the a-axis. Ring centroids involved in 
7i-n interactions are joined by dashed lines. Cgl represents the center 
of gravity of the phenyl ring (A). 
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Table 2a: Atomic coordinates and equivalent isotropic thermal parameters 
(A^ ) for non-hydrogen atoms (e.s.d.'s are given in parenthesis) 
atom 
Nl 
N2 
C3 
C4 
C5 
Cla 
C2a 
C3a 
06 
C7 
C4a 
08 
C5a 
C6a 
CV 
C2' 
09 
C3' 
C4' 
C5' 
C6' 
OlO 
Cll 
*Ueq = 
X 
0.3268(2) 
0.3558(2) 
0.4078(2) 
0.4120(2) 
0.3042(2) 
0.3353(2) 
0.4887(2) 
0.5133(2) 
0.6563(1) 
0.7924(2) 
0.3844(2) 
0.4096(1) 
0.2323(2) 
0.2076(2) 
0.4665(2) 
0.4500(2) 
0.3756(2) 
0.5131(2) 
0.5920(2) 
0.6081(2) 
0.5453(2) 
0.6884(2) 
0.6863(4) 
( 1 / 3 ) SiSjU.j 
y 
0.4186(1) 
0.3845(1) 
0.3418(1) 
0.3416(1) 
0.3875(1) 
0.4182(1) 
0.4235(1) 
0.4551(1) 
0.4629(1) 
0.4346(1) 
0.4834(1) 
0.5169(1) 
0.4767(1) 
0.4441(1) 
0.3013(1) 
0.3051(1) 
0.3454(1) 
0.2669(1) 
0.2258(1) 
0.2213(1) 
0.2587(1) 
0.1788(1) 
0.1677(1) 
ai*a)*ai.a-,. 
z 
0.3047(1) 
0.2295(1) 
0.2635(1) 
0.3703(1) 
0.3924(1) 
0.4814(1) 
0.5211(1) 
0.5985(1) 
0.6440(1) 
0.6127(1) 
0.6357(1) 
0.7089(1) 
0.5989(1) 
0.5225(1) 
0.2012(1) 
0.1021(1) 
0.0595(1) 
0.0450(1) 
0.0834(1) 
0.1815(1) 
0.2397(1) 
0.2125(1) 
0.3109(2) 
Ue,* 
0.036(1) 
0.038(1) 
0.033(1) 
0.039(1) 
0.035(1) 
0.033(1) 
0.034(1) 
0.034(1) 
0.047(1) 
0.047(1) 
0.035(1) 
0.045(1) 
0.043(1) 
0.041(1) 
0.034(1) 
0.040(1) 
0.053(1) 
0.052(1) 
0.055(1) 
0.049(1) 
0.042(1) 
0.077(1) 
0.080(1) 
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Table 2b: Selected bond lengths (A), bond angles f) and hydrogen bonds 
(i) Bond lengths 
N1-N2 
C3-C4 
N1-C5 
(ii) Bond angles 
N2-N1-C5 
N2-C3-C4 
N1-C5-C4 
06-C3a-C4a 
O10-C5'-C4' 
(ii) Torsion angles 
C5-N1-N2-C3 
N2-C3-C4-C5 
C4-C5-N1-N2 
1.406(1) 
1.502(2) 
1.490(2) 
107.2(1) 
112.3(1) 
100.8(1) 
114.1(1) 
115.6(1) 
-22.0(1) 
16.2(1) 
30.5(1) 
(iii) Hydrogen bonds 
D-H...A 
09-H90...N2 
08-H80...N1' 
N1-H1N...08" 
C7-H72 ...OlO"' 
C4-H41...Cg2" 
Cll-Hn2...Cgr 
Cll-H113...Cg2' 
D-H(A) 
0.91(2) 
0.91(2) 
0.91(2) 
0.97(2) 
1.01(2) 
' 0.93(3) 
" 0.96(3) 
N2-C3 
C4-C5 
C3-N2-N1 
C3-C4-C5 
1.291(2) 
1.530(2) 
109.3(1) 
100.8(1) 
06-C3a-C2a 126.0(1) 
O10-C5'-C6' 124.9(1) 
N1-N2-C3-C4 3.0(2) 
C3-C4-C5-N1 -26 
D...A(A) ] 
2.607(2) 
2.768(2) 
2.917(2) 
3.398(2) 
3.783(2) 
3.863(3) 
3.843(3) 
H...A(A) 
1.76(2) 
1.88(2) 
2.04(2) 
2.55(2) 
3.12(2) 
3.04(3) 
3.03(3) 
.7(1) 
D-H...A(°) 
153(2) 
166(2) 
161(1) 
147(2) 
124(1) 
149(2) 
144(2) 
Symmetry code : (i) -x+1, -y+1, -z+1 (ii) -x+1 /2, -y+1, z-112 
(iii) X,-y+1/2, z+1/2 (iv) x-l/2,y,-z+1/2 
(v) x+1/2,-y+1/2,-z+1 (vi) x+1/2, y,-z+1/2 
Cgl and Cg2 represent the center of gravity of the phenyl rings A and B, 
respectively. 
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S.No. Compound Structure Molecular 
formula 
11. 11a C,8H2oN204 
MeO 
'^ C NMR data 
Carbon No. 
C-3 145.51 
C-4 41.73 
C-5 65.74 
C-V 116.52 
C-2' 152.37 
C-3' 114.62 
C-4' 117.12 
C-5' 153.93 
C-6' 119.32 
C-l" 
C-2" 
C-3" 
C-4" 
C-5" 
C-6" 
-OCH3 
-OCH3 
-NCH3 
'H NMR data 
Carbon No. 
112.24 
130.93 
151.94 
146.73 
116.59 
108.39 
55.98 
56.03 
43.43 
3.04 (dd, IH, J = 9.46 and 9.46 Hz, Ha-4) 
3. 21(dd, IH, J = 9.46 and 9.46 Hz, Hb-4) 
3.83(dd, lH,J = 9.46Hz,H-5) 
3.80 (s, 3H, -OCH3) 
3.87 (s, 3H, -OCH3) 
2.74 (s, 3H, NCH3) 
4.95(s, 1H,0H) 
6.95 (m, 6H, Ar-H) 
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S.No. Compound Structure Molecular 
formula 
12. 12a C23H22N2O4 
MeO 
u C NMR data 
Carbon No. 
C-3 
C-4 
C-5 
c-r 
C-2' 
C-3' C-
C-
c-
c-
c-
4' 
5' 
6' 
1" 
2" 
C-3" 
145.27 
41.64 
62.52 
116.72 
152.40 
115.65 
117.22 
154.09 
119.51 
112.62 
133.86 
151.61 
'H NMR data 
Carbon No. 
C-4" 146.89 2.97 (dd, IH, J = 9.46 and 9.46 Hz, H-4) 
C-5" 116.58 3. 24 (dd, IH, J = 9.46 and 9.46 Hz, H-4) 
C-6" 108.52 3.57(dd, lH,J = 9.46Hz,H-5) 
C-1"' 143.31 3.80(s,3H,-OCH3) 
C-2"' 112.35 3.87 (s, 3H,-OCH3) 
C-3"' 129.42 6.52 (d, IH, J = 2.52 Hz, H.3') 
C-4'" 116.83 6.47 (dd,lH, J = 2.52 and 2.52 Hz, H-4') 
C-5"' 129.42 7.02 (m, 3H, H-6', H-4", H-5") 
C-6'" 112.35 6.51 (m, 2H, H-2", H-4") 
-OCH3 55.97 6.45 (m, 2H, H-2'", H-6'") 
-OCH3 56.03 7.03 (m, 2H, H-3"', H-5"') 
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Table 3: Mass fragmentation of 3,5-disubstiuted-4,5-dihydro -IH-pyrazoles and its 
derivatives 
S. No. Compound Molecular formula Mass fragments M* at m/z 
10 
11 
12 
la 
2a 
3a 
4a 
5a 
6a 
7a 
8a 
9a 
10a 
11a 
12a 
C17H18N2O4 
C18H20N2O4 
C23H22N2O4 
C,7H,8N204 
C18H20N2O4 
C23H22N2O4 
C,7H,gN203 
C18H20N2O3 
C23H22N203 
C,7H,8N204 
C,8H2oN204 
C23H22N2O4 
315[M+Hr,298[M+H-OH]^ 
191 [M+H-C7H70]^ 68 [M+H-C7H7O2]* 
329 [M+Hf, 312 [M+H-OH]^ 
205 [M+H-C7H70]\ 82 [M+H-C7H702]^ 
391 [M+H]^ 374 [M+H-OH]* 
267 [M+H-C7H70]^ 144 [M+H-C7H702]^ 
315 [M+H]^ 298 [M+H-OH]^ 
191 [M+H-C7H70]^ 68 [M+H-C7H70]^ 
329 [M+H^, 312 [M+H-OHf 
205 [M+H-C7H70]^ 82 [M+H-C7H702]^ 
391 [M+H]^ 374 [M+H-OH]^ 
267 [M+H-C7H70]^, 144 [M+H-C7H702]^ 
299 [M+H]^ 282 [M+H-OH]^ 
175 [M+H-C7H70]'', 68 [M+H-C7H70]^ 
313 [M+H]*, 296 [M+H-OH]^ 
189 [M+H-C7H70]^ 82 [M+H-C7H7O]* 
375 [M+H]^ 358 [M+H-OH]^ 
251 [M+H-C7H70f, 144 [M+H-C7H70]^ 
315 [M+H^, 298 [M+H-OHf, 
191 [M+H-C7H70]^ 68 [M+H-C7H702]^ 
329 [M+H]\ 312 [M+H-OHf 
205 [M+H-C7H70]^ 82 [M+H-C7H7O2]* 
391 [M+H]^ 374 [M+H-OH]^ 
267 [M+H-C7H70]^ 144 [M+H-C7H702]^ 
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Table 4: Elemental analysis of of 3,5-disubstiuted-4,5-dihydro -IH-pyrazoIes 
and its derivatives 
S.No 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Compound 
la 
2a 
3a 
4a 
5a 
6a 
7a 
8a 
9a 
10a 
l la 
12a 
Analytical data % found (calculated) 
C 
64.96 
(65.20) 
65.84 
(65.96) 
70.75 
(70.86) 
64.96 
(65.20) 
65.84 
(65.96) 
70.75 
(70.86) 
68.44 
(68.53) 
69.21 
(69.34) 
73.78 
(73.66) 
64.96 
(64.83) 
65.84 
(65.78) 
70.75 
(70.63) 
H 
5.77 
(5.80) 
6.14 
(6.14) 
5.68 
(5.56) 
5.77 
(5.80) 
6.14 
(6.14) 
5.85 
(5.56) 
6.08 
(6.12) 
6.45 
(6.35) 
5.92 
(5.82) 
5.79 
(5.79) 
6.14 
(6.10) 
5.68 
(5.45) 
N 
8.91 
(8.85) 
8.53 
(8.58) 
7.17 
(7.09) 
8.91 
(8.85) 
8.53 
(8.58) 
7.17 
(7.09) 
9.39 
(9.25) 
8.97 
(8.87) 
7.48 
(7.38) 
8.91 
(8.82) 
8.53 
(8.94) 
7.17 
(8.84) 
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4.2.2 Bioevaluation 
Seven compounds la, 2a, 3a, 7a, 8a, 9a and 10a were studied to determine their 
effect on the expression of TNF-alpha in LPS activated Neutrophils. 
Two compounds 7a and 10a showed increase in TNF alpha expression (Table 5) 
when compared to LPS activated control. However, 10a showed maximum increase 
in the TNF-alpha expression (Intracellular). 
Five compounds la, 2a, 3a, 8a and 9a showed inhibition in TNF alpha expression 
when compared to LPS activated control (Table 6). However, the maximum 
decrease in the TNF-alpha expression (Intracellular) was observed in neutrophils 
treated with 8a and 9a thereby showing them to be the most effective possible anti-
inflammatory agents that could be taken up for detailed anti-inflammatory studies 
(both in vitro and in vivo). 
TaWe 5: Effect of p^razolines on TNF-
alpha expression in murine neutrophils 
20 
lii 
11 
^ 2 
7a 10a 
Test Samples 
Table 6: EfTect of pyrazolines different on 
TNF-alpha expression in murine neutrophils 
60 
S 50 
1 30 
a 
1 20 
z 
I -
a? 10 
0 
1a 2a 3a 8a 
Test samples 
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4.3 Synthesis and unequivocal total assignment of '^ C, 'H 4-methyl-2-oxo-
(2H) pyrido [1,2-a] Pyrimidine and 2-methyl-4-oxo-(4H)pyrido ll,2-a] 
pyrimidine by 2DNMR. 
4.3.1 Results and discussion 
Pyrido [1,2-a] pyrimidine derivatives have been increasingly subjected to study 
primarily because of their marked biological activities. The appearance of hundreds 
of papers and patents on 4-oxo-(4H)-pyrido[ 1,2-a] pyrimidines indicates the 
increasing interest in these compounds because of their biological activities such as 
antiallergic'°, bronchodilatory", anti-inflammatory'^ , antipsychotic , oxytocic etc. 
However little work has been done on 2-oxo-(2H)-pyrido[ 1,2-a] pyrimidines 
because of the lack of sound synthetic procedures. Earlier our group reported the 
preparation of 2-methyl-4-oxo-(4H)-pyrido[l,2-a] pyrimidine derivatives'^ "'^ . In the 
present work it is to be reported that aryl and heteroaryl amines are acetoacetylated 
by a microwave-assisted interaction with ethyl acetoacetate'^  and based on this 
observation, the present work subsequently reported the unequivocal synthesis of 
4-methyl-2-oxo- (2H) - pyrido [l,2-a]pyrimidine by PPA-catalyzed cyclization of N-
(l,3-dioxobutyl)-2-amino-pyrimidine/picolines/quinoline'^  in high yields. 
In the present study, the total assignments of '^ C and 'H N M R spectra of some 4-
methyl-2-oxo-(2H)-pyrido[ 1,2-a] pyrimidine (lb to 5b) and 2-methyl-4-oxo-(4H)-
pyrido [l,2-a]pyrimidine (Ic to 5c) derivatives, which were synthesized by reported 
procedures'^ "'* is also being reported. The products were characterised by 'H NMR 
and '^ C NMR (HSQC and HMBC) and reported data for similar compounds. No 
comparative data for the two sets of isomeric compounds with respect to '^ C and 'H 
NMR has been reported to date. The present work also made some detailed studies 
of the 2D NMR spectra of the compounds shown in (Scheme 2), including HSQC 
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and HMBC experiments and observed that assignments made for nonprotonated 
carbon atoms and those reported in the literature for similar compounds indicated 
errors in assignment and needed corrections. The revised assignments have been 
made on the basis of heteronuclear single quantum correlation (HSQC) and 
heteronuclear multiple bond correlation (HMBC) techniques'^. In this study 
protonated carbons are assigned unequivocally by the HSQC technique which shows 
one- bond correlation. HSQC spectra of compounds lb (Fig. 3), Ic (Fig. 4), 5b (Fig. 
5), 5b (Fig, 6) are presented. Non-protonated carbons have been assigned 
unambiguously by HMBC techniques, which show 'H-'^C connectivity between 
protons and carbons separated by two to three bonds. HMBC spectra of compound 
lb (Fig. 7), Ic (Fig. 8), 5b (Fig. 9), 5c (Fig. 10) are presented. 
A relative assessment of chemical shifts of C-2, C-4 and C-10 in C-spectra 
indicates that in 4-oxo compounds C-2 (p-to carbonyl) is more deshielded than C-4 
(carbonyl) whereas in 2-oxo compounds reverse is the case. To account for the 
difference we hypothesize that in 2-oxo compounds cross conjugation helps in facile 
release of electrons from N-5, because it results in induction of aromaticity and thus 
higher stabilization in the resulting canonical form, this effect also blocks release of 
electrons from C-4 to carbonyl, this hypothetical assumption also satisfactorily 
accounts for higher shielding of C-10 in 4-oxo-isomers than C-2. A comparative 'H 
NMR data (Table 7), '^ C NMR data (Table 8) and 'H-'^C connectivity data 
(Table 9) of 2-oxo and 4-oxo pyrido [1,2-a] pyrimidines are presented. 
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R2 CH, 
N/^O 
2-oxo-(2H)-pyrido |l,2-al pyrimidine (lb-5b) 4-oxo-(4H)-pyrido(l,2-a| pyrimidine (lc-5c) 
lb: R ' , R ^ R\ R\ R^ = H 
2 b : R ' , R \ R \ R ^ = H 
R^ = CH3 
3b: R ' ,R^R^R^ = H 
R^=CH3 
4b:R' ,R^R^R5=H 
R' = CH3 
5b:R ' ,R^R^R' ' = H 
R^  = CH3 
Ic: R ' , R^ R\ R^ R^ = H 
2c:R' ,R^R^R^ = H 
R^  = CH3 
3c :R^R^R^R^=H 
R^ = CH3 
4 C : R ' , R ^ R \ R ^ = H 
R^  = CH3 
5c:R ' ,R^R^R' ' = H 
R^  = CH3 
Scheme 2 
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Fig 3: HSQC Spectrum of compound lb 
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C2.CH, 
Fig 4: HSQC Spectrum of compound Ic 
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Fig 5: HSQC Spectrum of compound 5b 
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Fig 6: HSQC spectrum of compound 5c 
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Fig 7: HMBC Spectrum of compound lb 
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Fig 8: HMBC Spectrum of compound Ic 
183 
C9-CH, 
C4-CHi 
C-3 
C.7 
C-6 
C.9 
C-8 
CIO 
C.4 . 
C-2 -
H-7 
H-8 . H-3 C9.CHj C4.CI^ 
Ji 
• 
1 
I • 
0 < 1 
O '0 
• t 
1 1 
1 1 
k 
t 
A 
1 
' ao 
ISO 
Fig 9: HMBC Spectrum of compound 5b 
184 
C9.CH, 
C4CHj 
C3 
C7 
C.6 
C9 
C-8 
C-IO 
C-4 . 
C-2 -
U-6 H-8 H-7 H4 C9.CH| C4-CH, 
• 
1 
t 1 
0 < I 
e •« 
• 1 
1 
1 » 
1 1 
1 
A 
f 
100 
•m 
at 
Fig 10: HMBC Spectrum of compound 5c 
185 
Table 7: Comparative ' H N M R data (6 value in CDCI3) of 4 methyl-2-oxo-(2H) 
and 2 mcthyI-4-oxo-(4H) pyrido (1,2-al pyrimidincs 
2-oxo-(2H) pyrido [1,2-al pyrimidine 4-oxo-(4H)pyrido [1,2-a) pyrimidine 
lb 
2b 
3b 
4b 
5b 
2.47 (s, 3H,C4-CH3) 
6.35(s,lH,H-3) 
7.13 (dt, 1H,J = 7.12 &1.28 Hz,H-7 
7. 60(bd, lH,J = 7.12Hz,H-9) 
7.74(m, lH,H-8) 
9.03(bd, lH,J = 7.12Hz,H-6) 
Ic 
2c 2.35 (s, 3H, C4- CH3) 
3.03 (s, 3H, C6- CH3) 
6.14(s, lH,H-3) 
6.62 (dd, IH, J = 6.58 & 1.26Hz, H-9) 
7.32 (dd, IH, J = 6.58 & 1.26 Hz, H-7) 
7.42 (dd, IH, J = 6.58 & 6.58 Hz, H-8) 
2.42 (s, 3H, C4- CH3) 3c 
2.45 (s, 3H, C7- CH3) 
6.32(s,lH,H-3) 
7.52 (d,lH, J = 9.04 Hz, H-9) 
7.60 (dd, IH, J-9.04 & 1.25Hz, H-8) 
8.85 (bs, lH,H-6) 
2.45(s,3H,C4-CH3) 4c 
2.48(s,3H,C8-CH3) 
6.27 (s, lH,H-3) 
6.95 (dd, IH, J = 7.27 «fe 1.29Hz,H-7) 
7.38 (bs,lH, H-9) 
8.92(d,lH,J = 7.27Hz,H-6) 
2.47(s,3H,C4-CH3) 5c 
2.57(s,3H,C9-CH3) 
6.33(s, lH,H-3) 
6.99 (dd, IH, J = 7.12 «fe 7.12 Hz, H-7) 
7.55 (d,lH, J = 7.12Hz, H-8) 
8.92 (d, IH, J = 7.12Hz, H-6) 
2.47 (s, 3H, C2- CH3) 
6.35(s,lH,H-3) 
7.13 (dd,lH,J = 7.12«&7 .12Hz,H7) 
7.59(d,lH,J = 7.12Hz,H-9) 
7.74 (m,lH, H-8) 
9.04(d, lH,J = 7.12Hz,H-6) 
2.36(s,3H,C2-CH3) 
3.05 (s, 3H, C6- CH3) 
6.16(s, lH,H-3) 
6.63 (d,lH, J = 7.37 Hz, H-7) 
7.38 (m, 2H, H-8 & H-9) 
2.42 (s, 3H, C2- CH3) 
2.46 (s,3H,C7- CH3) 
6.33(s,lH,H-3) 
7.52 (d,lH,J = 9.0Hz, H-9) 
7.60 (dd,lH, J = 9.0 & 1.8 Hz,H-8) 
8.85 (bs,lH, H-6) 
2.44 (s,3H, C2- CH3) 
2.48(s,3H,C8-CH3) 
6.26(s, lH,H-3) 
6.95 (d,lH, J = 7.28Hz, H-7) 
7.36(s, lH,H-9) 
8.90 (d,lH, J = 7.28Hz, H-6) 
2.49 (s, 3H,C2- CH3) 
2.59(s,3H,C9-CH3) 
6.35(s, lH,H-3) 
7.01(dd, lH,J=7.0&7.0Hz,H-7) 
7.57 (d,lH, J = 7.0 Hz, H-8) 
8.95 (d, IH, J = 7.0 Hz, H-6) 
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Table 10: Mass fragmentation of 4-methyl-2-oxo-(2H)pyrido [1,2-al pyrimidine 
and its alkylated derivatives 
S.No Compound Molecular formula Yield Mass fragments 
M^ at m/z 
lb 
2b 
3b 
4b 
5b 
C9H8N2O 70 160 [M]\ 132 [M-CO]\ 
78 [M-CO-C3H4N]^ 
CoHioNzO 58 174 [M]^ 146 [M-CO]^ 
92 [M-CO-C3H4N]^ 
C10H10N2O 69 174 [M]\ 146 [U-CO]\ 
92 [M-CO-C3H4N]^ 
CioHioNzO 64 174[Mr, 146[M-COr, 
92 [M-CO-C3H4N]* 
CioHioNzO 72 174 [M]\ 146 [M-CO]'' 
92 [M-CO-C3H4N]^ 
Table 11: Mass fragmentation of 2-methyl-4-oxo-(4H) pyrido ll,2-a] 
pyrimidine and its alkylated derivatives 
S.No Compound Molecular formula Yield Mass fragments 
M^ at m/z 
1 Ic 
2c 
3c 
4c 
5c 
C9H8N2O 
CoHioNaO 
C10H10N2O 
CoHioNaO 
C,oH,oN20 
93 160[Mf, 132[M-COf, 
78 [M-CO-C3H4N]^ 
96 174[M]\l46fM-COf, 
92 [M-CO-C3H4N]* 
85 174[Mr, 146[M-CO]^ 
92 [M-CO-C3H4N]^ 
89 174 [M]^ 146 [M-CO]^ 
92 [M-CO-C3H4N]^ 
88 174 [M]\ 146 [M-CO]^ 
92 [M-CO-C3H4N1^ 
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Table 12: Elemental analysis of 4-methyl-2-oxo-(2H)pyrido 11,2-3] pyrimidine 
and its alkylated derivatives. 
S.No. Compound m.p.T Analytical data % 
found (calculated) 
H N 
lb 117-118 
2b 98 
3b 126-127 
4b 130 
5b 123-124 
67.45 
(67.50) 
68.92 
(68.96) 
68.84 
(68.96) 
68.86 
(68.96) 
68.83 
(68.96) 
5.09 
(5.00) 
5.77 
(5.74) 
5.79 
(5.79) 
5.80 
(5.74) 
5.81 
(5.74) 
17.42 
(17.45) 
15.96 
(16.09) 
16.01 
(16.09) 
16.13 
(16.09) 
16.01 
(16.09) 
Table 13: Elemental analysis of 2-methyl-4-oxo-(4H)pyrido [1,2-al pyrimidine 
and its alkylated derivatives. 
S.No. Compound m.p.°C Analytical data % 
found (calculated) 
C H N 
1 Ic 80 67.31 5.12 17.23 
(67.31) (5.00) (17.50) 
2 2c 98 69.13 5.96 16.34 
(68.96) (5.74) (16.09) 
3 3c 150 68.73 5.79 15.89 
(68.96) (5.74) (16.09) 
4 4c 70 69.00 5.89 16.32 
(68.96) (5.74) (16.09) 
5 5c 124 69.24 5.60 16.03 
(68.96) (5.74) (16.09) 
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4.4 Experimental 
Melting points were determined with a Buchi melting point apparatus (Model B-
545) and are uncorrected. Mass spectra were recorded on JEOL JMS D-300 mass 
spectrometer at 70 ev and IR spectra on Hitachi 270-30 spectrophotometer. 
Microwave irradiation was carried out in BPL BMC 900T commercial microwave 
oven operating at a frequency of 2450 MHz. NMR spectra were recorded in 
chloroform-D at room temperature using 200 MHz Fourier transform NMR 
Spectrometer (Bruker, Avance DPX) equipped with 5 mm multinuclear inverse 
probehead with Z-shielded gradient. Chemical shifts are shown in 5 values (ppm) 
with tetramethylsilane (TMS) as an internal reference. 
The pulse programmes of the 2D experiments (HSQC and HMBC) were taken from 
the Bruker software Library and the parameters were as follows: 
200/50 MHz gradient HSQC using pulse sequence invigstp 2D H-l/X correlation 
via double INEPT transfer phase sensitive using TPPl, with decoupling during 
acquisition using gradient pulses with coherence selection: relaxation delay di = 
2s, evolution delay d2 = 3.44 ms, 90° pulse 6.6 [i s for 'H, 12.5 |a s for '^ C hard 
pulses and 65 ^ s for '•'C GARP decoupling with gradient ratio GPZi: GPZ2: GPZ3 = 
80:30:20. 1024 data points in t2, spectral width 9.4 ppm in F2 and 145 ppm in Fi, 
256 experiments in ti, linear prediction to 512, zerofilling upto IK. 
200/50 MHz gradient HMBC using pulse sequence inv4gslplrnd, 2D H-l/X 
correlation via heteronuclear zero and double quantum coherence optimized on long 
range couplings, with low pass J-filter to suppress one bond correlations, relaxation 
delay 1.5 s, evolution delay d2 3.448 ms, delay for evolution of long range coupling 
de = 65ms with gradient ratio GPZi: GPZ2: GPZ3 = 50:30:40. 2K points in t2 
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spectral width 10 ppm in F2 and 175 ppm in Fi, 256 experiments in ti, linear 
prediction to 512, zerofilling upto 2 K. 
Elemental analytical data have been determined on Carlo Erba, Model 
1106,elemental analyzer. Column chromatography was carried out using silica gel 
(60-120 mesh, Merck) as adsorbent. TLC was carried out on precoated plates. 
Generally iodine vapours and then Dragendorff s spray was used for visualization of 
spots on chromatograms. 
4.4.1 Synthesis of 3,5-disubstiuted-4,5-dihydro-lH-Pyrazoles and its 
derivatives (cyclocondensation of a-P, unsaturated ketones with 
hydrazine and its differently substituted methyl, phenyl derivatives 
under microwave irradiation, without any use of solvent/catalyst). 
Equimolar ratio of hydrazine hydrate/methyl/phenylhydrazine and a-p, unsaturated 
ketone (prepared by following a standard procedure, by the condensation of vanillin 
and acetone or appropriately substituted acetophenone^ )^ was taken in a 100 mL of 
conical flask and stirred for a few minutes. Then the reaction mixture was irradiated 
in a microwave oven at 400 watt for 2-5 min., to complete the reaction. After 
cooling, the product was washed with distilled water and corresponding 3,5-
disubstituted 4,5-dihydro-lH-Pyrazoles (la-12a) were separated by filtration in 80-
90% yields. The products were thus purified by filtration through small silica gel 
column using chloroform as eluent. 
1 -(2'-hydroxy-4'-methoxyphenyl)-3-(3-methoxy-4-hydroxyphenyl)-2-propen-1 -one, 
l-(3'-hydroxy-5'-methoxyphenyl)-3-(3-methoxy-4-hydroxyphenyl)-2-propen-l-
one, 1 -(2'-hydroxy-5'-methoxyphenyl)-3-(3-methoxy-4-hydroxyphenyl)-2-propen-1 -
one, 1 -(2'-hydroxy-5'-methoxyphenyl)-3-(3-methoxy-4-hydroxyphenyl)-2-propen-1 -
one were used for these reactions 
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4.4.2 Synthesis of 4-methyl-2-oxo-(2H)-pyrido-[l,2-a] pyrimidines derivatives 
were carried out in two steps, 
(i) Preparation of N-(13-dioxobutyl)-2-ainino-pyridines/ picolines/quinoline 
(acetoacetylation of hetaryl and aryl amines by interaction with etliyl 
acetoacetate under microwave irradiation). 
A mixture of amine (Immole) and ethylacetate (2.5-3.0 mmole) was taken in a 
Borosil glass beaker and placed in microwave oven, alongwith a conical flask 
containing silica gel and irradiated at around 600 watts for 5-50 minutes. The 
reaction product was washed with pet. ether (60-80°). The reaction was monitored 
on TLC. After the reaction was complete, product was washed with pet. ether (60-
80°) and the corresponding acetoacetylated products (lb-5b) were separated by 
filtration in 70-80% yield. The products were thus purified by filtration through 
small silica gel column using chloroform as eluent. 
3-amino-pyridine, 3-amino-5-methly pyridine, 3-amino-6-methly pyridine, 3-amino-
1-methly pyridine, 3-amino-2-methly pyridine were used for these reactions, 
(ii) Preparation of 4-methyI- 2-oxo-(2H)-pyrido [ 1,2-a 1 pyrimidines from N-(lv5-
dioxobutyI)-2-amino-pyridines/picoUnes/quinoIine (PPA catalyzed cyclization 
of N-(l,3-dioxobutyI)-2-amino-pyridines/ picolines/quinoline.) 
Phosphorous pentaoxide and orthophosphoric acid in the ratio of (3.5: 1.3, w/v) were 
taken in a round bottomed flask fitted with a reflux condenser and a guard tube. The 
mixture was heated for 4 hrs on a steam bath with frequent shaking. The resulting 
PPA was used for the cyclization reactions. 
A mixture of N-acetoacetylated product obtained by microwave assisted 
condensation of 2-animo pyridines/picoHnes/quinoline and PPA in the ratio of 1: 10 
w/w was taken in a round bottomed flask fitted with a reflux condenser and a guard 
tube. The reaction mixture was heated on steam bath with frequent shaking. The 
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progress of the reaction was monitored on TLC. After completion of the reaction, 
the reaction mixture was diluted with distilled H2O (20 mL), basified with ammonia 
solution and then extracted with CHCI3 (5 x 50 mL). CHCI3 extract was dried over 
anhy. Na2S04 and concentrated under reduced to obtain lb, 2b, 3b, 4b and 5b. The 
4-methyl- 2-oxo-(2H)-pyrido [1,2-a] pyrimidin-2-one derivatives were purified by 
filtration through a small silica gel column, using chloroform: methanol (99: l,v/v) 
as eluent. TLC homogeneous fractions were crystallized from pet. ether (60-80°) in 
52-72% yield. 
N-(2- pyridyl)-3-oxobutanamide, N-(6-methyl-2- pyridyl)-3-oxobutanamide, N-(5-
methyl-2-pyridyl)-3-oxobutanamide, N-(5-methyl-2-pyridyl)-3-oxobutanamide, N-
(4-methyl-2-pyridyl)-3-oxobutanamideandN-(3-methyl-2-pyridyl)-3-
oxobutanamide were used for these reactions. 
4.4.3 Synthesis of 2-methyl-4-oxo-(4H)- pyrido [1,2-a] pyrimidine derivatives 
(reaction of 2- amino pyridine and differently substituted 2-amino 
picolines with ethyl acetoacetate). 
2 - Amino pyridine / 2 - amino picoline (differently substituted) (1 mole) was taken 
in a round bottomed flask fitted with a reflux condenser and a guard tube. It was 
dissolved in CHCI3 (dried over anhy. Na2S04), to the solution ethyl acetoacetate (1 
mole) and SOCI2 (1 mole) were added. The reaction mixture was stirred under dry 
and ice-cold conditions and progress of the reaction was monitored on TLC. After 
the reaction was completed, the solvent was distilled off under reduced pressure. 
The residue was dissolved in water, basified with ammonia solution and then 
extracted with CHCI3. The CHCI3 extracts were dried over anhy. Na2S04 and then 
distilled under reduced pressure, to obtain Ic, 2c, 3c, 4c and 5c. The 2- methyl- 4H -
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pyrido [1,2-a] pyrimidin-4-one derivatives were then crystallized from acetone - pet. 
ether and their purity was checked on TLC (CHCI3: MeOH; 95: 5, v/v). 
2-Aminopyridine, 2-amino-3-methylpyridine, 2-amino-4-methylpyridine, 2-amino-
5-methylpyridine and 2-amino-6-methylpyridine were used for these reactions. 
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